var title_f32_32_33280="Fluorouracil: Drug information";
var content_f32_32_33280=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluorouracil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12624501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12624502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/42/10921?source=see_link\">",
"       Fluorouracil (systemic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/58/13221?source=see_link\">",
"       Fluorouracil (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8464 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-0817467D97-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_32_33280=[""].join("\n");
var outline_f32_32_33280=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/42/10921?source=related_link\">",
"      Fluorouracil (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/58/13221?source=related_link\">",
"      Fluorouracil (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_32_33281="WHO head circumference for age boys 0 to 24 months";
var content_f32_32_33281=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 582px\">",
"   <div class=\"ttl\">",
"    Head circumference-for-age percentiles, boys 0 to 24 months, WHO growth standards",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 562px; height: 423px; background-image: url(data:image/gif;base64,R0lGODlhMgKnAdUAAP///+Xl5QAAAAQFBICAgPDw8DAwMMDAwEBAQLy8vGBgYKCgoM3NzYqKihUWFTY3NtDQ0ODg4O7u7iUmJVhYWCAgICoqKuvr65CQkFBQUNbW1rCwsEdIR5ubm2hpaHBwcDk5OXJycqurq3l6eausq4+Pj97e3lVVVcjIyBAQELq6ukdHRxwcHGRkZJ2dnQ4ODj8/P/Ly8kJDQvj4+H9/f8/Pz7+/v5+fn9XV1W9vb4eHh42Njenp6c7OzgAAAAAAACH5BAAAAAAALAAAAAAyAqcBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmbAqytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIxIfJzM3Oz9DR0tPU1dbXtMsCWaxY3UwBT+FO207jTedM5ejiT+vg7eTx7PLm8+r3S+lL7/r5Sd+89ZsSkFDBKgcJDjyyT0lDgP+SPESyEMlEhu4iWsxor2OTihg94hPprx69k/xARkkohSUglytVkpMp5KIRm0VoDsFJhOcQ/501NR4BCsBnUJPwSCoharQoR5QlPwq9OVMLTHdE8biUMMBB1StXd07NObbn06RQl5YVizQq2pFpJZ51S1etUrkfsy6tyNWrOr12wn61ItjpXYprj0o9HHJx3I1tHSYGwHRyZcZGLj/ODJhi55yf58B04PXBAAoDBjQYKiCAawAdJqR+0JfDgAkNZFMQcsE1K9fAgwsfTry48QCtjytfzjw58+fQgTuPTl359OrYh1/Pzh159+++wXf//Tr27Nq3c5/mHXx06dOpV4PWloQ0ANMJEnRlPYTBANpC9AVAAwN4AIBsJhBRWFNNafYWP5M1GOFckmFGloVmRYbXZplNmP9Xf/9JEOB+BBqIIGf1vZfffvMZ4t59AzAgIIpCEDjCEALaCCMDCurEIIUbPmgXh0VIiCFbjgkZJIRHKgaXkpAlWdeSAK2j44he6Wgajy0eYd+WM/ZIHxJfxhhmj8D5ByAAOQ5w45YA9IbcduI9R2edduKZ3Z16WtdndXz+WVyggmpXqJ3OqSkimyS6uWOc7YFUpowsiumipO9R6leXsMkWYqNvxmjplFE+SWpjplZIpIIeSqkqlEO1miqVtCLWpGF/EWHep1k6CienRUx6phCF6cFKagNIIQOyxe61KpKzlnpqh7ca+ayTTF6La7SoTnuhttbCStWH3AiArLKpNav/VWhovhaFnOQdehyh8oZXr5/3zpuvvvsO2q+//woXrxRy+sYusQfDoW6VAoELpLSvZitukQ93G/GQE2foaq0WQ1RtxeNeuzDDYCX8xsj8leywhhBzTO3KG7csc6wfs9zxzC9nDK3E3mqcklUJo0yH0KC1IgUM2CSt9NJMN+3007McDUvDl5ZLdc87Y4w1tlpf7PK3OnPtMczchhw2ZbLy7DXOo6rsdiFEt03Fgpal3fXXPquNd9Zjnx3u1tvqzXbedw/Od8pXI2SyG3H/5BzBBgfcnuQCUz655fZiTm+9m8vbeaEDvxtp4oM0jjDphottK9mC3+x6zoD/vfbrYMcO/zLFtzq4temnv22QyabTnbvdfdtus9mA6z477MvjHjPthBfffPSI+z734m3wHjoU8H7+p/eCgv895plbLn6f5+uZfp3bP1HwnKgHon3QPtZd8/PIT/8T8av7fTv10Nvf/crmvLDxjjL0G1PJgAO5OWmOfN4h3/rYB8EJiseC4MHgeB4nOukksGrxiwnrChdA1dFshNLbmwmZp8LAkTB/LVReDPlHoxBC4YDZA94HjYe/AiaPhixMnQtTKETZtdCIRfzf4Up4wOBhjw3zYyARPDUADgBgBKmZAJe690AJVvCLXgxjF83HwSFQ0YpYvM0WR2c9QcwPCRPoABEowCMK7P9Gbkk8ng/1Rywg1o6PQ+wfDwkIQBgKEpBILGEga1iEOM6xjncElkIUSJiKeOoBCRrCCCLZu0G2zpCKlKEQRRlKP7JqgJ/c4wxRSTIjXDKTQthk9a5HScUZzQgSeEAkE+CATCINasAMpjCHScxi3rIIudxlL4XwS1fY0A/HQpY0p0lNaoalAVbsFJfwqMhEgvKbfzyiEleoykOKU4+FLOcJ/YfOJYLTcUvAphBis03QVPOe+MQhFHV4hARwQAK5XA0H1iTJbo5zke8UIArNmccepvOhCmWnQ92pziAalFxF8CdAHyBQgjKSliBcoLuEYALTVFECJphmgrhoPjCOsaX/YoTpSyXXvpKm5p8pleZK2VjJWoK0pxIlJEUh2kdWEvGiEyUnUdFmVIYiVahKHWon29iSJ67hjVRNaFSLutB1evKFFQ3rKbtqUa0iNJwNhepZidrEHf6uXFLkXuRkSlfKaXA8Lq0rTSVYRvfxVHE+nWRWxSpVrgY1lUv1JmG3ylSyovWpiC3sWiP6Vc8A7Zl9wCpQK+tUsyo2sQf9UTsZ+1nJlpa0oU1MWzHLhyiO1K8O1GvA7sod2u4pr3bFLXYkMIPe+va3wOWBwPrqhPc5MbBVZe1kGUtKszZ3sY09LFhBO9rlWve5S8Vucq02WGjys7umTe3wmupVRIpXW9pl/64pKds81Jx0QKlxgBxnCVjwtlaHcYVtvPYa09z2l78zBTB3YjCgCYiIAyPgCgmuOAH2RCq/xf3rT9+q3J9J96iePe/Z0nvd9RqWs+U9Z1IROgIDD+gBB6KABBrASW4KdrMUtm+uLtxZ6J7WujcW7Yh1rFYeRxa11bWJTbuC4gY8gAMTSIBluQvj0unwmE9opjGnTOUqWzmYNCiCHf0jIv2ISMpTiwKY3epkXNomRADgpRrpu10Ql9XGGv4hed9M3R3bz7Fj1RmBEuCfBXdgAF92RQVWi8wzA0jNWvyoGwdign9KADcAcMBqRoBiRbfZvEG+M41DnNYf4zjOgORwjv+XIBtHwrcr813AAg4Qgak2GQCNBiikJX3FSrv4D1fhKJfTnCzOQLgJLPVvgGerW2L/19jR0YAIShCCFYBgB7D14K+ZYFyV6BrQvLb0S8yVGiMYOdu8zuSy0kXmTk83vJkeL57ZK+Iea9rNjxVCBA6AAQKAwACvSAECblBfgZyrCN/WjxD0I25yI9cDANq1wLV9w/qpe9N0RredHw7vPFec3ebuGwQOQIAPIGDQrrAAAj5AgANAwAju/ScAPCDNJYcQ4SJSeK9v7V0jlNRAQ6A1pVkz7SUEW8DClu2/bIsdogMKcyoQgQBaAAIWvMICIAgBAUSAguMQODcHvpEHcD7/hPfFtildlzCsH8D1SE/a1vAM6RD+jKwGI7qeaX81ZM8N5Imj18PRvfiHMW13Ic274x9/BQIyQIBVFwBnJRbRt1l+GyUXYeOE1pU03e6ANRd020zuN9/dTfHNe9rHdP90uu9+KxTQmwAIwLcrBl/4AzR3yA5Auwf8gnoDsD7ymmcDau7onwEsGKOV7LkSfo5soffL6NRBfnSUDx0NisAFzQbB06M+9apX7jsEniMnF96D4Qo/CdVW7u6F0PvfY2H8ACj/YOQuQojHG86j3zDeRQ3qVdJj3hjwOMhZoe8PhMDkfQcAG4cBNkAEe3YfPOIB2cRw7cd+WrYe6Zca5ncF/+infsCnOBB2RmlWeYkGKV8HdCBYfEE3giEoHCoAfStgAa8AAisQAiUgArfFHM8XAicAAlDXgiWAA0JQavPlXg+wRg/2WgeCLFb0dg5mMOIHgRZ4fkoogeuXe2Y0X0Kgc2iHQOu2d+32ee/meaEHehgGf65yAAuAevsnACwwchjAaqFmBAUghgSQAR83cv93AFzgEqY2hWfHZg2oBBXohFngXtM0gc4SQq8kc5cHhpxHeleYd1z4hXWWiBtGb/onaAjQeqL3EaeXerZHAGnYapKFFXA0GyZgiAz4hEgAiNIkiFXQh75nigoBZTiiSwtHcAAwZld2i7iYi7pIDFkGAP8p12UcyCW2CIsBIou9RotjloS854dMuIyteIETdgTYRIpx14g19oha2HlZ2IVb2G5uGHitgAAKIAAA6D9tWG+px3qGh4U4g3UAgGBmV2tCMIYIkI7XxAHUSHOuiHJN+IzNSH7MaGFUpVEBFY87p491B4lytoj0F38LGTYQUAJk6AoGQHgbcHLsSDtumAH3VolpeHjX6E6Jd2KkWAMHAJJWaAQEyVEGWYWu9mJ82I+qSAWsOJN6GBP5NWQqZ4QeuF8iWILHV2xDBx7KRoMq2AosEHUuoALGkT5JR4M2CAItUH3L1x0oIAI6CHsPMIsDsFNBmA46CYyWF34yVpNxoFn/UDh3jihxCrmGc/Z+2MiNQgAB9JgCrdB/CyACStSGBFB74kgAG0CHzvUEIrABgFcBrFeA2pePCLmPDYdcexiNGReSCZmNiuh+FmeNnFYEfKkACECRhKeGkrUQf+eZm1hyKOmWRTBvYwiHtjeVByCYSHCAVOhyMiaQMRZ8Qghsc0WCP/mbQ3lsAVCUK+B0rPACUvmCFHSC0WcBLegCMMg5TxkCUdmCVKkc2ceDAxeMR9ibDYSEt5kHaCmZakmZl9iW9oeZGFeeJ8SXGbB/+gaYKDAWEGCYGSAAf1mOkymAHOdx+KYAgHmSgASKmUeemFdhg6h3jLiNa1mZcnmZelcA/wLwhvBZiRvgiZVZn29oewDKag25cYDHoQGakWZFoAjaSr+DTypqTcTFmx8InEEpnDH6LyJAACdgnGaolNb3HcyZgiBwAiFAdYZSJ0/JdFAHpNDZlOCRfS4qbbtJbZGyolI6APp0Vd/lgHHZoOdpmfL3lpmZhRGwAB53l5UoAKk5O+domitQchiqpelwjn5pkQcwaknAdlm0ci13k5EJk2V2orbJoObphYHajfsZcaTFlwhgl6xgAB+wABi5oKWioelYeBh5WgfgAm84qR85mE1CAQaydbiJpY6ZBoynGo8pEN+HBMQXnMPGqsaHHShQAjeKlGsanUO6HEV5AhZgAf9AKgIa8B10omwEYKRSGaQ7SkHYRwS0yHhJ1p1f953wE56lKh9bYBurIRvUOmPhiaKAupkZ5pCqqZ4kWk4QgAEZoKgCAAKAeaab6Z62FwKOencgapqVuI4O6qZN8AA3QgSzN4+oZ4+Lc1xNYK1DmK1XoB/YxnILqK2iCo3saahb+qBdypD3wHGJyn8ZgAEnFy4RYJhxCJieKKhDoKH3+ZcXqZkQyxMd4ACLMgQLZ5IoiXsGmlGpISIKuwUkQE0uya3XQ4xMMIy7GLRCO7RD24uPRq0/uHLZBLSAkYwylrPTtLNUgLCwdKrb+qeFCpdsyaUPqaA0cQAfoHoCwKgL0Kb/FVUAHotvqHk2KmCfIiqaX5q1cWsEECAC9eaaf1kDNWJiQuCDcFeNDcuwSUC1YGAad9QAZReqM2uiKKu19zqo2ii3GAcBqNcKBtACG8CuFkNvGbCJmQuprlOatncCbIqeo8SGB2CY9KoA8Aq3fsqzl6YEhlsjiYsFaYRqjIuBT+pzvQmU+8J8eRJTKkAAK/ACrMACJ+ACv1odKlACLQB1LVACTHl91bFsxBoCS3l0ElSj1BmVLRCk04ud0eadHQSegRtLyCJfcjCefCq545qlkAuhjasgYaoAIJcCClC2YsWXIFABCpCGPxYBmPqeaCib0NWQdNuf9th6ZmtWMzCq/1ablgd6tXq6tRLbtfO7nt+6BGB7lxn7qIbUsWE7chugARVDl7WXAf/XwKX0MalLAKs7ou9rwVi7uBB8X3C1u8PXuzD6u0J5KBpQAsXbCkHKvLIKdUVcdMFhvTbYq8sLOnUygzUIveDLL2SUqkdAlucrnlcqwYjIteHqtXZTrqqXAhmwABIqDpxbkRo7ShigABwKwA/ruLgCovo3ciW3sfWXOjLbvvLTxTb8uN76xRccxny3AR8AchXwAQZME5SLABaQvyxcUXQJx58Zr+IKukOAfy2QjgAamKd7K7nrxaP8x0iQs0NAIP/xtwiExUawqjP6qvmCfLE6xOlKAMcqHf/FMbwpeAIlkMvUgQIuYKSkG53A2xzDMYPO5pwuaKvqs6Tj+6zlG61GgMo1Mht/W6VqwBJnBpA88m2l6LAbbLotTLEYEgEYUMb5q7kRVb8Vqb+mhagVubZ0LLKZIYnpSHKuG7H4qgQayJPh7IrdHIHf7JLaPAUm1RUGq7gD12s5yyO7doilPM5gnJ5izBgFsAD3KQAV0AIGvBRoC8cfPDjlqgAit64VPTOlmXoTumqZ/Fx32JLz6J/OVKAu69CiEtGAmwQJTWtfIAGV53h58W83PQTuVXmLMm5U2qLv2GuqrL49ecxWLMv3MkFBvALH2wLhuxwq0ALpmsTYIQLUyav/BLDVy3HMPbqrzzm9Uo0v3ZGdokiKSAMCxdo+Q2Ab14y7HmgwRN3QRh1f2AYA47YwQD0AQp0FJnC7prqPC2eAm3JrjMcoC1ZiEk3D8TuxLz0PGb3R+AvCF5HRcKwAG6AZaOufH3Ch2bUW9RkCnZufIDy3FH3BA6iYxUgBXFm1Oz0Eka1gDKaHjZ3Kj/2SSJDY0rTQVVDYu1F5xl3D4OayPn15lEYgO6hiLFbZgpyyhDrHsF0km81/om0x5Zp6BPCoRKECC2C/lfjRqX0XomsAACoCk4zdkft4HJep6CoAvZjK+Ihtv+1i0d1rE0DdLSbczb2dC10YyB1pi50FUCsi/8pdymc2AHLEeMv9CgY4ASbwZzVyZM1ai0T74SAe4leWZSu5GrXp4VGTyhiu4SeGZI7ntEUQ4RMeHxUsBA2u4Ms9BQjLACbw4DfssFSUGjLXsil50eZ85EgQAYksAC/w3UyAAhq9yBtwN+480vYMlx1rb7bXqOq93lfoeiGab6yXhvOZBGG5gZZnaUEeI/wd2I3J0Cop5D2+4Fmgyg/g4+K8p5IXgX7m5kWewTN83fWc3QvwmWO7ACa8BOhsABaAAfE9VqW9ia995V8qhv4Zmokuv9vYhq15sRRZiSXX5WA3qhreZ7Dh5wQewUpg53h+Mvj1pCz+1PMFyz4so7UeHP9dbbwv0ALAPBwoQAC7isvLN8xI7MyzPJw1qqs/OnXH/idJRwBj/QrIiaQC8MTZwaRQ+pVHEOvxNetiF7uLZtPgrt0aTMj9rIgZrXpnvEeLbgCOPlTo/Jmnzc7wSwR8Obb1+trmftlEYMfgaLl4rJ/lvlQTPe56PsFbDLuxfe6YLcYHoAB2WQEEwMLnkO7u3sAXgcjvHAEIXARrbKEdr4X+Xob4SXglsM/8Lu5+fPC49uqjHtWtGsuSowFmyArJqxxXbQHC/hy1zAIt4AKXcyjJDr3SG/SvepXD2nQriIO+GoNvHc123aTUTMprYBr7mueqvvL7Psj1Lt+rEgEQz9H/GEDv87gCF58UEDDC7+71SxCRYUu2+j7wlt2eGym2i7qm9mrRyyMBhmazeRrQWP/jRWD1hesogp8SrlwEtN7sMS/0J8AK0qccKqCrvP4cQayryWvtt/odYp2CtRq8lHOCAlCDxouUUnmdUJyssXa0K5e4Xhf12W6+VH8EhP8FtR/4h6/wW8/2GAyohc4KCtBqFVEA6ZwBU35Wm325cc/1OyPCBsCoqN1hRlX3rqBvn7z8/JzySMCSzHrYANCGox2w5cYEt58FDGAaEyAbVy+4gcz+5B7o2c/8lZnRg5YCBBCzRvDwFTD21AMEhUXGgIkAAgDlktkUNKHMJASjMCAI/4doMhp9dqFcsLRwwHwQFcFaUMEuDt/xUjxH2pdyex3ceDQ9HJRyrrAI1vDwEBPBFu0YHgYmJgZGGO0kHAY6ACItEx0vodYCSkUBLkpJS1lbXV9hY2UFZGttb11pcXdhUUJeBFhKNHJZfS1OVHA1SlYsCFB4i29FQkBYTkqUpWt1uWE1RAhaQIDZLFZCXERevb/fYd3hY5Y8HiSaEgaUUltX+fD0U6XnlJJQYDJt6lSpYJcOAwQt/KSIYMODBS9uYQSw0UaPoD7iSRJBwRoEG7o8GWJgQQEwXIQQMaIRZBcIBNIo2KAhpJ2KL5scWIAmBRsBCE5kgeCz5xyOKT9GEP9KQAGCGwBMPPDA5AEDAB44pPyJceyljFAeRvTUMMqIAX8kMjoraq7cslKajrnb5ClNRXnBiECwRoGWLhHafDgyR8PKmUBrLqFCRMGCxXcS9R3FSMQCnGrYGMhAYMNizU4AdznN5C4EMwQygHAzGsOBpUoeDtA9AQAF3V3FsnWylyIet3DXCmfSQJKS5MWVAzBKHAqM6dexZ9e+nXt379/Bhxc/nnx58+fRp1e/3jwNRta1n4JvNHrdJcx5x42uhIHuBBIomcgnAXQr0MADETzQPuicSs0LB8OQC0IAIBgshRBc6mIBBAqTbowICDBAAQhWowOPCBYQQETLGsxMQsn/NsCpqDVSwKIEw/Z4USQIy4ixpCtos021/YYjco0EkUxyQQD6G+C/AInE7TcoQaFuwPqoK1EJLT100cu/voSCpDUIKICjAjAQ8bKfhEAAgZa2hPCAD67AwErMdgSlisFCG+2Ay7jk8s5AJTuAAJwMuOJQ2wZlZIYqjbyzEStze4DKKNlackBWTunnH3hADUCeUOEZlRsUTljjhGh6acGCEIjxxxUVTniVVVKNaQYZF2I1FVdbxKnVKBBaIICdX3nx9Z1wSgjhBBAsAOEEdUSIdZpQ6UlEoIE4FWVbTfWSFNMowQ0XyzzRZSrMFsFMF4ACShJAgcvwPMCKBaB6F4MK/3Qa8ksI6EQAg9tYmxAvJsywgo0aD6F3DEIjy3EJqTzLAAFFa1NBR4kxLddc5Twed7+QvRC3ZHcf3phdjtVFtwACikLA4Ts2zABHLzaQKUN/8WjMCp123mzdhxM2wCgsSsvDYBMjBkOqQy92k4DaZhbUYBL2USIBTSbw6uSRTR4lbJGFI1nsbi/xVFlku2G7VG40+EUAEI59pQRkbgUnBAFa2AZXFAiw4Bm/20YWBRfIGbYFbWJZ2+1ZXgmHAGuiTaeEah93HJdsOdBtCQcaAGAEuLYV1ZtO/RmbNdXJJgvsc1leeY5Gh+4oMwxivpmJBQzA8MN7aY8igjSLiMDq2v/NyAA0FVtYgGC9lo4TlKksxviAoCFuN/Yo9OFvAHy6Z6KMOFhfHfbW0Tf//EyzjL5LlCHTfowDWGgDpSgWqKDMvg5w8/7gJ5amDMBJevJLGQAisAE0LMxPBWzZ9uIHBddQ5WICmNqfZHdAA0awC+Hz4ABMAABCSO0Q5cuDCc2WPrqYUDqn8xa3HpesGHJDcyhYgQBeUIJYiAAbebMbNginuV4EbgXDCJUQA6ACAqygfmuwwOJ8SMMZtkIEzXIGCNLhgm0gcYqiwlW2ABC+/oAva6X7B+pYkcITqpCNalwjyNpXu3zBj2cPjALuBPABnkChf/M6mBJepr+ZDQpgoiH/oF/s2ITJzCgFDdRgIjkYhTJgoAVpQMAHqDZHCNZxdh4ZH9QQUIIlhA8AoBMdXMQWqfWxkWxuNAgK40jHB8kRkZ3swgGMZoCl8KGPVVMCSSpwSNTYYXgsGGDQOAk9RWIgA4zMAAY0RkuhoWySaFDUAkSgskdm0HaSPECM0GABN32ANNdjQud0w4mtScJrqXwdHFmZPle2EG3nzNpXdBM6VMCwi4Xrpy1MpYEW4JAAsBABCOgmCxcgtG6Ns4WujBhDXShxBebABgEIN0MuBkBy5IhWCC4Hqo1qNAAoqKKzroHQEIRABA19BRjtYEYXNqFz9cgnP1K3ynh2jIVz8YDn/77Sta9xM5nd3GQtlbm7omQAewisiu52xwI/QpJCVlCMA4kqQQE0cw38YlGEpDlMMAglnG+AKl+0GUm1AvKbFDxKkM6KVTv8tEDB6QJdleABodq1bCzc6VD72oXRMQcAEnASX7eZWKNmFazai8BgKgBVFDx1rCJCgcqGx6/7MU2W79qAAkDj1ZmhNawFY8LTiMCh2pjJfQBsUVutSUIhuXauW3HaWQa7D8Mm4GOB/avI5jmd5UzABA8JI0RuCoD5sIe5zXXuc6EbXelOl7rVxY57okDXCfBWudsZbnH3oQ9NDECfy3XlPH9bpChg7T66cQAn3NkEShioP0rAWgjfyP9Y0m6wqP190AHUIDM+6u8pveSsTyAA2quu1S9CUMCMKvCBzdKWwUooWh5rc9TGUtUvBzBUbEcDB+Ol1b9zCIQSahC0jMy3QPUFwH3j2wT2KoE5EIGv+tJLrp+gUwmGJYHo8qNeh2TtvS/+Ho4VW2Kxani/PsmAAFKw2SUUwGJHAEj/EKA7LaUoA1KuMF9uYrQ1PHOQ7rtyFa7wAee9j8l/5DBbPbOCqJFzA3E9Hro8jAGqXGUMpBRyFIxbSk5gDR9/XgKPCzuAH48gyPnN8TuhQMoJUEACDaBAyeq5hEAngBJF3qfp/unPUMPCBWtogbVYETgXxMKGCf2GL1iwt8f/ueAE5niiS6/1uHCEgInEYlyuR90OV5x0BSltAUsziqy1hcMFISAHtIgFUhGoAKZc8QpYcJq6TEtJa52G77fGImlKWzrGj4ZjXZlASj9wYLtLkEGBzhvLNiuttAfuArzW8DwLG+ADTXVqlhmc4GAaxEEOntEKvmrLzlq4CuJUs76nOW+53tKCVUmzUjasX9NSjIKFWNQBuKQE37ylnYZmH7pHec91t1sJ7x4Aes19FjEeWR+FXt22Y8rPYMtq56xQgQUEkCpXCBQEyS7ps3CNixJgsaEjHXoz1vCCbKD6Fk53xeE8mg2jQy7YJnU2tAc67Z6btFmpqlwIjLV1WVR7/wwyxfkcwN3BrI3xuDZ/pblVyb25KxoAD7H73eEpcTy9ucmMxV0K8KWH/GFAki2ogJfr+DJ+l/lLKHoylPtl76RyzFBE8JO/+YvUl5TBM1EbTZ1Nu/CDcdziCAgSBChcENfECL0y3/uP/W5yvLsOCuhUSI09rfsVql7zi02y6N/1ZF0SHIEcQqYS8keAqFgBA89nvkiGJ2bNIn+WxCwBnfid8IxvnrFSOQMCxHnB0dJ74bCVjesvCPHrC14JbmGnEsxb+x0XiBPAv7Gjd88iemqmGEFteg7Y+omH+MYf4sYCkk4FpIXqqAGhVk3UZEEDAmcNWKBvlK0WUKAEamUFjP9FouDB657lo0JKGqzOpCan2KLl2FpKBb+oCyjAKyjg0gBAB9AuBs/ohdIIlgIw8ISQfYhv4jRJ4zTvEKLMCQxA+qBA8gxjy6RK/iIOfy6PBT6ACguP/CgEzZ7pNrKH8CZGHCzu9OTvzsBggioJSAhAxLivCsdAA9oKJxCgKLALDEYAB8uNCIcQ71jMA0pudgZQp95wC43vy9ysAAYDAZDpAwRgtDagCNxMQ/jlsppGMh4M80iktZRgMirgC8cPEdmvCarpYjIgBDZACyeR/NqqKtxAAUgjm+pt/gpFz1zxOq4AFm2gzxwAv/ZQAAmxC/4wEJUDaxzAKxpAnxikr97/ru107gCtThpcABhCYFZeZVRQAIuiqBYOalWkqBUAp4mKqJ9UQACcIRu28Z+8QQWaBdqkLQEFAKVeENmCTQCqgdfKYTpeAItWqqWoju00ba8+7QebEQzirg/BwBiRURn3o3Nsa/iC0SzkDQlp8fjAyhEjqwl4ZykIggAyMhQBwMCMcJbaZA2KxxBLzMFE4xFncfDAoAy2KhdXS8lWEYE+zJIcUUgEjyM8DJSu4xXbUCeLbww44B56CyFPQVMcsnWeQyIhjQ8p0iW5UBS3BAKMhqnEJwOw8n1wyQmRSiSH0gvspShSIAtpsvgMRVFuI/aQL4E+AwtYsgiRgPQQBf5Q/28Uo1IEDIUOcfGSDsGc6M8EDsQXkcy3DHMOmhJTljIpB5AN5MO6IDMyJXMyKbMyLdO57tAO8o8+RCH/IpKmBuAhx0UhASAZ7eIpgXEnSawQl8ARl48JQkTfLMgAIA+ssEwLTyPB2ECYqBIANECBPvExuk/iIOD70uDzjvCRICBGqscMpfIQu0AOfSQNpgMoXQAwFY7+IAU1ec8OSNM0MWUCxgsQT/MztzMq0RAJSwIEgkYRP0CrykQksCyuwnJDCCMODCYmLOAD6DP1jqoAYsQUs+ASbaIEYCMXMQ4kh/O0XsNirgP+Mqkmk7M3L+A8kRIi8UA8dYM8gzC4CFBbnv+x56IRHIDuBFzBBVigAlvhbpCo1ZJuGUKgfl4gBFhlRMExcJ4hHR0KHsThitRBAquO1ZrtiqZFBHT0bViQcqaDBaItBt3GRnGlB9Mmpy40CC0UKrG0N9PTIiPAaBgPJtAAmaiMqagjRGQxXXRTRfDFPzMozAYIUFYzDCBgKBLl4ViT3sqg404PTqXJ/BZoOhQlQUdSQeFQS680S7vTShmTOxdVNQnUvyCgKNZ0CpqQj1iiIoNCf57TX+xTXs4qeArpmAh1yW4JNizgmfpzUCUjRaKmDXEzJOiygozCaNQPPeMUJe+0hfLuMBXVKbGkILvAAA8wjXBlGl+AcAIn2UL/wAJuRVla7UhjIW5klEa5bhdoDRtUlFR8pRqgBR1/JVgEJymg9BVUYEhBYEmJxVhqdFgRUEQ/NCColFd79VATNTVt9VFFL0Uq4HlOQAGQqUvfk02XIESkrEReBhiCyfoENgrsZT9TVVVTD0CtScJAT2LyNLXsFC8TK1aXB8o4RFAL9SwhVmMNdRnltVEDsEmIURAZFUMtEldDFql+ZGcKoFKbYAM+UmABLD4ldMpgZm4eFlMnhk4KIwxnR4EUBTthdsoOIARSizS0cFD8tA5n1ay2tGRDb1R7VvhQFlHBQGXJBmwlMknIFkGktABDdOeiUQNS5QSs5ed0qBXYdgWA/9QdnhVu5MbVdiGgiChuYwhxgI6lSKVHP8oFoJVYLzBYznVYskjtcGFctZVdCdIUfHAgyvZyX+5OxNZKPdQ8R/Zz2YxdalZemAAC9hVPrJLx5ohg1eplcgd0CcIxkMloJQMDLkbCQlc56fSS1gx2g+L8ZsQkkgKDopIttZZkRXZTf7FemffRDGsAVvYovdZlsVYMmcYqBWBNoQ8BwFAJ0kQVn2BnFRarXPcobuZ47GXykrcOUAS0KoNe7gQFApRfMixXpaP0OlZEssA0OLElr3Z96bV5qXcMnjd6laOAB5gscK6m2ou7hJVdR0oFXiCHWiFwUE0DiAVI/aHYDldu8//2RffWVU4AhJcFcEVw6xyHHUOQpTR4FyRHWM6hcUVUchFXcs/20O6pNA9rIE3Hc5cAgUUGiMuzSvFKSnYYAAEYX8MgRVLgeRTAX5nABR7PDjZAAGpTI8oX4O50AwZDe5FweECA3x72JyZDNAZGeTcMtZanRnLSf291a5d2YZP4Su4KqPrOPwDLXjFBNwxYOIQ4gBP4lAjrxRwAa7gLie33f6OgBFTkMqgsYJdgASxgfAFJAZ6METDwdStM8ubFeEN1ASyxXQwlJ8QPjZtABQI0eN2ANNbEzN44LI9XaBM5gHPLvgr5iAtTgKPgj6OEl+kYjhzzPojLuPQhAQSTuzb/8zKVeZmZuZmd+Zkh87uI2UmOGf+uw4d7jI/JxpdZlhBZbEMP5JB11VGzNpIFYJIlI2ff5YnRODZleQlw6ZyDViprRneCRyVxd2lH2WiUloMuNnj1d56NN46Rd5aVmKA/d8UOhK4KRJwB72S7gJujQ6InBWxwLtCUoJo/7VOg8RYY2QKshYcIRwMswG9ZjVh4jtVS5QUK6h1grQW2caM+0Bk4UBoA5xx5xYukoUebKBjSgYSr1YZpWBWG+oa5bQk0+iAhepe1WVE7FwwwGitweZzvtZxTxABYCwB4J2iscrM4AmftGQx+FooJJX29OGbFBwPESTjjRyXJjFSFZyiA/45GkMb6FDmWTVmODbqc4bivHxrQclijuXaI55Wwp9dXq/rNrtolkuADttLCTtfe4OWxSRbAzBeWm6AE+GWMxyAmiiCU92BO1BI6qQC02AAEJGz9/PqdETqvCxqv77q1tUT/sLmwEZkxgTUKHnhYlUWCWSBW2NZEV5RZa+HnWlrYwPGGKPgb7gZW9jYWaO2JOrgUmIGJWiBbg7pHzWEfBXeKIPeIhlqnbfhdc+4Ha9u2qXqpDXuOqSpSm3gJQEB1W5MRG8udNeln+21UeWd/VAZg+EXf+iL7ikdQRpkNghPA+1cuY3u1XZu1GXy2/Sre0Hu9dZnCYTut3JtgFECUmP+AnTXisSA5X3D2KKjwKYSgCTPkeEBk+77yAz7xkFYjLUPjfas3OxPbxl+WwQd6tWm7Sid8sO0it6Fgtzt6VibYb06gBeT2GWoBRYFaVLIRh0waRmOthQHqborIyllBA671BLDbFijqHAQgp4W6qMP7u0uFvOEuXg/7x3PZvrJGMA2EMP9aj2uc/DJ8CdiZCyrkrJvgBCh7UiyIkgcvkHjWr+1FANgaDFBgCCJMFdl3CCCsMlxixzFbry/8oB/8lUEXwndVxuJ8MIF8pzTBHo6MXhFtuPK4wi+91ecvz5XAw6cgsiUJAUIAD7BXwCzWIw8dZk+8MIhDPxddNQDUtKH/7K0xXbY5vcGZ3dJ9141N1mtTXZiXNwpKPRL+LjrGSzeyvaL1rgky4f9OSMibgMhnmLrrB8mFuxTuRkdRoKRxgQAmeKOk1blfzVWoVbxJjYmgYRdUYFlPOwTUDs3fxswNfrzJnQmUOh9yuLCC77at3UC6XTg0gSGrBOW0puFHhwlcLnN9mHZtZ3S118OVoASwOg1PVzOoTEVgjxFCQH8IXSq5+E3gOiStimA0AzidKJ9x/M6hc6+tt9OXHeRXXQAx/riaYOPdTTfApeJbx+kD2c8Ee9R/Ocdd3UNEfgmqYHfQWUO4dyQ3oCgCljoi0XdcJkSmaskKKfNWMSZmRGBG/0zTr37B537oE5ycuzkYpX6q63wMoF5k/t7C/YwCwkIsgvkSkhmaFX/xGb/xHX+ZH1O4vn0JCB+x5iDwMQXzox0AfE+doNfb1bvuQcFotHerIxmrn4Lk5Qp7KbssoBB0NbtDOltFRPVh/LureF7HXVnuhZ73mZ3ue7/qT7bzjyt6m568nh75A3n5LVzZq6T0Tx76Th4gatYr7U0J/XwsFs+vecfs01BhVBsTzaEIIN3uW9LZm333+Vr0hb/NARkKNH/3PDThl8Dcg21vqpHdQZoV7gYINIEhcaiylIrKIQokAKGWAcFSBDoJpVpNiBXKagMl0Mo1DQdULZZAsCpF0f9yKXVuv9Pxen1970f3/QkWtREBHCImKiJeEAosQkYitklWWl5iZh5Sakpydi5+VgZokl5ufC4YFCAerCKaHkJUQESabqQIEHgmFigg1C7GKhYQVBCwAgwjRnxUfERMQkZgVLQZYBQsj2o+Zm5Lgkd6Y4pDmoeWqmeSX6Irvk+2gyqK0m/O3+vvh+bf2//zJ2xdpQgprB1SlQwABAQLlSFSFc1WgQwCaFUiR8DAgnCLih17uGxDBgQd6/XCYOAahokQv3Uj6C4mzJqYBJ6TaQnnQJs7eXYCSE8ov6IBjQIoNIReoymBBunRYEGACioqQIBRwQKMkhBY0Yhg04JrnrD/X/BwQYIm7QkVWqhoKLGiDYsWbqHieYr3j969e/r6zRtYkNJ4i5oOIRoUKNLGnhjfhPyznM5FCgR0FADhlSyM8AAoUGBpgYAUG25myODSI4BiHMMdUFBhwcNQFksrCJbT587KrG/6tkWTMu+MwXdfUgxKOTvJjp/jQ8o8MvHqkEiLTuqZ4fZEGrBZ+iDAQu1IGAQc+BZB9slIC1goSC8pgjHcpy0ZPpQ/6fGewIv/llx/n7EzYCL5TdecUQlCBx2DPxkCSlOFDRZGVRYIoQFVRGh1lxJSJRGGBnOtQJYUI851hwZrhKhFCSycEIcWLsw1HmAVynEjjmHouGMePgoG/6QdhTHlyILONajIBAMw6QED3SD52JHW4RdJARWkMBEC5MyiWy8GlFBJASt98JIkG1RwGmTVhCmJKtCYmZI1KeTGH4DCFXgncgLq6R+fVHKTJ6ABZhSllEU9uGSTTzpGwgAOPNlAA1BKxxMHAxwyApMTMCrPoHgusuV9BIjXmZeIjLmAORDkcpI5BXzg0CaWHBASOAWoggwsisTWxmwLObfffsEaKE2fBP736Z69HXuggpJcmummnSby4KGXOAopAJI+d6kHRx0ZYSIeMHkIBU9SQMEhE/YYWAsChDCECxacoQEIHhYBIholvPCCCHMcQQAhYaCwAhRbdHHWiQSwIf/ACf8q0a6QiU08ZMVzSDxxxkASqQi5mAJwbsjqAoCYU1Ni4m2SADwwwAjgIirQCA80ADIiI5Ds6UzFoZLBIRFUwIoAY556SKr6QXKeAV6Cs9Gp/oAkH9JGG6OrMBAokEsF2YxT7NTJ7qxsOs3uKmjYZzMrNrKTQTJzzYrgDIm140jW8stJqjyUoXK3IUoDE5jQgc0AJOCACYfA0LfiizPeuOOPQx655JNTXrnll2Oeueabc96555+DHjrlifwd+OCFHw5A4oujfEneDWYb6aTPxgyJokyC3AGn/ajtLKoGpBCMAhhM0p4iChg/zJgCZLe2SlKj1AoCCpQHAAofvOb/njUvELAaL2R//SfagYJdJfh29l52+eSPT7ftuJcLgO7UVrt3PZLFvu3sjk3gwKKUtg4SgjsEBx4gAb6lL3yXOQkGmlcqSAwPWbMQAPF2U4DpVW9WAFgPMCBRDAsYTxELsMbWNDCc9oFKfOZLIPpQuCzjnG9YXotToSoxQAAU8IDuq10m+ve/lS1HAPAbIhGLiLuOKWKAJhji4dglJAI4zAgYkpcTpHCCE4RBBP1q0YxYYAZABCAEFvjiEkpggXgtjA0s4OIdNsaxi+UIjmCU41voSIc+CBBTS4RfEx1hxD8WcW5A3IcgEcjDFe4MAgIwgNE8M4sC5CM0OSFN8Cqh/wEFZCCD1TLALiDREAVEYxnF0FryTojIU8KQhTKMoSnZh8rvqZJ2hySk/QYZxEoFkFDcKEAKsnQIBNyHaC0ETfPgcRnORAICFqigmC7jPaP9QmqxGKUATOKntLnwmqnM5tqw+coUetOV4oQlN32XnFreL5e2TFIh+yEuTThxR06AWAtaQIQ3UIwIVwzDCRxmoiJ0aA4isAAUpSBGNjKhBS94AsSg4kYfPXRHEcXRRCtU0cAgEZ5GmuU62YlOnfEjQcISTycXgABENNBYxJTEZYp5HQNE4B3Yi8Y8NsDJ8qDgMtWEnjbJ+c0X+nSc4NzmT3vaNVaarajdvBZHYdZRj//isqlAjYQLBOAzhnDGFcA6hCQjcZkThCeTNEzEZjqJvk8+sxhtiE85VdrW8IVTl3I9aiyTKtSpym2GCPooSGn5VCC2837vzEQ8A6OBF2wlAFK5iwZYIKMztACLWuinZLewAnvKQYz4gssJQNDQIvDrCY/FqB1/VNqBnRa1qc3najNK2I2GlK9/3aFUb/lWKN4nA+0xAE8x49JEtHSsP8seXDdogDLVYyMhPEStLnIAYbVyrngdW13XJ12j5hWp1h3qdevXmMD2dbaJYACTSBCyAeTsnFGNbfoi8IRDpJSrZp3EVSHIvOJyh6fLeN4iFGm1RERgSymoIHTt2l1zqvD/rtil7luFS9cGr7K6bFOn3jBB3gGYlwLodcyFM7xhWdJysJgo7F6cEIWBZkEuS6jKPwNA2X1ZAF9LsBcWliBGvayoDWOp2EVJu1rWtvbHQD6ta0cMW79eosPnTW9RlKxhJteQwrZVKgBQIbArTWQztbmSQIKrvkPEqnq3SNMiInDcYWIgFwjwXoG3O92lBvXAX44rd+ucXQnT+c0IjrKUF2Ph8i6Zw4B+MgBr6+dyYkkbvDXa0kKFCvu6dJoZ+C0sKiJWRfAXfc2tAE/xa2cGU3nORFUwnB8cak/fGcLR/XSpebdeJFvCyR9GiqyhzFRa9o0eqxMdr3vt618DO9jC/x42sYvtOV0zrs/jHfSskeK/SbXM1rRlr6H3rAiDnDQCFkAEqRZhUg0iwsufmUWnE7EACzxzhL0Vjy406WA9u/XU7wY1qa0dZ1bb29T1FvW94Y3qdL5aHwx6NsuabRTBofdS0jZktUH8aYvUIgMuOIRN+8uZdpCGkecwadGAmwET9iI1tTlAG1SjagPjm9/6lvO/o4fnUbN83i4/uXoD7lQbMokCChfvrRHhqHExaX/1E/ElSPwHEUTRCkZIbL7uRYQ+lGA8LR5DixULAswWwQVeXMK7BPBZIgv5DELusV/IvhezOxSPEjpyIn6OiI8JPTo8f45QLmUzD+xu2gKHjP85gMcKmAZAmIrQbbUSssgMLmAFldiMq6ApKwCvxCJ6XbW/ZV547SY45hGmeeZT3vLwwjoRdn973l099+8KJAEgk8AAEsDn0M/1PMTDwC4CEEFFEMClj8g44g0AckjUSjekcAUzEYELCg5z35+Pt/Itz3zNU37BraY39FFe+b2iPhKqPwTrXa/308cWd4rYPuEeFXREyOCIau+E0aPyAno1VggqVsK8liCAqE9RCmas+v7z1YKD5Us/scBdoJ1DhV0BDgICEsYBjt36adTTCVH8IAL5qZ7/DMD+pN8AgBf4eRckkB95HYKjpE4HUtsrXUZ6IE9rsEBtAE15XEPvsQL/OITGQ2hb8cnCSlDP83me84Eb5+WZ9OVbqsnb5g1h9E3fEYLe3mkfyIAgAIggwHFgbZEfADhABzjhAOgQCcLeUCmSzzTEIRDAfLXGoimCIiGTCHGGKCGAGM6CCCzCeaRACBHL+cwhC9Vhg92hvOVh8+0hy21gEpYfIlThFWah3EVhCYoe7lhhAizJILrTUqydUwgCCLxAFDgdCtCLEpyAwHzIQo0WEfSfFBwBG5mRjI3IeHyiAvIFA44dK/6YKv6FA74WBEKC3Q3AIjaiFULh3NWMA9TMBZJAy3CAw91cMS4LaezCAmQHAjxXIsSXIqyEQCiEOaHJqXyAWMVCcyEX//XtIBE2nzdWn5sBocoJ4TcaYRCOY1LIljoq27Y8yi82QDAOwDAWRS+agOpdIAAsSdx9nzFOGfvwUgW0RtBUmc/EgpYtgnicx0vVhimoxENc0DaaAhSZRr+lIw8mXzh23vWdIzleZB/uIEj62x8a4hYqgj3i46TsYz0+CgCwHoYV3N1MWGwRXbQQjv/kXfvNQQgIgBmEACdawGM1loyJgRuIHWjl3xJcEVeM4oc4wVfwiCsGWStS5Ss2YE2CTOEMQE6ynT8iQi+6JKDZDUs6QFjC5FjWnKF9zCH4IgDMzC7+hntlm8aF4dQYwH2QVQq8wjxM4yJ8hxgGnyK4QC6IYf85auQPIqFHzlwRWt9FgmM3duTySaZirCUVTspbmp5Jkk5LvqR5oeU+gGVnxiR1SJnbYAp5HdAUluRvbEk0MKNx7coHFOaVVFIL9SUxgBAaeo94cJo4JqZkZiRkNuZvYqRIfuTkDSc6/iZRmCYAoGYgZqYSVkJoiqXLkKVZeqZ1pmVs5dpXAs4AUeAAHM6uGVt5mud5omd6qud6rifpfCemhOd4JlvDUedZaidocmZ1yuTrmeTtMMlzqiY77kyijUk0HMBJIYIKnCEY6sLl3eaXqMrvsCFhPiZHJqdiKuflvZxFEmeFOmZkYiT2LYJ/DgCADg4gHpok1Gd27ufpkWT/kckPyLQlZuqkFvBkEoQAGjlWEXjWElQVCESMGCRlvqgFhxQpEUCRv/yFVKYWLC5pVU5la8niIdzQjD7AunRlhR0iImomlWYlTtKPSGEbbAIA7SXCBoBVGR5EbWDGgjJa41VjyC3SRHhoh4Jom23kh14ocNZphmKoDlrodi7CDWll6WmhdG4ponKpVx4IxAFABpzGlSzEmKAAMQBP0RyeBxFXADwkWZGJn/YgY/omqBYnco7qnwKncRKnqoIqSQrooiZqodEkJLJfYkgM0mGR0rkYF+XoEswFQqGAAHyiYh2pi1XWEPDLCyBUkFgllDYpk4LdK05p0WXpP8ZqisKq/7VGAgikACtUgIEi6M8I5DBA0Tb+DtQQF2ikabgtUtH0KaqWKuYhJqm+K5/e6QyxKqq66h+6KlKQgAUW4kx2qaxGgnuViZkCQAchQgakRzZWEwQtpKUaT2jEgpkxj5jdKx2aap7a6Z6GaMba4cby58ASoyT8K5MErLPBJLaGGK0+IIVowbugQPyJAdYFgAisgBKgQL+YSAlg0VPoiz4dqwssFCfihZPyAbSWFtIya5Q26bRagsnwK5L4j3k1yIWl7E8A0tbCz9RaAi+BAGh0hKQmwrcizfIUDUK2w9GEW3aQAhR1x3HKK8wJ56naq8fi6bzCa71+LGkeCddy7YNgbf+DvGTOsayiIq639eSBglnx1SXSLNBHmC36sC1XNY8GbMnjxVy+pqrI0m2gciy9giweem4/MmrJLkLhGhyt/ae2BgTRRa2tygELsEAAXGImMsGQQtGxEsEYPd0QBO0Q7BPwTgUaDQbTtpHS2hHyWoyzLi3UVoLU8pXgtu7VVi/BJq6WRgLJYYALLCP0KABeAgDSadzxzNcjVO5KMRpmaOzccqjo4i2+lu7K1W3o7i3qum7+QsKF0U9j8K/+Hq722lcBrEA0bEAxMW4isIAviVB9bUL6dtUY3p/8ui/9gq7e3q3d9q0G5+3n6qmgkqzfJtn1Psf/BrDedGcnkCd7snD/C7vwC8NwDAsbsrFOwy1biSaJCWPv6Yow7mnGB4TJ48KXuRpE2BJD3CbFxDbP8nREB7/v/cZv+26oBX+w/WawFW+wwIYwCEuCDpcwCfdw9uqvXgJABQQA0PQCQbKrCizCXS4CFAHXEq9E40mxD3pwx3IwBU+xYdYvBmfxyIrxCe8vGEfhi0KvJNRo1JVACcTLCnzWCXARrnKd8RLBvPTB8BLr/fGY8tIR82IMJ8uRJwPCIUeC9LbjtZouAJcsAqQAAMCUCIQrQ8SyK3frMCyAA3cGJFnuuZZSHYsqFjsxFeMxMOuxHT/xFQMyD3MxKmuxMjezf0GAz5wA9CgsfCHf/0EuqDA9QgQz8TD7cTDz8QXfMfzmsS+bYxQn0L5O7zqCnyHDbvTKrlIK68M0Fmgd62HhLvESJT5NASZLhSbDkSjPUbMStNM+q7S+MyJXqyAzcyoztMPxUiYJJMIO5EOc4NRYE6Y1z32t73L98ThDcTmHbAWHcxV/czH/cjILcCA3NMNl6+GexwFgAPH4HrcVH8k1Dyl8gLkyV/k+Wkf3MUgjs1B/9DEXtTCTMzGb82H2HEvjb0vD5d4ldCnHcxHQbgBshQhUFiYqASU+1hgsAQownVbUwT8vq8aAckCn9cUIdFQitMvOoq2e8lN9TD7u8BW+Hfy4NOKiwgLExqNCgP8pvGZENCgioEA2N9oYKpIEe3RIK/VI7zE3irNRg7NkmzRRV/ahaqbbAUBdn+irXkJd82NRXIpK2nUY45AEesC3NLW1ZkC3ZgAEmBlEkEQvHIQigECn3d6jZkY3n7NIky5JW7Y3YzZK//Zjv5U616Jqs/ZeQ0s+rmRj4OMBkQs9ojZ0dvameJ9guawEWOADHM4vOiKJBWuM0EsIhIhUPNa7fBaNLAEBVFYISJaNnDVbr/UmO+/S3reQZJR3Mwl4u+Oj6KIpe+DdaXd0LiEWZrd1G4WjDNGVNof4JUKAdnZZHkIGaiBQPMAIsJ55jcAE7KJ40EdHvEIACDFDWNWXVGr/ImgVxWkcJLGvMSO1Y5/0Ugc1ZRs3U+M4+DDHhne4W4J4P0j4BH62B1g4AGRggjg4/EA4UuDjCJ4whVM4aKfuBFjhBFCABDQAk4lCCpyUQB7wIRy2IrRmIoThMABNlqmxRTT2Ze84ZMt4SRP3mwd3ZC/mcau0S1q5Pmb5ljv3IUj5ZyfIk69MtB1CAzT3Mk/hAzyJBzC4PKRwXtNjAzwAB0yA962wDGv6pnN6p3u6ei5CdR96pV864sznIix6oz86lUuCoW9LoiOFpjCJI6K2LVqhhg0Ao/95IlCAkyi46hXiJxiAQK5ZgCECeaBKBajxITCsmew24VVZNXFuvNq5/4bG+XAndY3DeUoXN48DRa+baMrWnSKeV67374PIuoAnqju7bAeQzAOcC0wKzgHFE9KFQBMEQAuEiAscK0+S0c3mbBHANxHItxEglobsN38n/Bvl9/JeZbu/e7yb17yXzELfNVQjuDEyQMvkenjPui7qzGX4wmkIJLOz8c88bNnSKQC0eJW9+KUG52TP+FDTuR7Or5xne7dvO5439cb/t8ere8arMsavplNTByRRDyMtAHKZWSyUObeZ1RlP7iMxe4xPO99mtrVze83z4c1jO43rfHKvo9cSfTPrzVRDghPxpAgwsu3GAXoTAdLZLCaCgVRAzGINAU9iXVvXUcN38v/CQxTgUxQpp73FP3XZG/KUVAAjBU0E1NcqmEKiJQKkJsJPLuxJoEIsX/3o2rxw37mOz/xR4zzYc70fjv06l73ZD/05kYZfi0b4UpxovG2MM1csRwALcFt2sMqyx7ybh37WA6rvjz7N/36O33jxe3v22TDRs/t+MIKtUqKLiYBU3NNd7CyQFkFQ8ijE1B+xvoCM8b1pGXS0FvRBl//zov1hGP5185z/eEDLZK1DXzyUCMAHXAkALEAnzbYyOCoQAIQYglB4yAQAkEpBmBEsjEbB1HpVXrWA7NZa9Vq7YeGYDCaX00ZzGJ1ue+PbN3muvV/r4bx4LdyT++P6EwgcnDL/RKQ71HIY8HgYkFhMexzApCxsRFSs/DKMIJAyiBAaFRIRUJgqaJoqDSgwgDgV+NDi9PvrSxzsZRvUnQJWK/xFPuZNXhsOXlZeKyZsdq7+BB28zMT2emyo9OwGFAgwr7wwN1wJsNBQYTd3N1950TA3PynBDwgJod8XwIUAEPz4lTOYUOFChg0DIHQYUSJDiBMtWqx4UWPDjBs9Guz4UWRIkRsN4UN30Jqbld/GhXG5SNy4mdgMbdjASsEBITmFRFg15QCCKREMnGK1JMWrXMzgCHNqByo0aVOrUk2zcto0rVHdeBV07SW5sTVhDgA31hHacCtZlq2CIIIrIxlqASAg/+CuEFpTMmwAUICFk1kp9uoBu4VrYjxWn2I9wxiLY6mQv1oO20zyrqxu3740642t2isxO3lmZAg1DNWtXb+GHVv2bNq1bd/GnVv3bt69ff8GHlz4cOK3K7F2DVfbaNJTTAtDnSt6UUMfpDBFBWCDgBJGXDkxUsEUBARK8uK6fFV91s3EKPNpTyW+Mc2YFb/P/Lj++sqdSYeWqSXmmgNtumwKPOqApAAwADwFBNDACOumIKAIABA4IIDtiIrMvsai0S/EDvmDD8T+REwPxfxGVPE+E0skkZH/DKSCRgK7MQQTHXfksUceTzpnkXQeEuCfE0Qwx4UTzNFAgCXNUcECfv80mKeEJVV4gYV7HCKpJI269BKjML0Ec8yIyjSTozQ/QnPNhICcxogh1RHARzvvBPBGPROxkawC5zrqibswECBDITCcQgHAvivAAsP2a/FDSE+kNMVKV7QUxkgR83CyFzEFlY75qPFPrTyh2zNVGZUrEC8pADAqvAoIWWBBAIYS4gMMAPhAgF0n1fRSUTvljD1i3fvUxRiHXVZSY5v1FNhQnf2MVZr6VHUTUyFKich2tgwhIBUEIIBJLfmxQIUAogxAlXgkatNNkOT9kt6L4rX3oXwnwtfefuWFs1s6rc0221NRLdAnvhwUwJQACPh1CPQwdCWFCJOlNthMp4322U3/i2VR2Iy96OpY+Uymz2ORO662VZcLNhjbg6uxq6ekCkghAyFQCFSI77RjpdcNFkOZVJU15viLUYmGFuSNlf3Yl6KZjvqZUgm2CVuYW8aRWyHplJIedQMoQQAXzAmXH30CoFIDd+vd98y45Z5bzbopuhvvvBX6182Av8Zn5qu3DsMDHdPSFutPDHk1Vr5mFcIC8G7lsEIGU3AYP6hXVnpqzUfe/GnQR+e0aWSlDT1pqU23+gytBXd9EMMxQZw0DtiaYMDYFW/LiOyAQm+DE6ZAoJYIZs3rV6o5P/1o1VsPGenUma065eift150lqVvynOxeA/wj9vByb32lxLgxnAO/xAuECUjJLjkAROEmD2tIeGcJ4AWBEAhn7HJboE5QCACFBDEI33z2974psA3MXBeDgwcBCMowb8JAX6YkB/9aCeEOREJfFZA3yQAoL7mkKBHD2DftcjwgBGMcAIMkI7NjJACDrkiCz/bgM4QoBfoac9p2ANAyVgHiKV9bntAFGL1glhEjB1xenrQBQtdCMNVqTANJuQRCkkTwvn17oMAkMAEOiCBASRgVQq4ywKiIIQFYCALugpMKbZjoeyRjImoI90Pqce8HtrRe3h0Yh5Xp8TlcS+QB9pCGMdYRq4tzhlcTJUkKCCEBngghV1TzRVIiL5LpAU5xQFlKEU5SlKW0v+Up0RlKoOjyQGsj5MbBMAnM/myFQ5gkgCo5I1GoCMHdOCSWSMDBTzAgAEIwYRdJAsGGhcUWOlMCYiKVV4A07zrPfGQnRui0aopyD7u0ZB67F42CwnEcVoTnIjcgjCJacwBILNGX7TCLjHRS8INrmvuE0IHbvmASdLThJS4XznyFwIBjK0FAbESPQhowJFIUB0O1ZdDEbimiaapoma6aJgqCAB9CoGfAPCnCDsIu0bWc0ZbMKEVGsBIKGqBAZIYQAYTkDt68klB4ekZ5DTQIMoBAAqHqaM3yWnEcxZ1kHwMajgJSVRqfvOoTu2mUpGqTZIF4qUYnN9MB1BTdE4hpVP/WKkZu2rSk17hdsU0QgcwIdaxtgWNPVmjdtBTAguJ5wDMNOrJxMnUqF7zqUNtYl6TWrqlBrapSLzj7nh31imolaV8IqueAIQ+I5DAASZkK5/wOYiAhi0AJ4CQ2ATYP38EAAT2IBNEM6pR1bZWoq6F4Eb/MNJDUNaYl33sOyNLoBxhAoRoRV8CTPBYGeiIpFV9VQGYOYufgABWDVIjHQW7xD86z5yHFep1+4rNwgJyuuXk5mC5O9ViHJclOvqtEII7XLYWdwDm3a1i0ztCHmXWT9cCD6F4AgAM/IoA3fkLACrAFL/qtbvWDS9V/bhXw24Xu1KFqnj/ql0JG5i8iQOf/21npyP7wje+Vd2CbY3AXulsdrZ0wgcLWJDiLblDBAXJS0BS+1oaUxC2sb0xA2W7BtqGGK0jzu19P0xMSOSOA5r43hTOOgBfCoHELXUZBHwlBAgkRUEBKAXOIEdh6jLYuw8uMBGru80wKzi7CQZvmdP8XQzT0ghLbjIAngzZNBDZA0ZG8liITD5I/NKRrHqQg6a5ExfgQpoR7vKByczmBlfY0Ym+cKPNnOAkTrXSEfZwDN28hT0DIHeWJA2RSQCA290yyfcMEiICyrYXvCtsVArAClSggRcUBKM51jGuFbjaGduYgl5TtUrgKQRRk9qWzSk2BY7d5q4pR43TXAB6ov/dKLwUytKJXTSYp3tpxI7Zh9oGt4URveZwOzrTULYiGZK9bLWs29T2BGarDLDlDJjCpxFYAAFwxiFEc5vL/qY0tr/tYIKL2csIVjNfH13e1/VJcO5GNiZGrex3yxeT8JWlKjW+cY533OMfB/nHj/OaYQMA4qGWOAAo7mcvXqtX9s6OMiOQhBT0rN8CX7CiB75whU+6zAD/Oc7PnPBTN3vTLk35yj9M56MHiIZG4KmAC2Cdsr3q2t7OeaS/XHCfj3fcPd8K2EcFdMGeu63hW3rJO2NiHtOJO+YQwZNUsCQpqRhgut4br0ui94bWGMe/Znsaetz0tJ9mW3BJgRF2IgT/RSlIjVa/+sGzzXVyU17sRSN7uSH9dUmHvejxTnfhQR/6rKGHuXwBwE4Q8ILJRV7nWef81nne+bELHcKAlX3Xy212phtd9KNHdZw4SKexleAfAKTSuI6fQL87kO9swnvenn9AiQKbs8Im/O/h/eeXleIJ+P7Ag1BQe6wPndG59zz6yS/5neue65kvOO91S3rtsxzt3dgOGGb+k6PYZRXpR7jzC0DNq7zZUz/Msz3C0roBtLzP4z76qz8HDJDAI4N0KCCEOChzqBAUsIC8QBJ6mT6TiL67CUG48bUTdD7rO7HAcTitGYvcwYRhsj/Dc5meaRBlGjD3ezT428EE9Drc/2NAAwxCHSRCHixCH5y/7GO2MIBBSKAi0jAhB4ChBjCf87qTK/yRFgQaKtMZA7irXQHAyRNCMSTCAizDy8smIzTDMGw/NqyiAsHCOHwva4jCKazCcbgdULu/a9msC4opZAqr4fOWEzAoF4AH0OoffxnBuinBe1nEuWlEMQG8VAOj+AFElho8CNSCPIykAWihltNEI5AijlorUKALIZiVD9iAnBnDNly/1zM/AkRDJVLDWXS9BSypKRhFx7IvIQM+L5CET9QTTgRF39MCRQIAy8IsUOivnsCFCtiOV3HDWGzAA0xDJBQ3ICTDabw9LlvD+TgVZFTGIPPFByQDYtSTOv/EpTt8w4vbg00qoyfLuJCjx3q0x3vEx3wsJVZypXhkqXlUO3WkwhuZgEuQwSU0Ry0Qpg0rxRrRmThKPQhIgQXhRgWMvSGsyB/0Rlu8ufLrRjTjSOw5mIWsL3QzRjIoyBh8wrSTvyAKhI4CgI9ysiC7iSHAAFeIxmrEyFfERVdEQI+0SG30yWsEyt5Lq30ytTkzyoSMQAk8jc26qj8EMrFaNXnQALoCrS3Jl0jkl0eMG66EF6/cF7DkEuuLygyaSarEvlBsynb8RS/av1JgRZ3cRp68yLr8SfaDPaHcy42kPZRpSZdUu7YsR6b0IuuIAAR4Nln8S6LUS2psxb4Eycb/pEVsNDhYNEm2REjCdEtHosAwqEopCZd6YESx3ErTVMTmy7VJFD4AyMST5EwQG0wQ84lSwKvIhMwzpMxbvMuhrMyinLDJtMbqCUz5C8wPa0njrAI0qjL9EkC8dEzMDEq/HE7e5MvczMjgJLrtM8w9XLoNY8fObIvP9IKA0oAVOwEXsIAVK03V3DXUBEH4vDvWFBgPUsIpAM8bGR9P051c9E5HaiMGAZ7t3Mm8lE6NFM4Cjc6elEwChU7ibDi128/yaY4QogQS2syvMrat6kXBRBDwywt7Y8zq7MjH/EgH9U3rpE4F/U0TPbtirKwfOysH6EXBsVD6Wh8oPCE/Y6x4/9IiUCDPLQgodpA1FvAsSJRP5kNB50tSiqq+INWC13wz3/LRzESpHd0iTHAnlhMxIxAmTbuWBZgFKYuYEWVRFU3QB0VTFG3Q50zREj3QJNTELhWCL33RKYCkPZEkStLDzkAvPP0xUpwAZHKvOZwlRJhHfVTURWXURnVUjxs51/hTI+hStRpUI3Av2NlTXOpTtZCnrYoz7qRTXJoAMG22BplLNsVOu7zOE3XTNjVTNYVTBl1VwIxQLRjVBijVO40nXgrVpZsstDKBDBoBBzDVrIGAv4grVXXVWH3TbnNRBGXW6UzTZ/03yyzO2hJWYjVWXo3NwoQzCVC2AZiADt0xwf+jk4OqB61szyVdTXd9T/fMuyelxBUcGLPSkTEa13K10m/tVxhtiwa5zVet1QXtTVilS2sNOODMxhWVVZG8Vc301+RsQQVYTIdV2KBj2Muk1WZNWITFTY8NWWqd1qV8y//0V2+tBii9goBSARBgz3mVV+lrUouq2VujT8C5V4n9VoqFiwFtVZIlWJHVTRKF1jht2GoF2aI9U0yLWNhMWZMF2AAhFKAaWqF11qXNzqQtWe28Wmn9Wq/N2oKF0LLi2dikWJa1goAyUiadWRK82TEhSy6JWzJRwbZjwdlsS58tkCk7WLJd07DlWsHl2L8l2q0t3KAF27H916mlwag91pP/PY2G6Vis/VjAnVXDtdyRXdzLPVxWxVjxdNwZTNm0pUQ/JFZMeCFBNARbe9e/g1eZjV2afVtItD7UnR95Wl3XXEuohVwPVUIpogAYooCKYxykTdzQxdyjrdzO5Vyx9dzNZdqHpbCDEV7irbjCRNnf5dtEEqMpGAHjFYDWU97PNdDmhd7nHVzGlV7E3TzFTd/plU3vDdXwjdzRLV2ZaQ1+xFMH6KJEfdQAFuABJuAChg3+pVT/FQKAvM+e1d9gArUO2F0jkDJncN9a3M3Mhd/1jV7nlV+tBV2lvd8psFMJXkmpfdzfReEUPkqPmiQOeIA8k9Pybd8Q7loOVt/kFWHz/zXYDdbhGwbexkJKUovh+fVdyDXdMThLExiuHZmfqnTb2YXb2kVSKv5KelVimJKfJtaRJ+5dyY3a3pLDK1TOaI3fC7bM96VhD0bjjVXjHa5hW52RMSZjF4yv7j1i9mVjGybcNwZiP+5jDDbaa93YbNXbpkziboGT141i2HXkRoZkRt61u0XXvG1gtH3gBm5jM8bhD15eQubkHw7kNBZki8vjzUTiTObZTUZeQNbjM+bjV+5kVkbfWQbHpwXj/N0WtZ0CKJbkeJXidn3kX5bdFORlOfni7kzlw9PkWO5gWD5fzd3jaPZhV35mW5ZjZj5bzsTjXM5ha/7mUqbehQ1lcP/2ZB5uUeQ15EvmZv09Ztad24WIZ70J5iqu5yu24q2k5ApMZvydWFU+5XAm5YF2Y3HO2G0j6FBe520mTIo91EEAYAOW6Imm6IreuEjdX3ZuaID25nOO4x5eY2gGaTie5pH+Y4MW3e1lYRUO4oDmzlEu6IRuZZT+ZHKeaWzFZWUOY3euV7xdZGAeZqCOZKEmZtqNrX0GzX5W6Z3WZpemZWkW6XSuZVGWZaq+ZqsW6ELOaX924Cs1At09Ye1daZKO6sCtanN+6mqmaXQ266teaCvQULBuXKbG1x8bXpXLXpd8Z971lqAu5qH+66Ke4nvW572WUiHoUZXD3rnWZVwNVCH/sF/GdsqrRmtnzupyXuuPlmqoxuYhemtAvYLIXuH8nVT1euwEUGAhKNQyvumYdm3MlumprmxqDmmxDpDSBgA6RW1CxYTjvGNtbawJBtKeruSfDmyiRu7jVm6j9msSROryVOpKFe4ZVuFgfbMiTmlUPuvMLunNVuvY5mys9ujuRqrPplQZxW7J7uq6ZjIu1lL1NmWy7mzvrm3xTuv6nm2ThmmF3mo4c+92UllM3uXTtcTcfoTd9eXkZm7AXnDBFmYGZ8TbLXDUJlcqOmyuFnB4kiIHAIcR+FHbpmzuLmsNxm8Rn++2vmx1jqIW4nAA8PARHmvu5WgrUCRiogQ6FZz7/5Zv+7bs8R5x5g3v/KbvHQ9HMbLx3H5sEJ/sf96Wh9agfjTt+Yloi6byKrfyK8cN/rUt9JFyktPovZ1xK1AnEcJxC+5xHT9p8P7u125t/obgIx/Vltbpxj46mPyoFn/x0U5x2TZxHqftHRdyFPfxE3daLbDzfurwD6fupaZzPqTEJTbwCodnwj7NfK50Sk9NTAcYs9TirDpwC1fqGF/mQ1ZvNN/vNkd1PlfzEsdps3XpDP9yGN/uVQf0Pg90Eq91Wgdi88bwdh7w1kzw5R7s5h52CH9wB//K5xbSUCddJid1lTX1WWdzVZ/2ILf1Pud1Rnf2WC/1M/f2P0/zal9z2P/WalfvaFh3dGBHMWI/dgUvdmTHZ033G2WPUmbX7kZ/df+UdnLn91S3dl0/9anOdlGna26H9m/X733393FfeFYv96Y+93bG8omn+Iq3+IvfDZYGBYzn+I73+I+f6MTT+JEn+ZI3+ZNH+ZRX+ZVn+ZZ3+ZeH+ZiX+Zmn+Zq3+ZvH+ZzX+Z3n+Z73+Z8H+qAX+qEnenIk+qNH+qRX+m5YsgwKMpYyev2cpw7dmvrZrZWKqbAuGBOg0Xy6hF9VFa4XK8dqyK3v+tyGQWHMFrn2qPAkkKjs09tZes7kAEuCH3aEeqrfkzwnqzvT+q0hpilU9ILBerEaAV9qgG4l/IaUYJP/KnyPaqFjgpm7Ll4k78896YAWCnwNSvK5/726lzMpBIAyCi4eGS6YAns9sVOTIiO9hxkTgqEjN6kgs6x6Yimyd/sbYalIYICZkuG1NzUOyP0bISMY8vCV8vy2bHpfIv3RgHpw0NVssdQt3ZpXuvzJnycRmv3MMoEJGDXCCTK1+ns9YakEeADDGf4KTW1SS//m4IAW0lUTUKvkb0rQx6VJaH4jyHuO2lUgAAiHxKLxaGxMkMymk8gYCEkD0/OKTTqyXOcgMWQ4Ot1y8WtEm8tqBwkgca+7nQmDyGnMu5KHRzgxICi4V2h4iJiYxfEH0OAg8ZUgJTTwBoBWp0hk8mA1/7K1eTUGQCUhipXgoIfapKZ014qkRkHWASl7BgbgMAIgdpnL8XCKx5oLoEpW1EGJ/AwdvTg4QSbp7CFokrmEKkEhOLErLZQQSEoulD1wHN0w+Bc4uJz7Lvhnj45sP/CnKugL2bZBVSaFe7bu3pBm6Ro6fAgxosSJFCtavIgxo8aNHDt6/AgypMiRJEuaPIkypcqVLFu6fAkzpsyZNGvavIkzp86dPHv6/Ak0qNChRIsaPYo0qdKlTJs6fQo1qtSpVKtavYo1q9atQbNxeBbF0hMTgehxPYt2adhuhahMKLbp3QMhYYM1mYQrrd69Q0cMsruGA7tWcukKAswEXEC+jP8b5zzXbwiJBwMmBAr4SBAFuEK2hfoFMBAHBoInWAFQR9Bo0P1ES6AyiEJYD67hgBP0eRJbx7x7uzT4LlScAWQo+3r3FRyFIlS+GibOa8BycF/dSsArIayeQPgGzGW9PbLxIw6q+D6P/qTX6GSCCxlf/k2zz0LeNWJ9Z7zfuYIbBWpQFwCCLVcYa28MGB0HI3AGQCCxpAdhhByVp8d6+703wIIEDcKZfWEIkl+GAFw4HgDGBaicI94990aK/AzgHCADPChhjTZGBBtBkLzTDXzQIdHchzOaKOKF/ckI4GEAuLiigUtKN8QI64xT3mk3XollNNQNQWFYCUhw2YjenUKbQoydDfBZWCH6cqF1umWnZIrznYIilENgV05lWe7JpzcUDgHOXLfA+F998ohYhGCsqEkkm02mBuMddS4noGaTRjIIB8Eo1mennoJVHo1NWIcRnp+eimohlAnyAGJNrGcRWT+mSmuttt6Ka6667sprr77+Cmywwg5LbLHGHotsssouy2yzzj4LbbTSTktttdZei2222m7LbbdZBAEAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_32_33281=[""].join("\n");
var outline_f32_32_33281=null;
var title_f32_32_33282="Rash - Henoch Schonlein purpura IgA vasculitis A";
var content_f32_32_33282=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Skin manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows the classic skin manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis), with clusters of typical ecchymoses, petechiae, and palpable lesions on the legs in a typical distribution (gravity/pressure-dependent areas).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Susan Kim, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_32_33282=[""].join("\n");
var outline_f32_32_33282=null;
var title_f32_32_33283="Penile blood flow in erection";
var content_f32_32_33283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Penile blood flow in erection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 317px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE9Ae4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKK4jWfiboGkfEXTfBl59q/tS+VSkyopgjZt2xHbdkM23gAHqKm8W/Enwt4Y0rU7y71azupdOyJ7K0uYnuQwZVKhC45Bdcg4xmgDsaK52Pxv4Xa1064k8Q6RCmooHtRLexKZucYX5vmIb5TjPPFSXnjLwxYz3EN74j0a3mtyVmSa+iRoiMZDAtx95evqPWgDeoqra6lY3d3c2treW09za7DPDHKrPFvG5N6g5XcORnqOlWqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArkfH/AI4svAzaRc63GyaPe3BtZrxckW0hXchZQM7TtcE9uPw66uK+MvhVvGXw01zRoY/Mu5IPNtRwCZkO9ACemSNv0JoA7GCaK4gjmt5ElhkUOkiMGVgehBHUVJXz9+zzb654FhuvCPjDVBbarMFm0rTLvBiKEZcxSgncdxIaMfdK5wQ2a9x0XUf7Qtm8xFiu4XMVxCGz5bj+h6g9wRQBoUUUUAeO678EYdaudf1S71+6HiLUNRivrS/RHVLIREeUnk+Ztk2ruUM3PzcY5zal+DGn3WkeNYL27tpNT8SXMs41FLBVltVcq3lqSxZk3LnG4Zz2616xVC61nS7OYxXepWUEo5KSzqrfkTQB5PrfwaPiDUHvrrXrS6mms49Pv4Ht7lbabyiChEcN1GQQAuVZnGeQBWr/AMKk0uCDxvc3kFvq13rqyGL/AEZUngUxbfKSVmJ5IBySBnGfWtXwLr+jxN4jWTVtPQnWLhhuuEGQQhBHPIwa6j/hI9D/AOgzpv8A4FJ/jQByHwK8H33hDwNFHr+W8QXr/aL9mcOwbAVE3AkHaiqOCRnNeiVXsr60v42exuoLlFOC0MgcA/UVYoAKKKKACioL28t7G3ae8mSGJerMf0HqfauJ1z4hWtrdNZwMsN1gHyjG1xcgHgH7PFllHPWQoB3oA7xmVFLOwVR1JOK85+K3xg8N/DmPyNQke81h03x6fb/fIPQu3RF+vPoDWR4i1TUYrD7VdabNpyyOEW+12QTTyv8Awpb2UDne5PRSU6ZINc9afBy28c3smpfEXVNTuNdcxTRWj3Cl7W2DZ8twg2AvlshQAueMkFmAO/8Ag1rPiLxV4dbxN4mWO0j1Ih7DT4lwsFuPuuWPLM/XJ4wFwBkivQKZDFHBDHFCixxIoVEUYCgcAAelPoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiuT8d+Lz4RuPD7XFgJtO1LUE0+e68/Z9kZ/uMV2ncpIIPIxx61i6B8V9J1Cxur/AFCJrKxbU5tO0xohJdS6iIvvSJFHGW29em7GDkigD0aiuA/4Wr4b+0tMNSs20UaR/a/2tPPaTyhN5RPliLG0Nx9/fnjZjmtfS/F+n+Jl1S08K3sb6tZIheK9tZovL8wbkZkZVZlI5BHBHegDqK5jUfHGjW15JY2Uk+r6lHw1npcRuJEPo5Hyx/8AA2UdKrf8IXJqgLeLtZvdYDdbSI/ZLMe3lIcuOekjP2rp9OsLPTLSO0020t7S1jGEhgjEaKPZQMCgDzPxNpN54ytJdP8AHulxaVp88gk0q8hnD3VjOCNhZ1+VGz02lgehNUPCeu6pZeJU8KeNJ0svGEUeNP1ZVxb61AvTcOhcd16jqDXsFzBFdW8kFzGssMilXRhkMPSvGdev/B3jDULrwHqWrC6ktmD2GpQsRLZTgnCrL0LqQOQT6NzRa4HoGo+OdH0LS57nxRdRaVNbkJLDISzMx6eWAMyA4ONoz144NeK+KP2idRuGki8K6NDaxdFutRYu5Hr5SkBfxY+4rptJttf8SeH7jSvGvh+w8Q3ekXD2cl9Fdi2kDIAcsGGPmRkcMDgh+VUin6Z4FtLRhd2fgG0kbGUku9ZQwqfUlVY4+gP0rSm4L4lcTueJXmo+OvHtxsubzWNTDHIgizHD/wB+0AU/Ugn3qaP4M+LFQbPD4UHnGFFe6yeJtO0DUrabxD4r0+2SDPl6ToUO2HJx/rXJJkxg9Ng56d6xNZ/aFs4b8x6VpT3Fqpx5kj7S30FdEak3/DgKy6nhsfw18RQxatO+iu0dndGKbaobYdiNj8mH51z0lpHG5SS3RWHBDJgivqj4UfE3w9qmqeI4prkWU93qf2iJJzgFTbwAjd04YMO3AB74p3x00Dwze+ELvUEewt9Sgw0TxMoMhz0OOvenTxDT5ZoGj5Wt0FtcLPa7redeksLGNx9GXBrs9B+J/jbQyv2TxFd3MQ/5Zahi6U/Vn+f8mFM+GvhODxZrq2l7qENhbAZaSRgC3suepr1fxN+z9H9hE3hrUmkmAz5c+MP9GHFbVJ0VLlmhK5F4X/aLcSRxeLNECoThrvTWLBfcxNzj6Mx9q9YufH2hT+FjrOj6tZXFu4IWYvhIiBlmkB5UKOSCAeg6kV8q3/w48W2NwsMuh3jMzbVZELKx9jXtvgD4YaP4c8Jxaz4siCXluxvZ0lOIl2D5PMUff2n5gD3wcZFctenTik4Mab6liGz1PxXcxPIt3bwXIMkEchMV3PD086eUfNBGxHywxBWIHLD5gEnsLTS1srXS7ZbiKS4KWGm2qpbR39wv3pCEHEKYy0jbiexOQGn8N+O9K1vwhrup2qXtgsEgXUbu5cu5h+Ygo3dyPlVFxhnGAe+n4J03Ub65uNRmjFlfzIIJZAA32CAHKWcHbKjHmPyC+euBt55RcXZlFSJobbxZaDWNVEviG+Elv/a0luwtrVsgfZLQn5Ec88klm285OFHpmmada6bbiGziCA8s3VnP95j1J9zUE+h6bc6G2j3VnDcaa0flNBKu5WHvnqc85655rlfP1TwGdt493rHhQdLk5lu9PH/TT+KaIf3+XUddwywQHeUVDZXVvfWkN1ZTxXFtMgkjliYMjqeQQRwQamoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACio4J4rmFZbeVJYm6OjBge3UVJQAUUUUAFFFFABRRXN+PvGOl+CdBfUtWcsxPl29tHzJcSdkQevqegHJoSvohNpK7OkorxTw58ebKe3jHiHSZ7S4P3jaOJUH57T/Ou+0f4jeE9W2i21q1jdv4LgmE59Pnxn8K3nha0NZRZz08ZQqaRmjraKZFIk0ayROro3IZTkH8afWB0hRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGF438L6f4z8MXuhav5otLoLl4WCyIVYMrKSCAQQO1ctqXwe8MX/hfw7obpOkOg5+xzbYZX+b7+9ZI2jfceTlOvIxXo1FAHmlx8GvD89tPDJdX6LNpLaM32dLa3UQtcGcsEjhVA+44yFAx1BOTXSeG/BWneH/EOp6zZzXb3WoW9tbSrK6lAsCbEKgKDkjrkn2xXT0UAFFFcL8ZfGx8DeDJb218t9VuXFtYxyDIMhySxHcKoZj9AO9NK7sgPN/2ifiZd2dzL4Q8OTmCYxg6jdxth41YZEKHsxXBJ6gEY5OR89WpNqYzbfujHjZt424rb8N6DrPjLXpIbQS3uoXMjTXE79SzHLOx6DnPtXa/Ez4WN4L0rSbn7aLhriTyp8DAVvb1FelT5KNoPdkO7Oi1/wART2fgTX5vtEiXmorp+5kOC7GDaxP/AAFEB+grx7+2dWjsha/brtbVuQnmMFNfRvhvwPpnijUtQivHuJNL0/7JB5aqVSWZIBvGSOQCwHHHJFct+0ho1nY3Hhyw0e0ihyjIkcYwTzxnufqa58PUinytbjaPCiSSSSST3Ne4fBjwN4P8RaIW1m7WbVZWKrbrLsZB2IB6n/P02fAnwRtLfRbi78Zssc7oSqhwBAMfeY9Pwrkvgt4QF98S7jDiWw0t2ZnU8Pg/Lg/XFa1a0akWou1hJWOc8dfDq58N6n4kutNZp9KsdRS2LnhkJtYJRn/v7j8KwPD2iax4nvlstMhnunJG4AkhR6mvVPjf4nSw1Lxb4ehXMt9f29xJ6BRaQrn6naPyFen/AAF8MwaH4Htbvy8XmoL5srHqBzgf1qI15QpXe/QdtTiz8CdN0zw5Ne6jq0yXsMDSsy8IrAZxnr1rz/4bfE3WPDOsW1pc3z3OjmUJJHId2Fz1Unp9a1v2hPFt3deMbnS7O7nSztkEUkYbCs3fj61H8LfhC3jDQpdUvb1rSFiUgCruLEdz7U4/w+as73DrofUtjeW1/bJcWU8c8DjKvG2Qa8t+PfhvxDr+lQR+H55pIWZUuLFQoE/zcHd1+U4O0nGORgg58fa+8QfCDxkllLcG5t4sOIgx8uRD6CvpLwR4wsfGGgnUNLUmVBiS3LDcj44GffHWsOV0mprVD3OC8SaJofw7+HujxXtw7T2DtcxxIcJdXhXiRx/EEYgrnphe4FeJ+A/ihr3g7WDc/aJr/SJ5TJd2ErFhgn5niz9x++Bw3cdxa+M+u63rHjO4stYURG1fy4rdGyq/T1+taGufBrWtN8KRa2k8EqiETTwk7WjB5/lit4wgo3qvWQrvofVum31tqenWt/YTLPaXMSzQyoch0YZBH1BqzXzt+y/40KPP4Nv3JUBrrTWPYZzJF+BO8exb0FfRNcc4OEnFlHK2vhaTRtdW88NXKWWn3Epe/wBMdMwOT1kiA/1UmeuPlbkkZ+arV14x0G01TVtOub8RXmlWf2+8jeJx5cGM+YDtww/3SfTrXQV5J8afhfqXjjV9LvdD1GCw3QnTtVMjMrT2RkVyq4U5YENgHAO7qKkD07RdUtNb0m01PTZGlsruNZoZGjaMuhGQdrAEZHPIp+n38N+LgwJcp5EzQP59tJDll6ld6jevPDrlT2Jrxf4gfB3VNd8Yy6lY3UT6Wba3htbf7YtpLp5hxgQyG2nKgkZO0oTkg5FSr8ItTm1yKfUX0i60/wD4Sq91uaCUs4ktp41VUKlMF+DkH5fc0Ae20Vxfwe8Lah4M8A2OhatPBPcW0kxDQOzoEaRmVQWAPAIGMV2lABRRRQAUUUUAFFFFABRRRQAV4p8aPHE9xdy+FPD100O1capeQnDRgjiBG7ORyx6qCAOTxufGjxvc6HbwaFoE4i1u+Qu84AY2dv0MmP77H5Vz3DH+HB8Qs7aO0gEUIbGSzMzFmdiclmJ5JJ5JPWonK2iOrD0Od80th1tBFawRw26LHFGAqKowFAq4l5cowZLiZWHQhyKr0jusalnYKo6knAFYHp2L8er6lGSY9QvFJ7rOw/rU8fiLW4xiPWNSUei3Tj+tYH9oWX/P5b/9/V/xo/tCy/5/Lf8A7+r/AI09SbROmTxb4gVQBrWoYHrOx/masL438SKQRrF1x6kH+lcbcavp1vHvmvrZVzgfvAST6ADrVKbxPpqqfJae5b+7DCx/UgKPxNVGM5fCmzKpOjBXm0vWx3t98TvEOl2r3VzrLrGg7wxtk9gBt5JrzbX/ABFrHi7VF1XxFM0s6J5VtEVUCCPOcYUAbieSfoOgFULy4uNUu47i8jEMMP8AqbcNuwx6ux6bscADpzzzS19Bl2BdP97V36LsfGZ1mkKz9hh7cvV9/wDgBRRUUommngs7QgXFwSoYjIRQMs/4D9SK9WpUjTi5y2R4VGjKtUVOC1ZveBNVv7LxPb3lhI4s7CXzJU3sEmlx8qEAjIGcn8B617VH8X9TBPmadZMP9ksP6mvKdPs4dPs4rW2XbFGMDJySe5J7knk1Yr5DEYmVeo5s/R8Fl1PDUVS3fVnqkfxhugP3mkQMf9mYj+hqdPjG20b9DBb1F3j/ANkrySisOeR0/VqXY9jX4xW+Ru0eUDvicH/2Wp0+L+nFvn0y7UezKf8ACvFaKftJC+q0+x7hH8XdFOfMstRX02qh/wDZhU6fFnw+y5MOoIfQxL/Rq8Ioo9oxfVKZ78vxS8NkDMl0ufWE8VZs/iN4fvtWsdNsZbq4vLyQpGkds/AAJLMSMBQByTXzxXpvwA0D7Vd3/iu5TMfzWGnZ/uK376Qf7zqEB9Iz61UZOTMK9CnTjdbntdFFFanEFFFFABRRRQAUUUUAFfHPxr8W/wDCcePymnyebpenE2Vng5WRy37yUexYBQe4QHvXv/x+8Ut4Y+Hd4LWUx6jqR+wWxU4ZS4O9x6bUDHPrj1rw79nnwpaa94tEl2U+z6cgmEP94g4H4dK6aCUU6r6CfY9w+C3gH/hDNGea82tqd4AZMD/Vr/d/ln6VznxokPiXxv4a8I20qrmTz5zn7voD+Az+Ndh49+JmheEoZopLlbjUgp2W8fzYbtu9Ofxr5ZsvFmsR+MT4li3T34lMmWXcBntRSpzqNzYm7aH2vp2n2umwGGzhSJGbe+0YLtgAsfUnA5r5l+K+vfaPjbafaHxa6fNFEuDnGD8365q/H8W/iFNam4j0dDBgnzBbHAHrXjFzqDXerG+v5lDyzB5JJGwBk9yaujRabcuwNn0l+0x4jmsPDdjptlMVF+xaQqeqDGOfTP8ASuB+C3jfQvBWgazPemR9UmI8qIDhgAeM/Wp/2hdX0zU7Hwy2m6lY3ixwbHNvcJJtOBwdpNYfgH4ZX/iBg5txLGQMsWKxR/Vh1PsKIcio+89w1ucBrmtz+IPFur6tegGW5nWRl7Y2gAfpivrHwD8UPCt74ftIHvo7Ga2hSN4p/l6ADIPeuDtv2fnGpai0k9qsDCPyGDSZPy/N3459a8v+Ivgm58Haj5EzB145ByBkZBB4yOvYdKd6da0FpYNUZPja9XUfFur3iSiVZrl3Dj+IZ619Nfs4Xy3Xw5jhAIa3ndD79Dn+dfKdhY3WoXKwWUEk8zHARFya+x/g7oU/hr4f2VrqMQt7k7ppVIwVJ/ve+BVYq0YKIonhfxC1rS/FHxmtor63lfTY5Us5FU7XYZwSPx5rb1RLz4F+KDLpwe/0XUozsWXjDA/dJHccc+9UPCTaR4s+Pr3UipDaLM8sUTYAkkT7o/E847175498IWHjTQjpuos8YDiSOWPG5GHpn2JrGclFxi9raoZ8ba5rVx4i8Uy6peY864nDkDoOelfad1BHdeDZIJ1DRyWO1gfTy6+TbTwbBL8Vv+Eas75ZbeO68sXB7gHnp37V9TePb+Lw/wCAdUn3bVhtDEhPXJG0fjzVYlqXKohE+P8AwTqf/CP/ABG0HUUJVLbUUjfHaOQmJ/8Ax1zX3NX5/wBixbVbFmOSbuEk/wDbRa/QCjFq016BEKKKK5CgooooAKKKKACiiigAooooAKKKKACub8feLbPwdoL390pnuXPlWlorAPcykcIPQdyewBNbWqaha6Vp1zf6jOlvZ20bSyyucKigZJNfL/iXX7vxh4hk1u+R4YQpi0+1frbwZzkj/no+AW9OF/hqZS5Ua0aTqysZGrapIst/rniG5WS+unElxKo4JxhY0HXaBhVHX8STXLXviydgRAlvZrnAM7eZKfYRqevtk/StfxjGJdDdJAvktIglkKbjEm4ZcD1HXPbr2q7pdlp9vbQHT4rfy1QBJI1U5HruHXPrU05wjrON36nZWpVZ2hSnypeV2csB4j1Fjg3aIFGC5W2GT64Bb/Cnf8IpeswedrGeTrunMkpz9WzXa0VSxU4u8El8l+pDy6nNWqylL1b/ACVkcd/wjN7/AHdM/wC/bUo8L3hOCdMQf3vILY/DI/nXYUVp9fr/AM34IzWTYP8Ak/F/5nMQeEUVg0l9KG/6YQxx/wAwT+tZksa2msXFnBdPcwxoGYuAWiYn7pYcHjB9RW94h1o2bCzsAsmoSLkA8rCv99v6DvWDawC3hCBixyWZ26ux5LH3Jr0csjXqz9rKT5V+J4eeywlCn7CnBc7/AAJaKKK94+SGXEyW8Ek0pwiKWJ9q2vDGmyw+Zf3ybLudQqxk58mPrt+pPJ/Adq5+7ZUuLM3Af7GsyvOUQuQF5HA5xkDOM8V2dlqdjfD/AEO7gnPojgkfUdRXgZvXndUlsfX8NYWnZ4iTvLZeRbooorwz64KKKKACiiigAooooAhu47i4SOzsTi9vJEtbc4ziSRgin6AnJ9ga+sND0u10TRrHS9PjEdpZwpBEvoqjAz6n1NeDfBnRP7a8etqEybrPQ494yOGuZQVX/vlN5+rqa+h63pqyPKxU+aduwUUUVZzBRRRQAUUUUAFFFFAHzh+1pd7tU8K2Kn7kV1cOPcmJV/8AZ68q8Cp4jk1V4vCYuftkyGNjBkfKeuTXovx7aDVfjbpWnXT4tIrG3ikO7G0vLIW57fLsr6C8MeHdF8K6V5WkwRW9uF3PMSMsOuWb07+ldcaqp0lG17k2uz5F8e+Btd8KLa3WuAP9rGd4bdhvQn1r0b9nzxF4V06wvbXWRbWt8zAiWf5hIv48CpP2gviFpWsWC6BpBju2SXfLPjIUjsp/z2rybwB4dm8U+KrHTIR8sjgyNjhUHJP5VtZ1KN6mgtnoe/8Axc+KukWPh2fTPDt1Hc3lynl7ofuxKev5jisz4OeA9FsPCq+LfE0aySOjyhZgDGsfqVPUnniuT/aH8J6X4e1PSG0iFbdJ4tjr2yvG4/59a9D+IkIs/wBn+3hhmEii3gG9Twc8mueyUIqP2h9T5z+J3h/wbrfiFLjwKlxponnCS2sijySGbl4/7nX7vI9MdD9O+ANV8T2vhOwa003T9a0y3T7OIrXFlcxhOMBHJjk6dd0f0r5KBIIIOCO9ezfDP4t/2Bam0u4o2jdwzh2Iy2ACVboM47irrYbkScNQTPpqyuTc2MNy8E9uZEDmGZQJEyM7WAJ5HsTXjXxaktfGGlRy6fpN+FUiIX99GbO3cE8Lhx5rc8gpGwxk11lt4rtdY8VaHd293JaaXHp15cXAmkEa7vNgjj384PWQjr279PPvjL49huCrabMTFbqVtzgjfK3BcD0A6VyxTckluUeO6h8NblfFuqOPEtpaaBbRLPPNY3DOTkYaKNCQScg5JwADn2r2T4D+JPB8Sy+HbDTXsLy5XyzdzSeZNd9gGc855OAMAE8AV0Pwi+HljH4HuJ9RK3NzrUOXkK5Man0z3zz+FeQ/C7wt9p+LiacWYw2EzuzqccIeP8K2jCElK72Fc1PiP8HtU8Om81fSZxc6fG3mcHEiDPesXwf4w8d61qdlomma7eb5T5alm3bR6knnAr6u8UXFpbeH799QkiS3MLKxlxtJI4HNfPP7NFik/jnVbvfHm3hbavc5bGR+Bq4VOam3NXsK2pL4k+DWr+G9Jj1nRr6W91eCTfIkKkcdcjvx/n25Hxh428X+LdCNrqUDiwtSDMyRY+Yd2NfYdYniiy04+GNWiu4oY7WSBzL8oUHAyD9c4xWca7TvJXHY+GdP/wCQnYf9fUP/AKMWv0Br4F06HzvEOnQW+D5l/BHHz1zMoH8xX31WuM+JegohRRRXGUFFFFABRRRQAUUUUAFFFFABRRXlfxq8bS6Zbjw3oc5j1e9j3XE8Z5s7c8FgeztyF9MFuwyN2HGLk7I434u+L/8AhKtZbRdOk3aDp03+kOp4vLlT933SM/gXH+yM8bUdtBHbW8cMCBIo1Cqo6ACsvxFqz6bHFFbIj3c+7ZvOERRjc7ewyOO+awSlVlyx3Z6i5MLScpOyW7NO5uYLSEy3U0cMQ6vIwUD8TWQfEelxKqWzSTD+7bwsQPxxj9a5/T9J1HWmjvppMK43Jc3Q3uQe8cY+VB+vsa3k8MW4UB7y+du7eaBn8AMVuqdGGk5Nvy/zZyuvi6qvRgkv7z1+5DJfE6llW10+6k6ljJiMD8+tZs/iy6DEKNNiZuFjMrSN+Qxn8PzrbTw1pSrh7ZpT3aSV2Y/iTWjaWdtZoEtYIoVAC4RQOBT9ph47Qb9X/kHscbN+/VUV5L/M4VBfamwH/Ex1Bt2ScmGFSfrgcD6067i1LSIFknN9b2pYJlLzzApPA4POM+ldJ4g13+y5obeKOOS4lUv+9k2IqggZJwc9eg9O1c09wbyaOXUNRWeRX3rGrBY1bBA2r7AnqSa7cMqmIatCKj6f0zyMdKhg01KpOVTyb/4Ymt7eO3VhGDuY7ndiWZz6knkmpaAcjI5or6KKUVZHx0pOT5pO7Cobq4ECqAjSSyNsjiTlnb0H+eKmq74VthPqV5fSBiIT9nhJ6DgFyPxwM+1cuNxP1ek5rfod+V4L67iFTe279BkWgaobZJHvLcXB5aExEovsGBzx64/CqV7o1+QzXWlW11t5zFIHJHsGAOa7iivnI5jiFvK/qfazyTBy2jZ+TaOF0fWJNOiEkJkudMJO+I5MkHPO3PJA7qeR29K7a3niuYI5reRZIpFDKynIINcx4ls0stRgvoAFS6fyZ1A4L4JV/rwQfXI9KveDfl0ydBwiXMgUdgM5wPxJqsTGnUpLEQVruzXmRgKlahXlg6r5kldPrbzN2iiiuA9oKKKKACmzSpDC8srBY0UsxPYDqadU+k6QfEfiPR9C27or64H2kYyBbp88ufYquz6uKaV3YicuSLke7/BbQ30XwDZPcxlL7USdQuQRghpMFVPuqBE/4DXdUAYGB0orpPFbu7sKKKKBBRRRQAUUUUAFFFFAHyD+0USPi7qBBwRa2/P/AAE1o6R4c+JniXQrK0inuhpEiZjMk21CvaoP2mrU23xUEo+7daZBLn/aDyoR+Sr+de2fA/xbp2veE7TT7dil7YRCOSJjyQP4h7V2OTjRi0iep856f4G1O1+IOmeH9ZhEE80ybssCCueoPevrPQ/B2haFqs2oaVYR29zLGImK9MD0FeFftKWepWHjHT9btg8cXlBYpk6hl6/TrXMS/GPxgdGOmS3K72XYZzH+9IPv1/GnOM66UkGiL3x81d/EvxA/s7TDLcraKIVRPmBf+LH41zF54u8Q/wDCNL4P1BjHapIoCSJh056H25r3T4A+CYrHR18QarAzatdMWQyjlF9Rnua80/aThSD4iJJboEkkgR2Kjkt61VKcXJUrbdfMH3PSfDfwR8MxeHIm1lpZ7qWMO8yybAmR2rkX+E/hKDxHHE/i22a2ZxttwQ0h5+7kHHt/nFc/ovhr4h+PLWIyXF2tlEmyOS4kKLgdhXa+CPhJaeFdSh1jxpqlnujYNFF5mPnzwST1/CsnJwveeofI5yL4oaLrXiHxJotno+oW1xBpC6fbI0aPHC1vJM8rs2cgHMeDjqvPOK574J6Knir4gW66rIZordTOySHO/Hb6Vo3/AIXXwvY/EzxKxxJrGrS2VgyDP+j+aZHII/hLbV/7Z1zfw60jxdPcS6h4OWUTRfI7xOAcH+lOiv3cne1we59ZeKPFGieDtM36hPDbqqfubdMAtjoAo6D9K+W/BmseJm8cXmseEtPe4ubiRyVEW5dpPf0rch+EvjvxPqP2jXnMZZvnmuptzD8Otao0nx38Io7qXSxDeaO55bAYfUjqKIKEE0mm39wGr4p8GfEzxvaRDWbiyt4AdwtVcKB9cdad4Q+CviPQZxe2niOKxvCMHyVJ49DXmt/8QfHGv3B1GO9uhHancRbDakf1Ar6W+GvjK08T+G7SaW4jTUVUR3ETsA2/1x79aVT2lONtLArM8h8V/EXx54C1R9K1SW1vcYaO4aHh1Pv3rzvxr8SfEHi5Ei1C4EVunSKEbVJ9/WvoP9oez0qfwHLNqTrHdRuPszhcsW/u/T/63rXlfhD4R23iT4djXIr+WK+xIwjKgqwXtntV0p01HmktQdzgPhlaG++JXhS3Az/xMoZcf9cz5v8A7JX3JXyD+zzp5ufjBYZAJsLa5uT7fKIs/wDkavr6s8W71AjsFFFFcxQUUUUAFFFFABRRRQAUUU2WRIo3kldUjQFmZjgKB1JPpQBz3j7xVbeD/Dk2pXC+dOzCG1tgcNcTNnag/IknsAT2r5oD3Vxc3N9qc/2jUryQzXM2MbnPGAOygAKo7AAVq+LvE0vjbxEdXbeumQhotMhYYxGesxH96TAPsoUdc1zWsaza6WAkhaW5cZjt4+Xb39h7nArKTcnyo9HDUlTjzy3ZpVxfjO5sZnSW0vIZr2JGia2QlzIjdR8oO05HBPHrU5/tvxCkihFtbFf9b5T7QB6STHAUfl9agin0TTY9sKS6vInAjskKW6n0MmAW+iDH+1XTh8POMlK9mTjKtF03Ct8L7mbaeLdSs7RbZ4YSIAqtNMpDRL0BdFPI/wBoHH0q7qGsazZ3P2ZrqOW7I3GGCFG256bjuIX8TWPPdfaNa+1Xa2liWVkjtywyS3GMZOF6dSTzVHT4pYkeBpZreWNvnijwqjPdcDkH1rtWDp3Ta3PJjmNSTlTpNO2zf/A3sddpGp6vdLKZNT0yCWJ9jw3aEHpnIKkcHPXmts32qWUZk1TSZXte17YH7RCR65HT9a5jTPCPiG80dtYsNB1e7sJFaT7UsRfeq5BI7kDB6D6VR07U5bNxdWF28LL/AMtI32/gf8KzeEpT+FnZTxdWKXPuUPiIINXvIr+xvA4WMRtbzhomXk8qHAzn06/WuFZdpwy7T6EYNe0W2rWWpu0OtW8NvJIuBewRlcN6ug+Ug99oB5zz0rK1nwzbwThbu0hy43xzRY2yL2ZWHDD/APUaunGVFcu5bhHEPmi7M8xgnmt23QSyRH1RiP5Vs2XijUbcgSslwg7OMH8x/XNb7+GraX5FCtuOF/dgMD7bcZqeb4d29mzf2rrEViw6wn95KPbauSp/3iK1hWcXorehy18BGS/eJMk0rXYtTUJawTSXh/5d1XJPvnpj3OK7rw7YS6fpojuWU3EjtLJtPyhmOcD2AwPwri9J8P6DpM/2mPX9RMwBXNvbAHB7ckfzrTluNIlG2e78QSp6GcKD9QCM/jWOK9vibReyFl+Gw+BbnHd/gjs6K4yCTR0O231HX7P0bzBKq/8AAC2MfT8jVq4bVbS0F3a67b31nnbveNcqfRlwjDr9Pc1wSwdSJ7EMVCWiF8VyiXVNPtQciJXuXHocbF/9Cf8AKrvg5W/sczMMCeaSRRn+HOBn8s/jXGz6hNc2moalceW0s+IovKRlD4G1cAknkk+td9oMtnJpVuunSRyQRIIxsGMEDGCOx9jW+Ij7LDwp9Xq/0PMwUvrGOrV+itFfqX6KKK849wKKKKACvRPgBpwuvFGvau6grZwRWELejOfMl/QQV53XufwD0/7J8Oba8YYk1SeW/b3Vm2xn/v2sdaU1qceMlaCXc9FooorY80KKKKACiiigAooooAKKKKAPmH9q0D/hM9CPf+z3/wDRleY+DvEt94U1yDU9OfEiHDKejr3Br6C/aO8Gap4obw9PoGmyXl5btNHK0ZVdsbBTzkj+JRj8fWvFpfhZ42iYK3h67Jxn5SrD9DXo4eUHS5ZEPc+gF+KngvWvCzXOryQNIqBpLKVNzbvQceorwDWbqe+8YReI73SZINJluFdVEW1BGD0GOgAqofh/4wgcsfDWqkxnPFszdPoOfwr6U8FeIYdQ8KQad4s0G+03yY1ik+3WDpA2BjIJXC/55rKUY0NY63HudDe+N/D9h4Z/thb6BrNUBRI2G4nHC7exr5F8X+K7jxD4ym1yVQSZQ0Ub8hVHQV7F4v8Ag1pkdnqusWGrOumCIzQQRjeN3oCDyM+lc38JbnwXosE0virTLn+0omOJJoGaPaP9k9D9eP6qjyQTktWDNtPiJ4+8XWK2fhbRDaKsYV540IPTsTwvtiuU1z4ZeNm0S61rW5+IlMskcs+X474r2qH4xeB4Y1jhvWjjXgKkBAH4U7xd8TvCS+FLqRb+G9+0wsiW6Z3MSMc+n+cVKnKD92NhnHfA3VbPxl4LvvCGu5l8kZTJ+Yxk9j6g/wAzXJWFxL8HvitNbESS6XNhdueXjbofqOPxFebeG/EN54b1+PVdKby5Y2JCnoQex9qseMPFupeK9bXU9UMf2hQAoRcAAdBXT7B87/lZNz7YvtXsLDTBqF/cx21oVD75DjgjP4n2FfNfxt+KS+I2TS/D08g0xf8AXPjb5rf4f5+mp8O/D978VxLqHijU7j+zbNlijtY2wDgdPbpXsVt8OPCVtai3TQ7QoBjLAlj+Oc1yR5aUve1aK3PIP2V1jluNejlVXVo0yrDIIz6V6h4++G+m+JLCT7AqabqQO9J4RsBP+1j+dePeNLqw+FXjKK68DXkcjToVurUsHVRn7uf84r0Dw/8AHjw3e2yf2qlxY3O35wE3Jn2NVUjKUvaRWjBaaHNaX8FNe1S8X/hL9caSzi4VEcuzD8eldF8V9UtPhv8ADuHRfDr+RPOfLjUtlth+8x+v+NL4o+O2gWNhu0NX1C6bgKwKKvufWvnDxt4q1HxRqk2p6mzSS4PlxLyFHZVFXTpzqO89kJu2x7V+ynoMrNrvia4BCysLC3z/ABBTvlb6bio+qGvoSub+G/h4eFfAui6MQBNbW6+eR0aZvmkP4uzGukrlnLnk5FIKKKKkAooooAKKKKACiiigAryb4++IzBpUHhazkxdaqpa7KnmO0HD/AIucJ9C/pXqtzPFa28txcSLHDEhd3Y4CqBkk+2K+L/G3iu51zWb7Uo2db/Vm3xbhzaWa5EQx2bbzj+8zHtSd3otzajDmlrsiprWuTefJY6QUTyvkluSMhD/dQdCw754HoelV4LGy0a1/tDWi7vMPMSFpMS3H+27H7qe/U9hjkSabDb6LpS6hNEjnlLKBxkSOOsjA9VX36tx60zwrqAvdTW5g0fUvE3jOWRpLa2lj3W1rg4WaRRlpWGNwztReMnIrshTjRjextXrtPlW5ha7rM+sPa+bGslhA28WUI2xhSDgqp4bsck5OOpqMte6tdW9lY21womdYo4IRmaZicBQF6D/PFemS/CfW7axvvE3xJ1yDRLUt511LIRdXczn+EBTsDHgAAt2AGK1/BPiH4SeDbxNTtYPEWp6rCpMVxeW4ZkODnYo2opPTOM+/WtlibQcYL7v6ueVUw0KtRVJ6tHiGo2v2OK5tPsz292kjQNCUw6zK2NrD1DDnNPurhReXl1MflhRYiyjj5eWA/E12d/oPiH4j3viPxXo+hXC6Y1zNdGU3CRhNgztViRubA525AORmua0DSbrWtQsNI0O28+8vW2QRFsDoWZmJ6AAFifbvWsKqcd/UJUr1FPsn+J6DoWr2fwssRNpmsXOp+L7m0G7T4ZM6dYGX5z5mCQ7rxwD1PYHNdL8Kda0/4ieO0s/F3g/Qb/Ufs8lzJqUVvtZijDaZY+Vb7wGT3x+HlPjfww3g/wAU3OhS3cGpG0MEk4hQwK+5Vd4cgkrwcbuuGBxXfa98VdGs/Dh0b4a+GpPDd1fBEuL1Qkc4ORlI9m5pGPQOSCAeBnpxyp3jdK7fU3ueZeJXEPiC9V7Sy0xLS4mtXht4mjyVkKqGUsRkYPIAznnOBWz4euRqGiX9iXWRYE+12xBztIZQ4B9Cpzj/AGBWv8Criwtvi5oZ1JQxMk0KmZdzR3DKdpbPIYnIyect7123xi0Gw0T4vWMmmQiBNXsJTcwoAse7Y0e4ADglcZ9xnrmtefl/dlU3yyUjzrT5/wCy9NutUQD7UrLb2p/uOwJZx7qBx7sD2rlbiSQI8gVpZPvYzyx+tdDfCR/CsaQJvme/CRrnG5imAM9uSK9Q+I/wq8NeBvhG13ezzTeJxLGsd6khXz53YZjCE7fLChjgjICk5zmr9qqenVmmJvKo/I4LwD4N03xZour3E3iZdM1CwthdSpNaEW8EeTy8rEFuh6AdOM1v6L4L+H7PbLc+NbrX75gcaZpNuI3uXwTsj3c8deSM47dKb8DdR0OWDxR4N8SzQ2dt4ihHk3juI28wDb5W48ZG4Mg9Q/XOK5n4leBL/wACavb2l5qFpexysWt7m1k8uZGXDAvHndG3QggkcdR0rJ8zm4OTXYx6XOZvntZdYvH0qG9tdND7Yra+dXniYfeDkAYIORg5I7k1QQWpsopbrzrqeV2XyN+BkHnI4GB71u+I/ENx4nvLC6vobFdRt7cwXV1bqBJfHI2yS4AG4YPPfNYa2yy3N1KJI7SONR5s2Mscj8h0HPNddHm5UmtfP8zkxajy3lJpJ9OvkaaPHqEFrPAVjeJyVilHy7gCpUgEdM9QaYkt1aahHIqmzupGCLNEd8cp7K44zntkfQ1r33w6vLP4e6d4zmks5NLvJVhgtW3GWKNmYK+emWK7j3+b2xXNyW8hgeFLmUQupVkfEgwfTdkiicoYhNta/wBdCMJDEYRJU37rd+V9Pn3O90jXkuphaX8Ytb/oEJ+WTH9w/wBDz/OtuuOsbqw8Twpp+oPFHqSqFiuWO0TY+6JPRvSQfj61b0jUbzTtS/snWvMLFvLhmk4cMP8Alm/vxwe/16+PXwzhrHY+ko4hTR01FFFcp1FTVvOOnyxWnN1NiCAesjkIn/jzCvrfRtPh0nSLHTrUYt7OCO3jHoqKFH6CvmrwNYf2r8RPDVoV3Rx3LX0vssKFlP8A38MX519Q1tTWh5mMleduwUUUVocgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBmjQtLFz54sLfzN/mfc43f3sdM++M1pUUUAMlijlULLGjrnOGGRVWXSdOmbdNp9o7AYy0Kk/yrgPib431fw7408MaJpZto4NViuZJp30u41GRDEqldkMDqxzk56469qz9M8falYeLfFq63cG80zTdP06eOJIYrDa0ysXbFw6FMnB2ySZXGOvFFwPQ5PC3h+Xf5mhaU+7O7dZxnOeueKqS+BPCUq4bwzooGc/LZRqfzArltF+M2ga5BZDRrDVb7ULy7uLKGwhEBlLwqrSNv83ytgV1Ibfg54zW7Z+Oor/xFPomn6Jq9xfWggOoFPs4SwMq7lWRjMNxA5Ij39DjNVzS7gX7XwhpGnknRoDpTEEMbE+UG+q9D+Ip8/hmC/jK6zd3t+SCuGmMKgHjhY9vbvXmc/xjS6+Hqz6al7d+IrzSL7UIXtrKOBbZIWkQTSJJM4Chk6B5Ccfd5216R8OdRu9Y+H/hrUtRl869vNNt7ieTaF3u0asxwAAMkngDFTfqBz1z8GvA05LNpEiuTkuLyck/m5qnL8DfBLsCtpdxjHRbpsfrmvT6K0VWa6sVkeSSfALwg+7bLqqZzjbcL8v0yh/WorH4B+HLHWtM1C3vtSlFncpcNBcmN0lKnKg4VeMgHv0r2Cih1ptWbCyCiiisxhRRRQAUUUUAFFFFABRRRQB4/wDtM+Kl0PwVDpSkmbWZDC6qeWgTBkUf7xKR/SQntXzpoViLiW4u9UlIjQefeTKOccAIn6Ko/H1rvf2jdSj1j4oR26Nvh0W0WDHUCeT53P8A3wYh+dcH4rkNjp0WjwMFkVRcXTA9ZWX5Vz/sKcfUtXXh6f2jpjL2VPm6s7f4e/Du++Kb3utXl7/ZOiQH7LaiKMOXK4yq54CLnGe7bvQ1x3gnx7rfw+utQm0G8sp7SZyJkuog8UwQlVkBUhgcejYOelbOvfFy91PwpYeFPDEK6LpNrZJa3YidXlnG3aVDY+RSM5I+Y56jufA+78I6Z4yluvGhtEhgtQ1i11GXjSUOMkDBG4DGCeRzir97kcprTojk6mpqHhT4geO7UeI/HOpwaTo8KfaI5tWlEMMSkcFIF+6TnGXw31ri9Z8Lw29heXVp4s8N3mnwIolnjlkEiu27aiw7dzs2OMcdckAE11vx88dW/jXxPb2ukXAuNB0xB5brnZPOwBZ8HqFGFHvv9a6b9m34b22ueGW8S+JRZanp2rxssNlLBzbtFO6hg3r8p5GCM1m5zpwTva/QLXZ5XqPjjxxYaDZaXrk2uaFpTWot4YPsAsoGjK4wpCgkEZ5Jq98G7swfE7wpNZSjDXfk7kOQyMjKw9+D+Y9q+z7jR9OuNFOkT2cL6YYRAbZlynlgYC4r5btdU+HPw4+K17p9t4d1O7XRZ41ivotRNxHEzqDI3lcfMhYrjLHhuhAFTCr7rhy7jt1Mux0yx1rxt4k8Q/EoXOn6Ck1zKxYNAbmfeBHDCODIQgzgZ6DPWtL9lZo1+Irx3No01ydKkMc2M/Z8Om4n03AgZ9RjvXHfEiy1WPXE1rVL3+14NWje40zUg7Ms0IPEYDAFCoKgpgdc8810mmeOdJ8F+Djpvw/E1x4h1KFG1HXriEx+UxHMcSMMnbkgfwg85Y5q7OULLVv8LC6mp8d9Rsb/AOOGlRaSYYryzks7e5ujIsa+eJg65YkDKKRznPOO1a/xo1vTdX+LmhRaXew3hs7J0naFt6ozZYLuHGcc49xVP4T/AAUsvGHgn+29d1HVbee+kke2EZTBTef3r7lYuWIJ5IyDnvmvPNGsItJ8eTabb3UV7DZ3U1utzFHsWbaGBYDJ7gjgkccUU1FuyeyY1ubHhmGymvfCcGqyLHZXOvKJCzhAQgQ4J9CWUfjXTftO6td6t8Q9P8PeYYLSzhiMfcmSdtplx32qAB/wL1rznxTtXQNGgdA6yRyzbGIAO6QpyTwP9X1NdjrnwN8ZW/hufVr2awuZ4YHaW0N27SpGuThXIKk4GcZA96qaSkpNmlZ3mzp/jl8KPCfhPwONW0drmzvI5IbdYJZmmS+ZmAYMHzh9u5srgfKePTw+XRby30SHV0toYtPup5bOGXf+8eVF3Hj07ZJzx0xXr9nq8/xh+G76JfXKt410L/TrEng6lEEIIxn75BKnHQ7W6EivPvDvimGPwzP4c120kvvDV3P9sU2/y3djPtwJYSTtPujdctzyQVTc0mt2n+Bkztvi1baLJ8NPhvqei6dFZ+bA0JKxhHKiJchiPvfMmckn17muR+HfgTS/HN5qFtc+JrfSdWTZ9is5lyt0QCSSCw3Y4GF5HXmuj+MNlJb+Dfh+3h0X+s+H4dOmFtMkB3PIzKTvUD5TjHX0bHeua074VfEDW9Ag1W18O2tzaTkhbV7pI5sAkbjvIXHH19qUJxVPl5rO4NXZ0lp481/wXol54B8YeGNM1iCz/dJBdnaEUtuBztIkTByrAKw4ycjivoXhnwv4+u7m18K3EvhbXFVXg0zUrkXFvdZB3LE/+sBBHP3uCDt64raDo+hav4BvNY8W3+t6Tq+g3J0y5hEImkmBbdFEFY/eXLLk4wBzwBUnhTwPb+LbM3PgTxDcR+KNOIu/7M1GFYZRscbZI5VJXOcc8jJAbbUpxUeZXT/ABmsaJrHg7SZtI+Ivh+6fR5MR6fq0Mnn/ANlzHPzRsuSY2JBMTbc7SQCax7Gf/hKtOfTL1lbVbfMdrcxk/wCkBDwoY4JPGUYjPGPSuh8V/FXxhq/hrUvCPia008XG9YLuSW2MdwhUhuVDbN2QCGAxjkDoayV8Ba1H8NoPHlrcwy2G9mkgQESwRrK0fmhhwQCASOCBk9jWkFZXqaXKjJxd0XPDWpvf2jRXWBfWxCTDGN3o4Hof55HateuT1S8C/wBmeKIgoMm6G/CDAYgjecfQpJ9d1dYCCAQcg151el7OVj2KNTnjc9B+AVj9p8Y65qLD5bKzitIzj+KVi7j8oovzr3evLP2eLbZ4W1e8PW81SUg/7MaRxY/ONvzNep1UVZHl1pc02woooqjMKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMq+8PaXfeINN1u6td+qaakqWs3mMPLWQYcbQdpyB3Bx2rK1z4feGNcu9QutU0zzri/MBuJRcSoxMOfKKlWGwrk8rg885rqqKAOLj+GPhOKMiLTriOX7ZJfi5S/uFuBPIoWRxMJPMBYKuQGwcc1fTwPocerxapDFfRagiRI88Wo3KNOIgAnnYkHnYAxmTdkdc10tFAHEH4VeDRp9lZJpLxW9pbzWkQhvZ428mVi0kbOrhnQlmO1iRzxXWaRp1ro+lWem6dF5NlZwpbwR7i2xFAVRkkk4AHJOat0UAFFVdU1Gy0mxlvdVvLaysoseZcXMqxxpkgDLMQBkkD6mrQORkdKACiiigAooooAKKKKACiiigAooooAKKKqausz6TeraY+0GBxFnP3tpx096APiOymfxFr4upmLyaremZm9fNkz/ACIA9gK9T+AvhXT/ABb4p8UeItc021v7OG4ENqLmISIJSxdiAePlUx/99dsV5X4EKrc6bOmdlvAbkH0EcZf/ANlrc8GfFXX/AAp4XHhzw9Y2wuXuZLj7U6tO5VsHCxADBGDkkke1ds4twtHyOjEu3LHyPYvjp8LDrtjHrOgTWdjNpdtIWtGiEcU0Yy7fMo+VuOOCPXHWvmvQdM1DxFqdlpmiWrXOoXf+rjzhVHd3P8Kjuf6kCu21/wCI3jn4h6db+ExbedPK7i4hsIWjluwvO2QE4RAPvdAeM8cHAuIPFXw28VywrNLousi12FoWSVZLeT0yCPvJ1xkFadFzhFwT16HKzufiZ8LdJ8AfDu3ury/F74lub6JVm3GJQuG3Rxx55UAkknJPB44Ai+Dvxw0/4e+B7bw34l0XUpEsS5gu9PCSrKryPIdwZl2kFsdTkenfH8O/D3xx8SX/ALfciWOb5E1HV7kqZFXj92oVm2jHoAT+Jq3rXwz0fwzfPa+NvHWnWRWAzNa2Nu0tw4OcAA9M4OMg59Kzag42nK7A7b9or4leM9Evk0Hw9Yw6bp99EWg1oXCyPcx7E3mMD/VlS+3JyTwRjrXzxp1oLO1WLcXcks7nqzHqa9/8beK/B8Pw68INo/hiHW9EguJbKGDUXeKSIRqN2G5OTxycivMPiVaaTa6zZ6p4esW0/wAPavZQXVqDnYrkESR5JIDhkOVz796rCtReq1fUJGp4w8ZaRffB7wf4aso/tOp2A+1XM20gWuBIPLB7s27kcgAc84q3q3w50vT/ABh8OtGMtz9n16zgfUNshG+TjeUJ5UNnBA6dsHmvNfMt2AaYedbKymZIzksmRuAwe4zXt/7RPjjS5dT8FyeEr6zlvNNB1OC5hZWjjU7RGnHZtpyvHAGeooqQdNqMOtwWov7SPiTVdC1fTvDulz3ujeHLewRV+zloI52+YbA64yqogG3Pc5HSvKvBSxpqEskQCpaW1wcAY2MI2UAjsQxFeieMvjtrPiDTfsWmaTYadG6DdPP/AKTIHxy0YOFQg9Cd1cHoUf2Xw7qt0SzS3UqW+92LM+SZJGJPJOVTJ77q0pRlCDTVvzLguaaRF4vAaeytnAKx2MKkezr5n/s9ez/Av4k6rr9/a+CvEMFteWjWLxR3a7llZUUDbJyQxK5+YYP1614r41Qtr7MFjfy1t5I1kBKMBGhUMO4IwCPQmvafhd8Qfhfpk6XUmhR+F9aMBSSZomkiboWWOQbiAcfxBScd6Vde4vd+ZLd5Nnkmp+DdX0j4i6l4b0Kc/wBo6R5lzb3ZmMDpAsYkD70yQ2xgOOp9M1t/BbwZY+KYPEGr6wEurTR7MypZySMTLOyl1eTB+ZRtPBPzEnPTn079nZ7TxT4n8f8Aiq4tAs+oXSxRpIMmO3YFgh9yAm7/AHR6V4Houtaj4buNUXw3qBtobqKWxkIRJRLBuYLywPIHIYfrms4udS8VvoLY1fAPj698P/ErQPEmt3ztp/kf2bebIUVIbZiWVVRFAVFchsKO34V9uWtxDd20VzayxzW8qCSOSNgyupGQQRwQR3r4C0zSbvWLmPS9LsJ7+4kQ7YIl3MVUcn8q9l+FqeNPhf8AD7xpq1/Y37WdlbwnT9N1KY7Efc+9kGflUbwSBgseM5waWIpRi7xfyGmbX7Y1jaR+D/Duq+SBew6wkKyAkHY8UhYEdDkxpyfT3NeL+AfEa+E/HOjaw7yiK3lK3Cwjc7QOCrjb/EOQceqjHIFV/HnjjxT8SbzTX8UrZW1jZZeO0slZELn+JtzMSe3XAA4HJz6Z8CvA+ieOPC3i2y1eBRcefB5N5GAJrdgjbWVvqTx0OSDVRTp0nzrcW7JP2hPFHgfxVYaTdeHbmO818Tcz28G0iDb8yzMyg4yRheoOeOtZvwR+Jtn4M+26J4nLHw7eEyxuIjL5ErYDqyjJKMMngHBB4+avO/Euj3vhjXNQ0fWFIu7FyrOFKrKnO2Rf9lhyPTkdQa9d+EvwVvNRubbWPGljYnR5rdvLsJHLzMHX5ZCV4QjqMNuHsaco04UrXvfYNbnmPhk297b6ppECH7LcB5rNGB4MZYqMHnmMsMHnOK1vB92ZdH+zzN+9smMDEnqoGVP4qR+Oa3/il4Etfh3428Ovok96bC9YyIblw/lSRumVDYBxhgfmyevNcaxkttZ8RWlsu2aeLbCnTEgdkA/N0FY4lRnTUo/10O3CT5bp9D6x+C1obT4XeHtwINxAb0g/9N3ab/2pXbVW0yzj07TbSygAENtEkKADGFUAD9BVmsDkeoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVW1O/tNL0+4vtRuI7azt0Mks0rbVRR1JNAHnvxv03UNRs/DpjsrvUdAg1NJNYsbRGkkngwcfu15kUNglBnPHBxWBr1/qmlLpUPgbS9d0DwpKbx5nsdGaSYThAYgts8bmGJnz/wAs1ycn5Qdx9B8HanrOvXFzq13B9g0OZQun2cseLh1znz5M/c3dk6gcnk4HU0AfO994g+LrabezyQ6laX1toNvdx29ppscqTXZm2uhJjYljGdzIpBU+mKf4q8Y+PPD1r4i+13uow28Op6VHY3kunRhnjnQm4jj/AHW19rfL0Zh0JJr6FrzXW/iJ4Wu9dm8Nazo9zdahb6rBZLZ3FtDJl3VpEuVDPjywqlt5wR6ZoA4tNX+KWoGws9Pu9Vs7W51y4tYtUvNEQzCyEfySzQlECfNnBITPepzrnxQt/H8lpeyyQ6bb6hHEp/suaaC7tMYMgMNs+2Q/e5nQKfl2gc1t2/x18MarHqMOkS3C3EVhdXttNJHFMsogVmb90swcHCkhZPLLAcEdac3xu0Wy05577T9YnS0tLC5vbqC2iSKNbtFaNthmLAZYAqNxGcZbrQBy+m+I/iTJpOuQz3GqjUEhVrbU5NGmNrvaXlI7f7Es6sE/iImQc57Uy/8AE/xQl0fR2s7LW7GGaa7S5urq2WecFVHktsisiyxE5PNuGPIJXg19C0UAfL3xNuPiF4k8H6zpOr22qzo+l2T2sOl6NKYtQn81TM0heHzIiu3IQ+X06EcH6fiyIkB64FYHii61zTJoNR0q2XUtPiUi70+NQLhhn/WQsThmAz+7ONw6EHAOloer2OuabFf6VcrcWsmQGXIIIOCrA8qwPBUgEHg0AX6KKKACiiigAooooAKKKKACiiigAooooA+KbXTv7K8XatoMuE2XF1pqt0wGLLG3sCCh+hru/wBlm80m18U6zYXlvs12eNXtpmjzmJRiRA3Yg4OOM/gaoftC6O2j/Ex7+MFYtXt0uVYcfvYgI3x/wERH/gVcNr8l5aapaeItJubqykulLi4tZDG0c3SVcrjqecejCu2K9rT5f60NqqvGM/kdHqGpDR/2kJdQZnVY9fEblDztkxG31GH5HcVc/aZuLiX4piK4UpFDp0Ig4xuUs5Zs9/myP+A1D8HLbSrD+2viJ4wmurq10adI7cMTNJcXbgZbLH53G9AMngsScYBFHU7/AFf41fEKZjc6fotpbQ7IzdyqBbREnbnkGSRjzgcDHX1SahUTe0dGc/Q2Php8dpfCvhqLQbzSItRWzQraSW8/ksy5biQNnoeNy/lkc+eaXp+q+NPGCWtuWl1jWLovJM5aQRgnLOxPJVF+nAAHavrrxB4B0a5+GP8AwjbWEd5HZaeYbNigMqSLHhXQ9Q5IzkdSec5r5P8Aht4rk8G+KrDXXsTdiGOSKaAv5TDcMMRkHkEdDj6iii01JwWoM6b436PP4RvNB8MxJInh7T7XzLW4df8Aj5uJWPmvI4435XhewPHBqx8IfiXb+FoToPiu1W+8LySGWJjCJWs5GYljsx8yEkngFgScZzxN8QPjdqfjDw9f6TBodrZaVqH7lJ5XeVyFYE4IAQt8p4Gce+K574UeBLj4geJDal7m30a1Ba9vIVGVOPliVm43nr0OB9RTil7J+0DroWfiDqGm/EL4mafb+CdPjsre4EWnRTfZ/L89jIxMxjGPlVWJGQGIBz2A9TutM+GfwWsmF3brrfiK4TaYpQk1zIDz9w4SKPI64H1Y15F8TND/AOEB+JdxaeF9QvrQW0SSwzGQNLH5kZVwr4yMgnBHIycGuStLWW7vBFbRyT3dw/u7yMe5J5J9zTjR9pFa2iF7DII2mkCQ26xtI52QRchdzcIvHOM4HFdPqyJYWtrpMbB3tSz3DqeDM2NwHqFCqufUHtUo+z+HQIrIxz6uP9bdj5lgP92Ltkd3/LHU49buV7JbI7cNQcXzyNDVbKPVPE3h+znufskV+tlbS3AGTErbYiw98AdePXitbxd4At/C/wAVdO8M6lqFymhX88JhvmKiTyXbaQW27Qwcbc46FT3rF1m0bVtAiurct59lH5FwEzuVMkpKPpnaT2wvrXp3jXSdQ+MXw88O+KNDtY7zWLCOWx1SyDhWdht3bd3GcjcBkZWTucCsKknFrWy2OWpG02mVPiR4I8R/CrRdVn8I61dv4W1YpFfhgvn2vzEIQ/8AdYPsLDB6Z9Rx/wAM/hrqnjyLUG0u8sbK3sGjiPnqzFiwJ4A6AACr3gH4j3nhM3vhjxdp82peH7lyl9Y3kb/arbcoU4VzyvAJUj1IPY8/4H1LxXok+p6p4EXWEs7U7roRQtPEIsts81DkEhR1HzAc5FTHngmk9e/cjc67xL4Xv/hBZS3P9uWkniPVVWzszaKVktYN2+aUFjwTsRMgcbutSeGfGsvhz4TzXM1rF4jk1fVprPUV1S5eUKvlAojE5I3AMRnrkmvNdZ1XUfEOrzarqdxJqGp3jKoc4GcnCIg6KozgDp3Pc19CfCz4JzWWm66njhLSSLVoEt/sUDFzGFYsJDJgYcE8benrSqxUYpz1kwXkcb4M8G+AfiN59roF3rHhnXo0Mh0+eZbmLbn70ZYbpEBIHDKR3A4Ncx4q8FeL/hdqsOpNLJAjN5EOraZKQrZB+Rx95cjswK56EmsDQtX1DwN4uF/Yzwve6PdTW7vIcxTqpaNwSD0YDOQeDg9q2/iP8SfEHjkWMWsrHp+mKfNgtII3RJ3x99mb7+M8AcDOeetWoyUkk7xfcDFKeJvHGuMUTUvEWqR23z5YM0cCt74GNznjqc16R8NfjnP4V8LwaJrOk3OoGyYwQTCdY3RBwInVlBBTG3qTgc9K3v2Y5hYeGvG+oRRI9xCUcZHLbImYKT1xnP5muQ+Beg2XxE+IGq3/AIvij1HNu9/JC6/u3mlfG7GeAoJCjtkelTUabkmtIgjV+M3xQ8O+OvB+kW+mW97DrUV8J2iniKm2UIwY7xlWB3AAA+5xiuf0PS31f47aJbRL+7k1FrmZccBEIuCp/wCBRqMfhSfFLwtoGl/FSPRfCk4MU+z7VaqdyWkrNjaG7fL8xGePxrsfgAItW+L+ual94QWcsiDHQzTDB/75Rh+NTJRVLTqbU3aMmfStFFFcpmFFFFABRRRQAUUUUAFFFFABTZWKRu6ozlQSFXGW9hnjNOooA4zRPid4P1i8ksoNctrfUYnMUlne5tp0ccFdkgBJHtmuzByMjpXhv7RvwdsvGdidf0yez03W7Vf381wwjhuIhj/WN2Kjo3pwexHgF58RtX8OyaFpvhXUQuleHGkWzuY4WQXe5iWeaMsxIYHGM4xyAp4Eymo7m1GhOtfl6H3Rqd/aaXp9xfajcR21nboZJZpW2qijqSa4fTLC78d6hb61r9vLbeHbdxLpmlTLtadhytzcKfzSM/d4ZvmwF5/4d63B8YWh1rU5rVdN01o2j0OOTeRcAA+dcDuA2fLX7vG7k4C+s397a6faSXV/cQ21tGMvLM4RVHuTxVLUxatuWKK8U8Y/H3SdOke38N2b6pKODcSExQg+wxub9PYmvK9X+NvjS9LmPUYLCI9UtoEAH/AmDH9a6IYWpLXYV0fX9YEvg/QZfGMPiqTTozr8MBt0u97ZCHIxtztJwxGcZwcZxXx6/wAXvFKHB8VXRP8AsuDj8hSD4weKCQP+Equxn1YD+lP6t05kPXex9bWvw88N2ltd2tra3kNhdRTQy2Ueo3K2xSUEOBCJPLXO4/dUYJyMGq83wu8HzWF/ZSaPutr63tbW4T7TN88dsAIVzvyNu0cjBOOc18u/8LO8af8AQxX3/fQ/wroNJ+NvjbS1iN3Nb38TruT7XbgblyRkMm0nkEZ55Bqng5rZk8x9bUV4x4P+PmiaiUg8RW0mlXB481cywk/gNy/kR716vo+taZrUBl0jULS9jGNzW8qvtz64PH41zzpyh8SHe5oVyWueHLu11KXXfCUkVtqz83VpIcW2ogDGJMfckA4Eo5HRgw4HW14/8Uvjt4e8HiWy0l4tZ1lcq0cMg8mA/wDTSQZGf9kZPHOOtZt23LjFzdoo77RfF2l6jp95cXUo0yewwNQtb5liezOM/Pk42nqHBKsOQTXnfiL9oHwzax6svh8pqtzZW/nR75fs8Vy29VMcbsp3MAcjA+bBAzXyh438Z6t461ptS1+7E86jZGqJshiGchFXuMnuSfeuw8DfCT4hXktrrek6VNZSwss1vcXsq27ZByCqH5gPqACPWs/aNu0UdywcYxvVmlf+v6t956n8NfHPxK+MOru9rJbeGvCtu+25urSANLJ38pHk3Zc92AG0YPXAP0hEgjjRFLEKAAWYsTj1J5JrF8E6bNpHhTTLG6stPsbiKECW309dsCOeWCfievc5rcrU88KKKKACiiigAooooAKKKKAPH/2nNGe98EWmrQRln0i7EspHJEDgo5+gJRj7Ka+fNK1EWqy211F9p06fAmgJxn0ZT2Ydj+HSvt29tYL2zntLuJJraeNopY3GVdGGCpHcEEivnH4h/A/UdMupb3wPH9t0wjcdNkm/fwnv5TOcOv8AsswI7E9BvRqKPus6KNSKThPZnkur6VeWOmXR0q9mudCnlWZ1jYhPMXIQyp/C/bPQ9icV2Hw7+Hvgvx0lvZ23ifU7bXEtUkubW7tYxvf+MxZ6qDwQCccHvXIWF9c2F1Ibd5ba5jJiljdSrKejI6H9VIqxcHR9SwdR0/7POp3Caywoz6+WeAf90r0rpknJaOwTwrWsNUd/4n+Gvj34cWN1e+FPEN9d6HbRmR0tLh4ZIkHXMBJRsDJyvPB4Fcb8NtY8C6RYah/wmnhq+1y+kkEltMpEqsmPusHdQDuLEk53AjuMGvcxW93YtZSeKNbfTmcSNZ3Su0Rb12CVlJ+oFVTY6DAuZL7UJQOuLdIh+Zc/yqY0001N/cZexqdEdF8VfihN410KDRLDQ7TR9IgmWaPH72YMMgFQoVUxubIGc+oya7W2+M2leG9EtvD/AMNfC87xwrsjlvTsDN3comXkJPJyVJryrTp9OvdRjsfD3h661m6IJKiR7kr6ZEQUDPvxxzXXahoOt6RbKviPWdB8HwSLn7Gr+bdOv/XCAFn/ABc9qiSpLQPZtfE7HOajZXmoatea141vmS/vJPMliRR574GAoTpGoAAG7kAdDTJdYMEDwaVDHp1sww3lnMkg/wBuQ8n6DA9qiuhoMJ22f9t6s4PM1w0dhC3uI1Ekh/F1rV0eW8j2vpfgjw/NtGfNurC5v2BH8W6WYqPy47Yq+d2slp9x0QgoaqN356HNWjG9kMdhHLeSL1S1jaZh9QoNbVv4U8T3CF4PC+vMgGctp8sfHsGAJ/Cu3g8f/Ee1iENvLpkES8COOziVV9gN3FTxfEr4mRyBzPpkuP4JLVNp+u1wf1qXOp0SLdWp0t955wyax4em+03WnarppjBDPd2MsSbehBLqFKkZ68Gt7wh4kudFv31HwfqkOk3VxzPYXIMlhdHGM9cofxHpuxxXo9p8afFdlGG1vwfBdQn709pM8S/gCrg/99VzWt+Lvhl4jZ5dV8E6xpt6/JutM8mNs+p2yLvP+8pqXOT0lEzk3U+OP3HOfFvxhrPiy0tIfEPhvT7C+gYG31GEuWC5+ZVP3WVhnjJHfqK7b9lrW9Jtn1/R9QvLaG9vZYngt52C+euwqQueGPqBz7VzWlaFZX7tB4D8b200khx/ZGvR/ZZZPYZBSU/RMe/pzfiLS7a0vf7N8Y6Bc6HqDZ2tGgMcvuqklHH+4w+lP3JR5FoYOnr7r/Qm+MPw9uPh5qce6RLnRb5pHtJY08sxsDu8lhkgEAjaQeQDwMVsvo3xb8MaDaT2d9q9zpUsH2pW027a5ESlQxBVxvHU8AEZBx1rnr628R3egf2RYa5NrOhrIs4sw/mMhXphHHmKOTwp28mrngf4n+KvBFt/Z9jPDd6cnCWeoIziD2jYEMo/2TkDsBV8lRxWzsZtcrs9Cv8ABLSrLxL8T9Ftr+QXFukkl7IrEN5zxguob/gWCR324r6d+Nfh6HxP4AvNPe8t7O6DrPaSXEojTzkOVViQeDyPxr5TtINT+JXxIC3F1plnrGpv5wnkzBChQABYgMsXwMgZyeSTXr1x+zxaJYpd+I/GUxkiTMk0sK+VHnqAZGJA+p5rKt8acnZ/kCMf9nrxtY+Eta1Twb4lghtJry8DJd+YkiecyKohd1JUggAqwJHzEcHGeH03UvEPwj8dapbaYsMVzbM1q0F3EXing3ZiYEENjbgggj0PcVl+MdN0HQ9at7bwfr8mspCxea5FuqwpIpRk2ODiTPOcccda0buK81LUp/EPjW5mnursiRYCQkkwxhQF/wCWcYHfHPbOSa1hBN8z2YJOT5VuVtDieztLvXL0g3V20qQYXG+R8+ZJ9AGIHuRzwa99/Zd0hbfwlqmstERLqV6VSQj70MShBj23+b+deI6P4f8AEnxG1b7F4egjigg2wz3hXbb2MfXao/ibBJ2jJ5yeua+xPDWj2/h/w9pukWX/AB7WNuluhPUhVAyfc4yfrWVeafuo3mlCPIt+ppUUUVzGIUUUUAFFFFABRRRQAUUUUAFFFFAEdxBFcwvDcRJLC4wyOoZWHuD1ryj4hfArwr4nt5p9Jto9D1YqSk9mgSJ27eZEPlIz1Iw3vXrdeRfHH4q/8IZGNL0cwtq0kfmSTPytqh6HHQseSAenBIORVRpuo+VDjNwfNF2Z8rK3iX4ZeNyql9M17T2wQOY5UP6PGw/yCONDxh8TdZ8X3QuddeZ9jZjs4xiCP2UZx+J5x3rltf1l9bu5r29knkvWPmC4nOWl9Qe/T+VU4oJHhlmiZndJNrRY/hwMEe/NKCnRm1Ralpf/ADserJ0sRFTxKcZJpNrz2bPcZfhSfHfg218UfD68MZkTF1o0knMUw++kcp59wGxwQc84rxLUdMm0++ms9RtpIbq3cpJFMDuRh1BBrrvh58UNZ8B2mpxaLNBsvVXInG4ROp++FPfGQfw9BWF421LTtQ1OO/0W2u4JL1DPcW8+SsUxY7tjk7mQ/eBbBG7GTjNcs51Kyvd+fY7KMKWFk4ys09urINF0m91i9Sz0uzmupzz5cS9FHUk9FA7k8CvovVPDfwo8A+DbbXZ7Rdeu7lStpBPdifzpBwwwn7sqpyGbBAxxkkA/NcGp3lppd1ZwXd5BDclWnRX/AHUu3OAyjtyfWq4uQ6Isjldo+VXPQZzx7ZPapcHTV1r+hq6ixM+STcLdNro0de1u51e8u5Zlgt1kdDHBaRiGKGPkeWirgKowOPfnJr3D4XeDLX4l/Bm401ZPs2uaLeSixuQxGFcB9j+qMxf1weR3B8AiiE9vPLvRTgeUrHBbBzn6HpXR+C/H2s+DZXXS7p4LWeaKW5gYDbOEJ+RjzgEMQcEZz7CuibqxUJSvscCjh5+0p02k+bS/9epmahFqmh6pdWF8Ct1bSNFNDNyUYHBG4f8A1xXSeF/EGseHIYvEunvcaei3H2VZh8ySvt3MhA4YAYzkdxVHVtDguPGiaboV3BNZ38sbWc0kwwscuGUSNn5WUNhs91Ney/tHaBp/hL4aeDtF04qYbeaQ7+8rbAWkP1Jz+IopYytFO7ul3NcTgsPKUIx0cu3p2MP4gftCan4i8KRaRols+nXlwPLvruFiS4PGyDuC3c9R0Geo8d1HS7rRNW/s4lhqUWIZYbflopG48hSOr87Wx3JUdDupoxhQ3bpg42wBxjLHq+PQCu4+CfiPTPCPjW01XXbOO8JBEfmHMsAbrMgJwXPPXnGcYzV+xnUs9m+nZf5s4+elQuo6pf8Akz/yR7v8BvgkvhxrHxJ4pBOtoC9tYjHl2mVwC3HzSYJ74XPGSM175VPSdTstY0+G+0y5iurSYbkljOQf8D7dRVyko8uhw1KkqkuaTuwooopkBRRRQAUUUUAFFFFABRRRQAUUUUAcl4s+HPhXxXdm71rSUkvSoT7TDK8MpA6ZZCCcds5rlP8AhQvg/wDv6v8A+Bp/wr1iimpNbMak1szyuD4D+Ckk3TRapcJj/VvfyKD+KFT+tdDY/DfwLo0bXEfhvSFEQLme5hWVkAHJ3yZI4967OvM/2itQubD4X30do2wX00VlM46iJ2w4H1Hy/wDAqLuTsO7k7XPC7rxj4g8S6hrdx4c3aNpF1OM3EEnkN9mQFYUMnAiTBZ9oOS0jc4wK5ZrrRNLuPJtYF1fUZWyzsXCO3+yARJIfckfTvVi4bTYrDw3b629xFoj3ck18bYEuUyq4GBnouOP7x6da67wO/iTx54nmt/h3bWvgrw/bfLNPZWqBkU9BK45lmIwdu4BR19T1aUtkXOTg+SOn5nPeEtTGr6rdW2r+JbHwXbWrJkfYTHPKDk5Q4GBwOWY9c49eq+KHwu1HS/CX/CTaP4mk8R6fEhmn+0SrzEeksb7trAdx3HT0PDeGvB2t+Odf8SxaZqsWpahZiS4N0/3tSYOUUqzHChsZBJwBgcUzxtaeO7LwPp/h/wARQ6pp2gwTMlqksYRDKSzqrupJbGG2g8Dt0FF5XTi9TFu+5Z8DeJ/AVhpSx6z4Tutd1SQBppp7pFCnH3UjB+VfrknuemN/WvG3w1e0EXhz4dxvqQVTL9vfZFATn+47F+n+z1HPauX8K3vwc03w1HJ4z0HxFqfiEuq3Mb3Dnb2LoyNGuw9g2Wzxkjmutu4f2a9S0lo4577R7mQA+ZGL1pocEEj5hJHzjHQ8HjB5GTmr6p/eBieAfB2o+JrHU9T0XXtG0y8S4l8vS4JZFm4G4KibiwBOQoyenWszQdZ13Xbm3s4LJteuZkMggki82QgDLfPkOPwauU0+4XT9dur/AEbUrxLS2vZDpd1PhZ/KDHY5YgclSMjAGc169+zlZO/ivXvFMtwJYdHs5biVSw3zyTbm47Bfkfn1Ix0NdHM4wcnt0BOz0OMVtC1hGhdZdNuMlHhul8yEMOCrHG5CDxgg47mus8P+LtQ8L240LxXpyeIfCkoybG52zNGv9+3ckhh1wucf3StUNN8NeKPjJrOv+KtNtNL09Bt3RgMkc8oVcRhuSXCEFnIwSVGB2wPD1w19oF/Zyqf9HQXkKuMNG25VkX2yGyR/sUWjUWu6N4VOdqE9bnretfB/T9T0OHxL8NtZVNPmh+0x2t9IxjC4ydkvLoRggh92CCMriuGbTPGE2jWd/rHhK91GyuIUnile3Ny/lsMgloW81eD0bGPQV0Pwm1yS88L6t4CSRhLql/CkIU4K20wY3WPYJDKc/wB6UetfUiIsaKkahUUYVVGAB6Cuf2koO3YJTlF8stfU+HJ7HSrtCs+iazbnPSJHdf8AvlkyPrupLy10yUIb628U3iodypJC74PsSrYPvivuaim8RJkNx/l/M+Q/C/hHxNqqJP4b8DTWadUvNWcIw9CBIR9ciP6dq73QPgHdXdwLrxnrxkLndJbafuy59Gnf5iPoqn3r3+iolVnLqCqNK0dDN8O6FpnhzSYdM0Szis7GLO2KPPU8kknkknqSSTWlRRWZAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzHxH8VweDfCl3qk21pwPLtoj/y0lP3R9OpPsDXwZ4k1q78Q6rc3d5M0zSymSWVjzK+f/QR2+npX0R8XPE/g/wAYePG8L+ItW1LS7eyDQQ3ltsaESnhzICMrgjaD04PQZNc98QPgRaaB4XTUfDerXWr3EpRba1jiRjODzlCGy3y5OFBJp1pyhT5Ibvf0O/AU6bqKdbbp2b/4B8+6hysSD7zOMUsLNJJMm4hFfJAONxx3+gqS6glivzFcRPFJExRkkUqylfvAg9OcD8DTwqxhmAAzyTXFzOmklu1+Z7UaccRUc3rFP8l/my94V06XVfFumaNYj99qE6QFuvl7mA3jPcDJpvinSLnQvEl9pcsrNJZ3cluTKScsGK5z6Ngfoa7f9m19Mtvizpt3rc/ksMpbKY2fzJ3ARF+UHH3+pwBt61F8edR0PX/iJfah4XvFu7O+jR5JBG6BHC7X4YAnhQcjglq35p6Qvfpb8zg5YOU6nLypq6dtrPT79zgUbcDlSrA4KnqDTkn8iC4iIUgqWiLDO1icEfrn86jtgfJUtks3zMSckk881XjU3F20jf6uI7VHqe5rGlU9lNyjtqd2JpfWKMITXvO3/BLCwxgY2gnuTyTVrQbKTVfE+laZYx7ri6uUt1wOAXIXn2G7JqvIxSNmAyQOB6mtvwzrUvhDxVpup6fBbXF1py7gtwpaMuwPJCkHPO7r1xTop2dZvb8xY2zccNBfF+S/zOr/AGhvDsHhP4qyw29u0Gl3kcU8YiGcKQFbA6Z3I54xnPr15fxfr7eINavLiGSX+zGmY2lu7ZWKIYVAB0BCKoOPSur+Pvi++8V+JfJ1C2s4f7Oj2RSW6MrMGVX+Ylj0OcYx1715e8+Zy8SKkMnV24UN3PHQGnKKqptb3+8xw8nheVVNU1fvb/gPT0HmOWWSGB23RcRIe6gkZH5Cnyr5s1z5i7X8w9+Vx0wfpikRvNjRwSrA5yp5BqNHf7bIJGLlhnJPJx/+v9KbquVNxfxXv92haw8adaMopcjVvv1/4B6h8HPiTqHg/WEJdns2ZReWucrKnTzFHZh/9Y8V9u2V1BfWcF3aSrLbzoskci9GUjII/CvzbjkMFxDMB91sH3U8H/H8K+1P2bdZ/tL4eLZu2ZdNneDnrsb51P8A48R+FdkZ+3pe0e60Z4uNw31as4LZ6o9WooorM5QooooAKKKKACiiigAooooAKKKKACiiigArnPiN4e/4SrwRrGjLt865gPkFuizLho2/B1U10dFAHw5DcIkc+i+IbKeKS1lYPH92e0lIG7APBBwDjoeCCOtdnpnizX9P+Hb+E/CQ0iWF4pIjcxK0N5tcks3lk4MmCRuUtzzX0F44+Hfhvxmu/WLHbfKu2O+tj5Vwg/3x94f7LAj2rxTW/gJ4ls5ZDompadqVuDlBclrebHocKyk++VHsOldKqRnZTN3KnU1lozzrwVM3hiWS/sfEdx4a8UQFoIoL7Ty1ncQfKfLdwGK5wOWHBXtnNZnjTxr4g8X3PmeIb37c1if3EEOxYFJH3l2ZBJHc5IzjjpXp0fw3+KEERWONTGB/q/7TBU+2DxVG78FfEOHP2zwfFdr/AHwllIT+IbfVxlDn5rkOkukkc1ovhzwZe+HpLjUfiCthqwRibc6bIEjbHAG4bpB7r16YBrH8A6Np3iPX0sNe8RWeg2IjZ2up2WNpjnCrHvwAT156dMGukudF8SWp/wBI8B3gwf4NIll/9AzWVMsO4peeE7iJ+4SG6iJ+obP6AVano/f39BexfRr7z2CLRfgp4L1EX9zqtpqV5aoZI4JrsXpVgOojXI3+mR9K8a0vQ9T+I3jDUm8JaO9la6pPLKVYtFbQQk9JGUbTyfugHkkDPJpVi09BhfDV6o9B5w/9lqS0eOzLLpnhy8jaRskL9ryzdPuoVBP1BrNR5dU7vz/4cfsZeX3k/wDaPjX4WajfaBDqkWny3MJlmgtpo7hEZgF3gdY3woxkDIwcGqml2D6HoNzJco8M97GLe3icEP5e5WaQ56A7QAe+W9K6HSNE8aXsv/Ek8I3du8jb/NbTktSWP8RlmCsfXOa6/R/gR4k1WXz/ABNrNrp6ycutuWuZz9Xbaqn3+eqVSMVrv1KhCMJc0nt2G/sv6LHeeLtb1103Cwtkson6jfIxZ8e4VE/77r6VrK8MeH9N8MaJbaTotstvZQDCqOSx7sx6lieST1rVrklLmdzOcueTkFFFFSSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXBfGrxsvgfwRc3sThb+cGG19VYjl8f7I5+uB3rva+U/i/4l8O+JPiFcL4on1KXw/o7C3itNNiDyXLA5k5LAKCwwSCSQoxjrWlOPM27bB1seGCw1K7sbjWpbW4e2MwikudpKK7AlU3euAf8AJrc1HSvE1v4RifVWmtdHtyZ7W3vZxEXZsAmGJjubPUlRjrzXrfiD49eGv+EQuNA8J6FeaaqxGO1kDxwm2fna4A3HOcEnOTk855r58v7yfUZZ5p7iW5uJMmWeRy5HqzMa4JRc592z6ejWUKN2lGMduv8ATI/OLys08m6QAKSzZJOMknPqSTRLJH5bZkQZHrQu+UB3dxnoOOB2H5VFKEtR56s6yj7rZySfTB4p1PZzqXu9+3/BJo+3o4dLlVku/wDwDrfho5hv9U1ZlZG03T7i5UEfdkZBDGT9JJUP4CuVmLFmCdNuxj6buP5ZrtPhvEda/tzRVE0V1rMCRwTLC8gDLLHIFdUDMFbZ1AOCF7Zq1Y+BdV0vUDZ6zorXMcMxMjW11EwlPODu3j24z/hWsIqVSUr7X+85atRww8abjvy39FqcjFpWo3UKNZ2VzIkh2rIkLMo9TkDHFMudJvtMVluLG7SEE7ZTE2CM9+ODXRa7H4vtrh3v7TVNMiiQbYYUkhhjTsRjAI/2u/bis2w8R6tZzK631xKoILJNIZAw9PmzWN6cY8jXzOy2KqTVaDS023/pmKSJFTYQ291Ax7kVNp9vLeXMcECtJcXEuxV7szNgD+Qrb8TWFjFcWWsWcghtbw+aIsfxD7ygDuDXRfDXRoNIFr4s8SXf9l2lvOG09Z4HJup/mZHUAEmNGCliM9h1NaVKShTST3d/kY0MU6tZ1JRs0rfO5z/xHljn8Y619ncSRpKYFdej7AE3D2O3I+tczbbDGQmCmePx5/rWr4o0u70LUJra7eOWTYsyTxMXjljdQyyKeCQQQfX1waybFVW3G1twJJz681h9h37nakvbQS6Rf6EABspuP+Pdz/3yanZN0qTYIO7YuRjcACWP05H40TzwIrLKykdCOtAm3GAyyBh5QVCWBxzyCfXpWsFeEpta2OSq1CrCjGS5W7+lunoyScZhcH+6a+l/2TNUK6vq+nO3NzaR3IB9UbBx/wB/P0r5inuoQrIJFLsMAA9691/Zwm+y/E/S4N3+tgmi6dcRlv8A2WurAwfsqlzjzipCU4crvufX9FFFI8gKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAx/GWpNo/hLWdRRtsltZyyof8AbCHb+uK/PLUJ57m7l8yZwqSHAUkEn1J6k19n/tJaydN+HbWcbYl1G4SDj+4PnY/+OgfjXxjq0Jtp2uBgwyHLDupx19xWsoVPYOVPv+B1YF0lXXttv1K0yGcATySSL6MaYkYCzJEwjiEZDlmwmeCB9aYlykzFYpEQd5H4A/xqVo1EpQHdHE2F/wBpu7H3P8q5KbnFe1qN/wCZ61aNGs1h8Old6t22SIpLkrtAiLFuQFZTn8jWl4e0G98Tazpmn6ZF9o1C8kKxQg4CAdck9MdSfQVUVQudoAz6CvYfg14h8N/DXRbrxTrWb7XLwtb2FlAQWiiz8zSN0j3MMc84HAIaopckuay6FY321OMHKV9dtl5fict49udR8ONa+DrS5ntks4Y4r6JHKJPcuS7swB+cLvCAnsmR15o+GNPaGPWFSSSa5l06aNFAxuJAwAPXiovin48vvG+vDVdRt7aCUbY4YrdMEKGyAW6sfc/gBXOxXF0l0LyO4kgug25Wjb7nGMe4/nWlKdKEG5K7e3oZYijia01CDtZXfr/wTQsdb1bTkMVlqN5bx7XjMaSsq7WBDDbnHIJBqlPbzW/l+fDJF5iCRN6ldynowz1B9a2LvxQmoabImqWttPehditt2SB+zAjqvfH610HitNHHiNLW9nm/4l9vBaw2cUZLzKsSEuZOgyzMSOMdqxlh5JqKd77HVTzGDi5Tjy23EbXJ9N0HQ1t9O0uTUtjNA8tmsgt4+hc78jeSA2ccntxXDazqd7rd9cXOsXs93dsGRZZJC29gcAAn26DpUur6lNrN4ZZQsduiiOOKPhFUZwo9QM/iSe2KpzBVt3HAUKenatHOFNqKV2tzmp4erXpzqSfKndr776neeGIR480JfD620s2vadAx02WPlpo925reQE9izMrduQeMY5TW9Dm8J6/e6Pr9oI7i3JVlJ5BC5GCOoIwQa2vhz451DwR4kk1uwitZ5HBilS4jBBQYBAPVenUfjmu9+MHiDw38UdCtvEmlONL8QWkTQXVldsAZ4j0aNujhWJHY7STjAFaUI2qtQ1szDF1G6UZVIpcyuu6f+R4pbwIihjGgc8nA6E+lPeFHYNjDDuvBpBcICVc7XX7wPb8fSpFZXGVYMPUGuOTnGV3oz2qUaE6ahCzQxYY0UqqKARg8da9O/Z4uJh8TNCQbnaK4aMHPO0xtnn2BNeaOwRSzHCjkmvXP2aLEn4l6K0i4YefO6kdP3TgfllfyrswHM3N9LHmZyqcacIpa3/A+0KKKKs8EKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8M/at/5F/Qv+vp//AECvlbXUytu7AFA5U59xxX1T+1b/AMi/oX/X0/8A6BXzLdQLc27xOSAw6jt716FOn7TDuHe46dT2dRT7MwMDGABj0qtDtgZ1OVQHBOOAc8c9uOPwqzh45Hhmx5qdfcdiKMMr74pDG+NpIAII9CD1rwopQk4VD6ypetCNahq1t6dUNDmRxHb4klboB29z6Ckw+2SFJj5SkpgAYY55JHfJzUkN1PFbyRRP96TaJCB8vGTjHemjbFEOioo71tNxowSpt3f5djlpxli6kpV0uWN1bz6kQjjEaSFCJIWCuSxIAOQpHtmniXeJPJG/ywC7ZwqDOOT254rX8N6TLql9FbteWWmi74a5v5ljjhiXktz1Y54UZPt1r6A0rxT8HvAng688PaZJJrc08Y+2Tx2PmtM45VnMm1MA4IXOPqcmtJ0lJx5lrbVHHHFyoRmqXw30e/8AXlc8K8CeFr/xVrkMEUezT1ZftN8wMcUKbgGy7DryAOOSQADmjxzdNqHj3V5oE2BrudY0/uxruVV/ABR+FV9V8U69q/lz32pzzW4cCONZsJEQcjbGvyIM9l6Vf+JtvKvjLULqKMpFebblJIxhGM8YkG0jgBstj8u1RCLhVjdWN6lT2mHk+bm0t+Kv/VjlY3RUVGIR1ABVuCPwNT2aC4n3cNDF8xAP327KP5/lUCIrqrozgEeuf50GCMj5gSezEkkfQ9qzpzpU5qer8jqq08TWpez0SfVXIpGjlkeVjHACcmMHOD7g8Z/CpRtdg8iyMZB8ryKfmA9CaSWWSeVIpgsiI2TIVG4nHAJ746/lTiNiNHhmgY7tqnlG/vL/AIVrNxnLlcnrr2XzOSjCdOPPGmm4uz6v5f5CmKMkHYoI6EcGmJFFDMrlA8ZYB1PoT1B61JEJWiDqnmp3aLk/ivUVCZEm3ZywH3Yx1Y+regH61FOnVpzV9F+BtiK2FrUm46ye1t7/AJhIiPI1zCBGq8xADIwOhOc5zX0J+y3Cbn4gNM2MxadJL+JZF/8AZq+fpFK22xfvEBB9TxX0x+yhCq+I9ZYZylmiD6Fx/gK7MLUlOFST2PNzKjCi6cI721PpiiiiszzgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDJ8R+HNI8SWsdvrlhDeQxtuQSZ+U+oI5Fef6p8B/B15k2q39gewguNw/8fDfzr1airjUlHZisfOHiH9mcXQ3aZ4gHmKDs+0W+0r/wJScj2214H8R/Bep+BPEX9i6pKs1wYVnWSA4jZGJGQSoJwVIPHWv0LrnPGfgrw/4zshbeI9NhuwgPlS/dliz3Rxhl+mcHvmpqSdTVpX9DooV5Una75eqTsfnu8sZtEhMXkPEdyOpLKT3Ddxmm2ZjmmczMNyKWiTGVYgZyT3x6V7t40/Zw8Q6dPNN4UuoNXsckxwTyCG5A7DJwjfXK/Ssr4efAXxD4j1iSPxTaXOh6VCjb5H2+bKxBAWMZI46knjtzniI1JOpGU4ptdTum6KoSVKo0n9nzPG3ElxFGZpncj5huwRn6UqwgKqsSyryFOMA+uBxmvouH9l/Uvt2yXxRaCyDf6xLNvMK9vl3YB/E4960dT/Zfi+yMdK8TzfagRgXVqChHcHaQR9efpWDVaV7v8TpjisDBpqP4HzDNlSxU9V3H6qQQf5j8a+n/AAHrvgLx38LE8BXM39mag1uIojeyBi8wJZXjk4Bw5OF4OCQBiufk/Zs8TWTi4t9V0y9cAgRgtFj6ZBz+JFcvqfwd8WaZI0svhiWU8ndbBZ8/QISf0rro4bmjG8kn+hw4nGQnOfInZtNdNfQ821rS7vw/fy2WqRvBdwzyQTxOP+WinGV9Qeo9c8cVnO87ytGiiIKOS3JH4ev1rufEFvqqSk6xDdrdhAqG7Rg3yjCj5ueAAB7CuIjdIUCS5jcfeD8Env8AWpxuHVK00rt/d/TOnLsTKp+6nK0V9/pfshJDLDDGMiSOMliAuG56n3qWOVJPunnrg8EfhUkUU8+PJhbB/jf5V/xrVTToTaQwzqHaNcBxwR9D1FTSwlXEK89LbGtTHUsHLlo6p7r/AIJjPFG5yyKT64pyqqDCgKPQCtA6Tg/JcyBewZQT+dH9kk8G6fHfCgGk8ur7fqaLNsMveUXf0RW06D7Td5J/dwEMQO7dh+HX8q+kv2UlY69rzYO0W0YJ9y5/wNeDW8EdvCsUK7UH6+9fTX7K2kyW/h/WdUkTal5OkUZPcRg5I9svj6g16PsVh8PydTwcRiJYiq6jPcqKKK4TMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKp6tqdho9i97q99a2FnGQHnupVijUk4GWYgDJIFXK89+PPh7VfFHw0v9L0C2a61CSa3dIlkRCQsqsxBcheACeTQB2Gia7pGvQSTaFqthqUMbbHks7hJlVsZwSpODjtWlXjXiHQfGviEeHbW3vvGWnWq6hJ/aN1Ne2FvcrbtEANv2U7GUN0ypYEk+mKEHhf4jW/xGE9xq2sy6RDqUT288MqSxSWYAUxzI11GBxyzCF3JGQT92gD2fWrzTbDTJ7nW7izttOQDzZbx1SJQSANxbgZJA57msHVvh34P1cE3nh3TWLc74ohEx99yYOfevIvEHgTxhr/wv1zRtXsddu/Fsql/tsutg6fdFbhHCxw+ftT5BwGiUAr1BxXu3huIw6FZRtbXtqyxgGG9uPtEyezyb33H33H601JrZgeb6r8BPCN5uNm2oWDHoIp96j8HBP61x2qfs6XK5bSfEEMnolzblMf8CUn+VfRdFaxxFRdRWR8iar8EPGtjkw2drfKO9tcL/J9p/SuP1Twh4i0rJ1HQ9St1H8b27bf++sYP51910VtHGTW6Fyn58xo0kipGrO7EBVUZJJ7CvufwDov/AAj3gzR9LKBJLe2QSgf89CMv/wCPE1pT6Vp093HdT2FpLdRNvSZ4VZ0b1DEZBq7WdfEe1SVrDSsFFFFc4wooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cross-section of corpora cavernosae illustrating penile blood flow in the flaccid and erect state. As intracavernosal pressure rises, emissary veins are occluded to maintain erectile function.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_32_33283=[""].join("\n");
var outline_f32_32_33283=null;
var title_f32_32_33284="Location of anorectal abscesses";
var content_f32_32_33284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Location of anorectal abscesses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 404px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_32_33284=[""].join("\n");
var outline_f32_32_33284=null;
var title_f32_32_33285="Normal ear anatomy";
var content_f32_32_33285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Normal ear anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 505px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows the normal structures of the outer, middle, and inner ear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_32_33285=[""].join("\n");
var outline_f32_32_33285=null;
var title_f32_32_33286="Pyoderma gangrenosum on penis";
var content_f32_32_33286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pyoderma gangrenosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A purulent ulcer is present on the penis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_32_33286=[""].join("\n");
var outline_f32_32_33286=null;
var title_f32_32_33287="Diagnosis and classification of osteoarthritis";
var content_f32_32_33287=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and classification of osteoarthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/32/33287/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/32/33287/contributors\">",
"     Kenneth C Kalunian, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/32/33287/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/32/33287/contributors\">",
"     Peter Tugwell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/32/33287/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/32/33287/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/32/33287/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoarthritis (OA) was previously thought to be a normal consequence of aging, thereby leading to the term degenerative joint disease. However, it is now realized that osteoarthritis results from a complex interplay of multiple factors, including joint integrity, genetic predisposition, local inflammation, mechanical forces, and cellular and biochemical processes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/42/19114?source=see_link\">",
"     \"Pathogenesis of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of osteoarthritis (OA) is complicated by multiple factors. These include a lack of specific physical or laboratory findings and discrepancies between symptoms and the results of radiographic examinations. As a result, OA is frequently diagnosed by an overall clinical impression based upon the patient's age and history, findings on physical examination, and radiographic findings.",
"   </p>",
"   <p>",
"    In an attempt to overcome these difficulties, a standardization of the definition, classification, and diagnosis of OA has been attempted using traditional diagnostic criteria and decision trees. These criteria were formulated according to the affected anatomic areas, and include the knee, hand, and hip.",
"   </p>",
"   <p>",
"    The classification and diagnosis of OA is discussed here, beginning with a review of the different types of OA. The risk factors for and possible causes of OA and the clinical manifestations of this disorder are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29370?source=see_link\">",
"     \"Risk factors for and possible causes of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12056?source=see_link\">",
"     \"Clinical manifestations of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF OSTEOARTHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoarthritis has traditionally been subdivided by etiology into either idiopathic or secondary forms:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Idiopathic osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic OA can be categorized into localized or generalized forms of the disease. Localized OA most commonly affects the hands, feet, knee, hip, and spine. Other joints are less commonly involved; these include the shoulder, temporomandibular, sacroiliac, ankle, and wrist joints. Generalized OA consists of involvement of three or more joint sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Secondary osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific conditions may cause or enhance the risk of developing osteoarthritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29370?source=see_link\">",
"     \"Risk factors for and possible causes of osteoarthritis\"",
"    </a>",
"    .) These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Trauma",
"     </li>",
"     <li>",
"      Congenital or developmental disorders",
"     </li>",
"     <li>",
"      Calcium pyrophosphate dihydrate deposition disease (CPPD)",
"     </li>",
"     <li>",
"      Other bone and joint disorders including osteonecrosis, rheumatoid arthritis, gouty arthritis, septic arthritis, and Paget disease of bone",
"     </li>",
"     <li>",
"      Other diseases such as diabetes mellitus, acromegaly, hypothyroidism, neuropathic (Charcot) arthropathy, and frostbite",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although not uniformly true, these forms of OA are more likely to present in an atypical fashion, such as acutely or with unusual patterns of joint involvement. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Joint involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Independent of underlying etiology, OA can also be classified by anatomic involvement. These include the site of chief joint involvement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of single or multiple joint involvements.",
"   </p>",
"   <p>",
"    Unfortunately, all proposed systems for characterizing patients with OA are flawed. A system characterized solely by the type or degree of joint involvement relies upon a clinical assessment at a particular point in time; however, the manifestations of the disorder are likely to change over the course of the patient's illness. In addition, it is often very difficult to determine if an underlying disorder or previous injury is absolutely causative of OA.",
"   </p>",
"   <p>",
"    Despite these limitations, the use of such systems may help accurately diagnose OA. The system described below, which is based upon characterization of OA of the knee, hip, and hand in patients with idiopathic OA, is a highly sensitive and specific classification system for this disorder. However, the predictive values of these criteria are affected by the prevalence of OA in the population studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical diagnosis of OA is often entertained in the patient who presents with joint pain. An essential component to the diagnosis is the correct attribution of signs and symptoms to the affected site. As an example, pain and other symptoms resulting from OA can be confused with soft tissue processes such as bursitis at periarticular sites; in addition, pain in a particular area may be referred from OA at other sites or may be due to a nonarticular process.",
"   </p>",
"   <p>",
"    A nonspecific complaint of joint pain may be due to a wide range of disorders. Such patients should undergo a complete history and physical examination and, if clinically indicated, radiographic examination of affected joints in combination with selected laboratory tests. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/14/28904?source=see_link\">",
"     \"Evaluation of the adult with monoarticular pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34039?source=see_link\">",
"     \"Evaluation of the adult with polyarticular pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If possible, the following laboratory examinations should be performed in the patient suspected of having OA, particularly among those with knee or hip involvement:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Erythrocyte sedimentation rate (ESR)",
"     </li>",
"     <li>",
"      Rheumatoid factor titers",
"     </li>",
"     <li>",
"      Evaluation of synovial fluid",
"     </li>",
"     <li>",
"      Radiographic study of affected joints",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Certain clinical features are more suggestive of idiopathic OA than other disorders. As an example, OA does not affect all joints equally; it has a predilection for the fingers, knee, hip, and spine, and rarely affects the elbow, wrist, and ankle. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12056?source=see_link\">",
"     \"Clinical manifestations of osteoarthritis\"",
"    </a>",
"    .) If the atypical joints are involved in a patient suspected of having OA, the clinician should initiate a search for secondary causes of the disorder. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Secondary osteoarthritis'",
"    </a>",
"    above.) The joints are usually asymmetrically involved in OA (particularly the large joints), and a synovial effusion, if present, most commonly has mild inflammatory characteristics (ie, synovial WBC &lt;",
"    <span class=\"nowrap\">",
"     2000/mm3).",
"    </span>",
"   </p>",
"   <p>",
"    However, the disorder has no absolutely specific characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33287/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]; in addition, radiographic findings may be misleading and disproportionately severe when compared to the findings on clinical examination. As a result, the diagnosis of idiopathic OA is not made based upon a few specific findings, but upon a constellation of clinical, historical, and laboratory features (",
"    <a class=\"graphic graphic_table graphicRef73969 \" href=\"mobipreview.htm?38/23/39292\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis: Summary and recommendations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A clinical diagnosis of osteoarthritis is supported by the presence of typical symptoms, physical examination, laboratory, and imaging features (",
"      <a class=\"graphic graphic_table graphicRef73969 \" href=\"mobipreview.htm?38/23/39292\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Among the clinical features of OA, none is completely sensitive or specific, and thus is not always predictive for the disease. In general, the more features that are present, the more likely the diagnosis.",
"     </li>",
"     <li>",
"      Classification criteria and classification trees, while useful for research purposes, have not been validated for clinical diagnosis and should not be relied upon for that purpose (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Classification'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Before making a clinical diagnosis of idiopathic OA, other disorders should be considered and excluded (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      The finding of clinical and radiographic evidence of OA that involves joints that are uncommonly affected by idiopathic disease (eg, the shoulder, elbow, wrist, and ankle) should prompt a search for an underlying cause. The presence of articular cartilage calcification (chondrocalcinosis) may be a clue to the presence of an endocrine, metabolic, or heritable disorder that predisposes of OA (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Calcium pyrophosphate crystal deposition disease'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Severe, acute joint pain is an uncommon manifestation of OA. We recommend joint aspiration in this setting. Synovial fluid findings in OA usually suggest a minimally inflammatory (WBC",
"      <span class=\"nowrap\">",
"       &lt;2000/mm3)",
"      </span>",
"      or noninflammatory process. Crystals are absent when examined using compensated polarized light microscopy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/14/28904?source=see_link\">",
"       \"Evaluation of the adult with monoarticular pain\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of osteoarthritis is not difficult in the elderly patient with knee pain, transient morning stiffness, crepitus, bony tenderness and enlargement, a low ESR, noninflammatory synovial fluid, and osteophytes on radiographic examination. However, the diagnosis is problematic in the patient with less typical features since multiple disorders can present with similar findings. In addition, the presence of atypical features (such as unusual joint involvement) and the coexistence of additional arthritic disorders may obscure the diagnosis of idiopathic OA and make an accurate diagnosis extremely difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Calcium pyrophosphate crystal deposition disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the arthritic process due to calcium pyrophosphate crystal deposition disease (CPPD) occurs in joints typical for OA (such as the interphalangeal joints of the hands, the first carpometacarpal joints, the knees, or bunion joints), even radiographic or joint fluid evidence of CPPD crystal deposition does not permit an unequivocal diagnosis. However, since the most commonly affected joints in CPPD arthritis are the knees, followed by the wrists, metacarpophalangeal joints, hips, shoulders, elbows, and spine, such a distribution of affected joints strongly suggests CPPD and not OA. The findings on clinical examination of individual joints do not typically differ from those observed in OA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7785?source=see_link\">",
"     \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoarthritis in the middle aged or elderly patient is most commonly confused with rheumatoid arthritis (RA) when it involves the hand joints. The different patterns of clinical involvement, however, will usually lead to the correct diagnosis (",
"    <a class=\"graphic graphic_table graphicRef57005 \" href=\"mobipreview.htm?33/49/34587\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoarthritis of the fingers typically affects the distal interphalangeal joints, and is frequently associated with the highly characteristic Heberden's nodes (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55802 \" href=\"mobipreview.htm?30/52/31567\">",
"       image 1",
"      </a>",
"      ). In contrast, RA typically affects the metacarpophalangeal and proximal interphalangeal joints and Heberden's nodes are absent. The carpometacarpal joint of the thumb is typically involved in OA, rather than the proximal interphalangeal joint in RA.",
"     </li>",
"     <li>",
"      Swelling of the joints is hard and bony in OA; in comparison, soft, warm, and tender joint swelling is typical of RA.",
"     </li>",
"     <li>",
"      Stiffness of the joint is a very common feature of RA, but is a relatively rare feature of osteoarthritis. Furthermore, the stiffness of RA is characteristically worse after resting the joint (eg, morning stiffness), while the stiffness of osteoarthritis (if present) is typically worse after any effort, and is often described as evening stiffness.",
"     </li>",
"     <li>",
"      OA is characterized radiographically by narrowing of the joint space due to cartilage loss and osteophytes due to bone remodeling, but not erosions or cysts (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55802 \" href=\"mobipreview.htm?30/52/31567\">",
"       image 1",
"      </a>",
"      ). However, many patients with long-standing RA may develop secondary OA.",
"     </li>",
"     <li>",
"      OA is classically associated with the absence of rheumatoid factors and antibodies to cyclic citrullinated peptides (CCP). OA is associated with normal levels of acute phase reactants. However, rheumatoid factors may be present, usually in low titer, consistent with the patient's (older) age. In addition, the ESR and serum C-reactive protein concentration may be somewhat elevated, usually secondary to an associated disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Infectious monoarticular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoarthritis of a single joint is usually associated with mild symptoms and a noninflammatory synovial fluid (WBC &lt;2000",
"    <span class=\"nowrap\">",
"     cells/mm3),",
"    </span>",
"    but can also present as an acutely painful synovitis that may mimic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33287/abstract/3\">",
"     3",
"    </a>",
"    ]. The differential diagnosis and evaluation of the patient presenting with single joint involvement is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/14/28904?source=see_link\">",
"     \"Evaluation of the adult with monoarticular pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of a lack of specificity of previously used definitions of osteoarthritis, the American College of Rheumatology (ACR) organized a subcommittee in 1981 to develop specific criteria to standardize the definition of osteoarthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33287/abstract/4\">",
"     4",
"    </a>",
"    ]. The ACR subcommittee utilized two methods to generate classification criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Traditional inclusion criteria",
"     </li>",
"     <li>",
"      Classification trees",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each method was evaluated for three specific joints: the knee, hip, and hands.",
"   </p>",
"   <p>",
"    Although useful in understanding key features of osteoarthritis and assisting in standardization of patients for clinical trials, the ACR criteria for classification of OA have several limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients studied had symptomatic disease. It is therefore unclear how asymptomatic patients with abnormal radiographs are to be classified.",
"     </li>",
"     <li>",
"      No cases of secondary osteoarthritis were included. The classification schemes are therefore not relevant to patients with coexisting diseases despite the fact that patients with inflammatory or other forms of arthritis may develop osteoarthritis.",
"     </li>",
"     <li>",
"      The conclusions are drawn from statistical analysis. As a result, these findings have less meaning in an individual patient. As an example, although the clinician may take comfort in the classification tree criteria for hand OA, which has a specificity of 98 percent, this number is meaningless in the individual patient whose disorder may fall into the remaining 2 percent. Despite these limitations, the ACR criteria provide a basis upon which to form clinical impressions, and help clarify which features help separate OA from other disorders that present with joint pain. The following discussion will focus upon the ACR subcommittee's conclusions concerning the classification of patients who have knee, hand, or hip pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OSTEOARTHRITIS OF THE KNEE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classification criteria were first developed for OA of the knee joint. The methodology utilized and delineated below for the knee was subsequently used for the hand and hip.",
"   </p>",
"   <p>",
"    An expert panel initially identified the relevant diagnostic features of knee OA. These features were then independently evaluated by each committee member for perceived sensitivity and specificity. The committee subsequently expanded the data set to include other potentially important historic, physical, laboratory, and radiographic features.",
"   </p>",
"   <p>",
"    Consecutive patients with knee joint pain of articular origin were recruited from multiple centers; any available radiographs were also obtained. Patients possessing features of secondary or nonidiopathic forms of osteoarthritis were excluded. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29370?source=see_link\">",
"     \"Risk factors for and possible causes of osteoarthritis\"",
"    </a>",
"    .) Approximately one-half of the patients had OA and the remainder had joint pain from other disorders.",
"   </p>",
"   <p>",
"    Traditional inclusion criteria and classification trees were formed to differentiate idiopathic OA from the other forms of arthritis. These two methods were independently evaluated for clinical findings alone, clinical and laboratory findings, and combined clinical, laboratory and radiographic findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Classic clinical criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic criteria method for OA of the knee is based upon the presence of knee pain plus",
"    <strong>",
"     at least three",
"    </strong>",
"    of the following six clinical characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33287/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Greater than 50 years of age",
"     </li>",
"     <li>",
"      Morning stiffness for less than 30 minutes",
"     </li>",
"     <li>",
"      Crepitus on active motion of the knee",
"     </li>",
"     <li>",
"      Bony tenderness",
"     </li>",
"     <li>",
"      Bony enlargement",
"     </li>",
"     <li>",
"      No palpable warmth",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria result in a sensitivity and specificity for OA of 95 and 69 percent, respectively.",
"   </p>",
"   <p>",
"    The inclusion of laboratory criteria to these clinical characteristics alters the accuracy of diagnosis of knee OA. As an example, if an ESR less than 40",
"    <span class=\"nowrap\">",
"     mm/h,",
"    </span>",
"    a rheumatoid factor titer less than 1:40, and synovial fluid suggestive of OA (clear color, viscous fluid, white blood cell count less than",
"    <span class=\"nowrap\">",
"     2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    are added to the six clinical characteristics, the diagnostic criteria of knee pain and at least five of the nine features (six physical plus three laboratory) now has a sensitivity and specificity for OA of 92 and 75 percent, respectively.",
"   </p>",
"   <p>",
"    The addition of radiographic data further alters the diagnostic accuracy. The criteria of knee pain, radiographic evidence of osteophytes, and one of three additional findings (age greater than 50 years of age, morning stiffness of less than 30 minutes, or crepitus) has a sensitivity and specificity for OA of 91 and 86 percent, respectively.",
"   </p>",
"   <p>",
"    The addition of laboratory or radiographic findings to the clinical findings therefore improves specificity, but slightly lowers sensitivity for OA of the knee. The alternative method of classification trees was therefore examined to determine if improved statistical outcomes in the diagnosis of OA could be achieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Classification trees",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using recursive partitioning, (also known as classification and regression tree technique or CART) the clinical features of osteoarthritis were placed in nodes according to their ability to accurately separate OA from other forms of joint pain. Unlike the traditional inclusion criteria method, the more important features of disease are more heavily weighted statistically, thereby resulting in improved sensitivities and specificities.",
"   </p>",
"   <p>",
"    The method utilizes a flow chart in which one proceeds down a classification tree and determines if a nodal feature is present or absent. Whether a particular feature is present or absent subsequently determines the next pathway, since each node contains only one question with two possible outcomes. To maintain utility, surrogate decisions in parenthesis may be used in some cases when the primary nodal decision is absent. Subsequently, the user proceeds down sequential nodes until reaching an end point that ultimately determines the likelihood of the patient having osteoarthritis.",
"   </p>",
"   <p>",
"    Three trees were formed for knee OA based upon clinical features alone, clinical features combined with laboratory findings, and combined clinical, laboratory and radiographic features. The sensitivities for these three classification trees were 89, 88, and 94 percent, respectively, while the specificities were 88, 93, and 88 percent, respectively.",
"   </p>",
"   <p>",
"    The diagnostic accuracy of classification trees based upon clinical and laboratory features or clinical features alone was validated via the use of arthroscopic examination of the knee as a gold standard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33287/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients who underwent arthroscopy included 90 with OA and 10 controls with rheumatoid arthritis (RA). Of the 73 patients with OA whose arthroscopic findings could be assessed, six met clinical criteria and 67 met both clinical and radiographic criteria for OA. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean knee OA arthroscopy scale (KOAS) for the six patients with clinical criteria for OA only was 17.4.",
"     </li>",
"     <li>",
"      Those who satisfied both clinical and radiographic criteria had a mean KOAS of 42.",
"     </li>",
"     <li>",
"      Among patients in the RA group the mean KOAS was 1.8.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differences between the OA and RA groups were statistically significant. The ACR clinical and clinical plus radiographic criteria for OA of the knee accurately predict cartilage damage as assessed by arthroscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Summary and recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians have two methods for evaluating possible osteoarthritis of the knee:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The superior approach is the recursive partitioning tree model in which the appropriate tree is utilized based upon the available data. Although clinical data alone is sufficient to determine the likelihood of OA, the addition of laboratory",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiographic data improves the ability to classify individuals as having or not having osteoarthritis.",
"     </li>",
"     <li>",
"      Alternatively, the clinician may use the traditional inclusion criteria method. This method, however, appears inferior to classification trees.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OSTEOARTHRITIS OF THE HAND",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of OA of the hand was examined by employing a similar methodology as with involvement of the knee [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33287/abstract/6\">",
"     6",
"    </a>",
"    ]. Traditional format analysis using clinical criteria revealed that the best diagnostic variables are hand pain (including hand aching or stiffness) plus",
"    <strong>",
"     at least three",
"    </strong>",
"    of the following four features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hard tissue enlargement of 2 or more of 10 selected joints. The 10 selected joints are the second and third distal interphalangeal (DIP) joints, the second and third proximal interphalangeal (PIP) joints, and the first carpometacarpal (CMC) of both hands",
"     </li>",
"     <li>",
"      Hard enlargement of two or more DIP joints",
"     </li>",
"     <li>",
"      Fewer than three swollen metacarpophalangeal (MCP) joints",
"     </li>",
"     <li>",
"      Deformity of at least 1 of the 10 selected joints",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incorporation of other hand joints did not improve the ability to classify patients. This tradition inclusion criteria model yielded a sensitivity and specificity for hand OA of 94 and 87 percent, respectively. By comparison, a classification tree utilizing the same clinical features as nodes elicited an overall sensitivity and specificity of 92 and 98 percent, respectively.",
"   </p>",
"   <p>",
"    Unlike knee OA, radiographic and laboratory findings",
"    <strong>",
"     did not",
"    </strong>",
"    greatly impact upon the diagnosis of hand OA. Classification trees with and without radiographic features were identical. There was no statistical difference in the inclusion criteria method if these variables were included or discarded. As a result, hand OA is readily classified by clinical features alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OSTEOARTHRITIS OF THE HIP",
"    </span>",
"    &nbsp;&mdash;&nbsp;In developing classification criteria for OA of the hip, the ACR subcommittee noted that, as with OA of the knee, radiographic findings significantly impacted upon the ability to make an accurate diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33287/abstract/7\">",
"     7",
"    </a>",
"    ]. As a result, traditional formats and classification trees were constructed with and without radiographic features.",
"   </p>",
"   <p>",
"    The traditional inclusion criteria format for history, physical, laboratory, and radiographic features utilized the presence of hip pain plus",
"    <strong>",
"     at least two",
"    </strong>",
"    of the following three features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ESR of less than 20",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"     </li>",
"     <li>",
"      Radiographic osteophytes (femoral or acetabular)",
"     </li>",
"     <li>",
"      Joint space narrowing on radiography (superior, axial or medial)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This classification scheme yields a sensitivity of 89 percent and a specificity of 91 percent.",
"   </p>",
"   <p>",
"    Traditional criteria for hip OA but without radiographic and laboratory data were also constructed. Although the sensitivity of 89 percent was acceptable, the specificity of only 54 percent was felt to be too low to be clinically useful. As a result, one",
"    <strong>",
"     cannot",
"    </strong>",
"    accurately diagnose hip osteoarthritis using the traditional method without incorporating laboratory and radiographic data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Classification trees",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classification trees for hip OA were constructed with and without radiographic features. The hip OA classification tree that did not incorporate radiographic features resulted in a sensitivity and specificity of 86 and 75 percent, respectively. Key features in this tree were internal rotation of less than 15&ordm;, pain on internal rotation, morning stiffness, age, ESR, and flexion of less than 115&ordm;. With the addition of radiographic features, the sensitivity and specificity improved to 91 and 89 percent, respectively. Key features in this tree included the presence of radiographic osteophytes and axial space narrowing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Rapidly destructive hip osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapidly progressive destruction of the hip has been described in some patients, mainly in older women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33287/abstract/8\">",
"     8",
"    </a>",
"    ]. Serial plain radiographs reveal decreasing joint space over several months. Involvement is typically unilateral. Magnetic resonance imaging often reveals joint effusion and diffusely increased T2 signal in the femoral head, neck,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acetabulum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33287/abstract/9\">",
"     9",
"    </a>",
"    ]. In one case this presentation was associated with osteonecrosis of the femoral head [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33287/abstract/10\">",
"     10",
"    </a>",
"    ] and with a stress fracture of the femoral head in another patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33287/abstract/11\">",
"     11",
"    </a>",
"    ]. Increased plasma levels of matrix metalloproteinase (MMP)-3 and MMP-9 and urinary excretion of type II collagen breakdown products in the urine in those with rapid hip destruction compared to those with more typical slowly progressive osteoarthritis supports a distinction between these two disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33287/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/3/43058?source=see_link\">",
"       \"Patient information: Osteoarthritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/46/16098?source=see_link\">",
"       \"Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/29/21975?source=see_link\">",
"       \"Patient information: Osteoarthritis treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57112907\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoarthritis (OA) is subdivided by etiology into either idiopathic or secondary forms. Idiopathic OA can be localized or generalized. Localized OA most commonly affects the hands, feet, knee, hip, or spine, while generalized OA involves three or more joint sites. Secondary OA is present when specific conditions, such as trauma, congenital disorders, crystal disease, and other disorders affecting bone and joints may cause or enhance the risk of OA. OA can also be classified by anatomic involvement, including the site of chief joint involvement",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the presence of single or multiple joint involvement. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of osteoarthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Idiopathic osteoarthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Secondary osteoarthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Joint involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A clinical diagnosis of OA is supported by the presence of typical symptoms, physical examination, laboratory, and imaging features (",
"      <a class=\"graphic graphic_table graphicRef73969 \" href=\"mobipreview.htm?38/23/39292\">",
"       table 1",
"      </a>",
"      ). No single clinical feature is absolutely sensitive or specific. Generally, the more features that are present, the more likely the diagnosis. (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis: Summary and recommendations'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Before making a clinical diagnosis of idiopathic OA, other disorders should be considered and excluded. The finding of clinical and radiographic evidence of OA that involves joints that are uncommonly affected by idiopathic disease (eg, the shoulder, elbow, wrist, and ankle) should prompt a search for an underlying cause. The presence of articular cartilage calcification (chondrocalcinosis) may be a clue to the presence of an endocrine, metabolic, or heritable disorder that predisposes to OA. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis: Summary and recommendations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Calcium pyrophosphate crystal deposition disease'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      We perform arthrocentesis in patients with severe, acute joint pain, which is an uncommon manifestation of OA. Synovial fluid findings in OA usually suggest a minimally inflammatory (WBC",
"      <span class=\"nowrap\">",
"       &lt;2000/mm",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"      or noninflammatory process. Crystals are absent when examined using compensated polarized light microscopy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis: Summary and recommendations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/14/28904?source=see_link\">",
"       \"Evaluation of the adult with monoarticular pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Calcium pyrophosphate deposition disease (CPPD) should be considered in the differential diagnosis of OA, particularly in patients with a pattern of joint involvement more suggestive of CPPD than idiopathic OA. OA may be distinguished from rheumatoid arthritis by several characteristics more typical of OA (",
"      <a class=\"graphic graphic_table graphicRef57005 \" href=\"mobipreview.htm?33/49/34587\">",
"       table 2",
"      </a>",
"      ); these include distal interphalangeal joint involvement, Heberden&rsquo;s nodes, bony enlargement, normal acute phase reactants and negative serologic testing for rheumatoid factor and anti-cyclic citrullinated peptide antibodies. Infectious arthritis should be excluded in patients with acutely painful synovitis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Calcium pyrophosphate crystal deposition disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Rheumatoid arthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Infectious monoarticular disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/14/28904?source=see_link\">",
"       \"Evaluation of the adult with monoarticular pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Classification criteria and classification trees, while useful for research purposes, have not been validated for clinical diagnosis and should not be relied upon for that purpose. The inclusion of radiographic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      laboratory features in the assessment for symptomatic idiopathic OA of the knee or hip, but not the hand, improves the diagnostic accuracy, particularly the specificity, of these tools, compared with the use of clinical features alone. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Classification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Osteoarthritis of the knee'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Osteoarthritis of the hand'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Osteoarthritis of the hip'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33287/abstract/1\">",
"      Claessens AA, Schouten JS, van den Ouweland FA, Valkenburg HA. Do clinical findings associate with radiographic osteoarthritis of the knee? Ann Rheum Dis 1990; 49:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33287/abstract/2\">",
"      Peat G, Thomas E, Duncan R, et al. Estimating the probability of radiographic osteoarthritis in the older patient with knee pain. Arthritis Rheum 2007; 57:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33287/abstract/3\">",
"      Doi K, Martel W. Monarticular erosive osteoarthritis: a possible source of confusion with infectious arthritis. J Clin Rheumatol 1995; 1:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33287/abstract/4\">",
"      Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986; 29:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33287/abstract/5\">",
"      Wu CW, Morrell MR, Heinze E, et al. Validation of American College of Rheumatology classification criteria for knee osteoarthritis using arthroscopically defined cartilage damage scores. Semin Arthritis Rheum 2005; 35:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33287/abstract/6\">",
"      Altman R, Alarc&oacute;n G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 1990; 33:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33287/abstract/7\">",
"      Altman R, Alarc&oacute;n G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991; 34:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33287/abstract/8\">",
"      Rosenberg ZS, Shankman S, Steiner GC, et al. Rapid destructive osteoarthritis: clinical, radiographic, and pathologic features. Radiology 1992; 182:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33287/abstract/9\">",
"      Boutry N, Paul C, Leroy X, et al. Rapidly destructive osteoarthritis of the hip: MR imaging findings. AJR Am J Roentgenol 2002; 179:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33287/abstract/10\">",
"      Laroche M, Moineuse C, Durroux R, et al. Can ischemic hip disease cause rapidly destructive hip osteoarthritis? A case report. Joint Bone Spine 2002; 69:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33287/abstract/11\">",
"      Watanabe W, Itoi E, Yamada S. Early MRI findings of rapidly destructive coxarthrosis. Skeletal Radiol 2002; 31:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33287/abstract/12\">",
"      Masuhara K, Nakai T, Yamaguchi K, et al. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip. Arthritis Rheum 2002; 46:2625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33287/abstract/13\">",
"      Garnero P, Charni N, Juillet F, et al. Increased urinary type II collagen helical and C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis. Ann Rheum Dis 2006; 65:1639.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5497 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_32_33287=[""].join("\n");
var outline_f32_32_33287=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H57112907\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF OSTEOARTHRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Idiopathic osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Secondary osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Joint involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis: Summary and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Infectious monoarticular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OSTEOARTHRITIS OF THE KNEE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Classic clinical criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Classification trees",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Summary and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OSTEOARTHRITIS OF THE HAND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OSTEOARTHRITIS OF THE HIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Classification trees",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Rapidly destructive hip osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H57112907\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5497\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5497|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?30/52/31567\" title=\"diagnostic image 1\">",
"      DIP osteoarthritis xray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5497|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/23/39292\" title=\"table 1\">",
"      Manifestations of OA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/49/34587\" title=\"table 2\">",
"      RA versus osteoarthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12056?source=related_link\">",
"      Clinical manifestations of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/14/28904?source=related_link\">",
"      Evaluation of the adult with monoarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34039?source=related_link\">",
"      Evaluation of the adult with polyarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/42/19114?source=related_link\">",
"      Pathogenesis of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/3/43058?source=related_link\">",
"      Patient information: Osteoarthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/46/16098?source=related_link\">",
"      Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/29/21975?source=related_link\">",
"      Patient information: Osteoarthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29370?source=related_link\">",
"      Risk factors for and possible causes of osteoarthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_32_33288="Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas";
var content_f32_32_33288=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/32/33288/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/32/33288/contributors\">",
"     Sunil G Sheth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/32/33288/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/32/33288/contributors\">",
"     Tara S Kent, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/32/33288/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/32/33288/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/32/33288/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/32/33288/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/32/33288/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic neoplasms of the pancreas include serous cystic tumors, mucinous cystic neoplasms, solid pseudopapillary neoplasms, cystic islet cell tumors, and intraductal papillary mucinous neoplasms of the pancreas (IPMNs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. IPMNs have also been referred to as mucinous duct ectasias and intraductal papillary mucinous tumors. IPMNs are potentially malignant intraductal epithelial neoplasms that are grossly visible (&gt;1 cm) and are composed of mucin-producing columnar cells. The lesions show papillary proliferation, cyst formation, and varying degrees of cellular atypia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. IPMNs may involve the main pancreatic duct, the branch ducts, or both. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/20/15686?source=see_link\">",
"     \"Classification of pancreatic cysts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the pathophysiology and clinical manifestations of IPMNs. The diagnosis and treatment of IPMNs, as well as an overview of pancreatic cystic neoplasms are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/49/41753?source=see_link\">",
"     \"Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/20/15686?source=see_link\">",
"     \"Classification of pancreatic cysts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3368?source=see_link\">",
"     \"Pancreatic cystic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8190718\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraductal papillary mucinous neoplasm of the pancreas (IPMN) was first described in 1982 when four patients with pancreatic carcinoma and favorable outcomes were reported. The patients were noted to have dilated main pancreatic ducts, patulous ampullary orifices, and mucus secretion from the pancreatic duct [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/6\">",
"     6",
"    </a>",
"    ]. With time, the incidence of IPMN has increased, largely due to increased diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/7\">",
"     7",
"    </a>",
"    ]. Prior to 1999, the distinction between IPMN and mucinous cystic neoplasm (MCN) had not been clarified, so many lesions previously classified as MCNs may have in fact been IPMNs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, improvements in imaging technology have led to more accurate identification of cystic pancreatic lesions.",
"   </p>",
"   <p>",
"    The true incidence of IPMN is not known because many IPMNs are small and asymptomatic. A series of 2832 consecutive computed tomography (CT) scans performed in adults without a history of pancreatic lesions or factors predisposing to pancreatic disease found pancreatic cysts in 73 (2.6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/9\">",
"     9",
"    </a>",
"    ]. In a similar study of 616 consecutive patients undergoing magnetic resonance imaging, the incidence of pancreatic cysts was higher (13.5 percent), with a median diameter of 6 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/10\">",
"     10",
"    </a>",
"    ]. Many of these were likely IPMNs since it is thought that IPMNs account for 1 to 3 percent of exocrine pancreatic neoplasms and 20 to 50 percent of cystic pancreatic neoplasms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The male-to-female ratio for main duct IPMN has varied in reports from 1.1 to 3:1, and for branch duct IPMN it has varied from 0.7 to 1.8:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/14\">",
"     14",
"    </a>",
"    ]. The ratio varies geographically, with a male predominance in Japan and Korea and a more even distribution or female predominance in the United States and Europe. The typical age at presentation is in the fifth to seventh decade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/15\">",
"     15",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef57759 \" href=\"mobipreview.htm?38/0/38925\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    IPMN may be more common in cigarette smokers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/16\">",
"     16",
"    </a>",
"    ] and in patients with Peutz-Jeghers syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], familial adenomatous polyposis syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/19\">",
"     19",
"    </a>",
"    ], or familial pancreatic carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8191002\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraductal papillary mucinous neoplasms of the pancreas (IPMNs) are classified anatomically as well as histologically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8191597\">",
"    <span class=\"h2\">",
"     Anatomic classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPMNs have been classified as main duct (MD)-type or branch duct (BD)-type based upon the anatomic involvement of the pancreatic duct [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Patients with involvement of both the main and branch ducts are referred to as having mixed-type IPMN, though pathologically the lesions behave like MD-IPMN. The characteristic pathologic features include diffuse or segmental dilation of the pancreatic duct without stricturing, intraductal expansion of mucin-producing ductal cells (which may be flat or projecting into the lumen), and dilation of either one or both pancreatic orifices, through which there is copious secretion of mucus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MD-IPMNs involve the main pancreatic duct diffusely or segmentally. The majority arise within the head of the pancreas and progress distally with or without involvement of the side branches. They are histologically more aggressive than BD-IPMNs and more likely to harbor a malignancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      BD-IPMNs occur in younger patients and arise in the uncinate process, although they may also involve the tail of the pancreas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. BD-IPMNs may have a lower risk of malignant transformation compared with MD-IPMNs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8191604\">",
"    <span class=\"h2\">",
"     Histologic classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five histologic subtypes have been described (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/27/44472?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathology of exocrine pancreatic neoplasms\", section on 'Histology and grading'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intestinal type: This is the most common subtype of MD-IPMN. It typically occurs in the pancreatic head, though it may involve the entire duct. Its growth pattern is villous (",
"      <a class=\"graphic graphic_picture graphicRef55059 \" href=\"mobipreview.htm?7/16/7431\">",
"       picture 1",
"      </a>",
"      ), and it expresses Mucin-2 (MUC2), MUC5, and caudal type homeobox 2 (CDX2). When invasive, it corresponds with mucinous (colloid) carcinoma, which is characterized by stromal pools of extraluminal mucin.",
"     </li>",
"     <li>",
"      Pancreatobiliary: Like intestinal type IPMN, pancreatobiliary type IPMN typically involves the main duct in the pancreatic head, but it produces less mucus than intestinal type IPMN. Histologically, it is composed of complex arborizing papillae. The cells resemble pancreatic and biliary duct cells. It only expresses MUC1 and MUC5. Its invasive form corresponds with a conventional ductal (tubular) adenocarcinoma.",
"     </li>",
"     <li>",
"      Oncocytic type: Oncocytic type IPMN is rare. It often forms large tissue nodules in the main pancreatic duct and produces little mucus. Histologically, oncocytic type IPMN is composed of complex papillae like pancreatobiliary type IPMN, but cytoplasm of the lining cells is eosinophilic (",
"      <a class=\"graphic graphic_picture graphicRef53658 \" href=\"mobipreview.htm?10/60/11208\">",
"       picture 2",
"      </a>",
"      ). It inconsistently expresses MUC1, MUC2, and MUC5AC, and the expression may be focal.",
"     </li>",
"     <li>",
"      Gastric type: Gastric type IPMN corresponds to BD-IPMN and is the most common subtype overall. It is typically found in the periphery of the pancreatic parenchyma, often in the uncinate process. The cells lining papillary projections in gastric type IPMN resemble gastric foveolar cells and form pyloric gland-like structures at the base of the papillae (",
"      <a class=\"graphic graphic_picture graphicRef72592 \" href=\"mobipreview.htm?8/37/8791\">",
"       picture 3",
"      </a>",
"      ). The cells consistently express MUC5AC and MUC6. They do not express or are only focally positive for MUC1 and MUC2. Its invasive form corresponds with a conventional ductal (tubular) adenocarcinoma.",
"     </li>",
"     <li>",
"      Tubular type: Tubular type IPMN is more solid than it is papillary, but it is included in the classification due to the fact that it is intraductal. This subtype is rare.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPMNs originate from stem cells in the pancreatic ducts. Several molecular abnormalities have been described in IPMN (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13513?source=see_link\">",
"     \"Molecular pathogenesis of exocrine pancreatic cancer\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      K-ras mutations are found in approximately one-half of cases, with an increasing frequency of these mutations correlating with neoplastic transformation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/28-32\">",
"       28-32",
"      </a>",
"      ]. K-ras is a GTP-binding protein that mediates signal transduction from growth factor receptors to the mitogen-activated protein (MAP) kinase pathway. Mutations in K-ras result in constitutively active MAP kinase signaling. K-ras mutations have been weakly associated with progression to malignancy in IPMN (odds ratio [OR] 2) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mutations in the tumor suppressor gene CDKN2a have been seen in association with IPMN, and a minority of IPMN will display aberrant expression of p53 and SMAD4 (DPC4) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/34\">",
"       34",
"      </a>",
"      ]. SMAD4 is inactivated approximately 50 percent of pancreatic cancers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/35,36\">",
"       35,36",
"      </a>",
"      ], but is expressed in most IPMNs.",
"     </li>",
"     <li>",
"      Inactivating mutations in the ring finger protein 43 [RNF43] gene, a component of ubiquitin-dependent pathways, have been associated with the development of IPMN, establishing the role of RNF43 in suppressing IPMN and MCN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/37\">",
"       37",
"      </a>",
"      ]. Mutations in the GNAS complex locus, which encodes the alpha subunit of guanine nucleotide binding protein, have also been identified in IPMN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/38\">",
"       38",
"      </a>",
"      ]. In fact, either k-ras or GNAS mutations may be identified in up to 96 percent of IPMNs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IPMNs have been seen in a subset of patients with Peutz-Jeghers syndrome who have mutations in STK11 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]; STK11 mutations are also known to predispose to pancreatic cancer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/6/37990?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of Peutz-Jeghers syndrome\", section on 'Genetics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      MUC2 mucin and MUC5 mucin mRNA are highly expressed in IPMN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/39-41\">",
"       39-41",
"      </a>",
"      ]. MUC1 can be identified in up to 90 percent of early pancreatic intraepithelial neoplasias (PanINs) and 86 percent of IPMNs, depending on the antibodies used for detection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/42\">",
"       42",
"      </a>",
"      ]. The presence of MUC1 or MUC2 has been associated with malignancy (ORs of 6 and 4, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypermethylation of promoter sequences can lead to gene silencing, and hypermethylation events involving tumor suppressor genes have been described in association with higher-grades of dysplasia and cancer in patients with IPMN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other genetic markers that have been associated with malignancy in patients with IPMN include human telomerase reverse transcriptase (hTERT) and Sonic hedgehog (Shh) (ORs of 11 and 7, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8191539\">",
"    <span class=\"h2\">",
"     Progression to pancreatic cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPMNs are thought to follow an orderly progression from a benign neoplasm to invasive carcinoma of the pancreas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/27/44472?source=see_link&amp;anchor=H14#H14\">",
"     \"Pathology of exocrine pancreatic neoplasms\", section on 'Intraductal papillary-mucinous neoplasms (IPMN)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IPMNs are graded according to the most atypical area in the lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low-grade dysplasia (adenoma)",
"     </li>",
"     <li>",
"      Moderate dysplasia (borderline)",
"     </li>",
"     <li>",
"      High-grade dysplasia (carcinoma in situ)",
"     </li>",
"     <li>",
"      Invasive carcinoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cancers are typically characterized as either tubular type (morphologically indistinguishable from ductal adenocarcinoma) or colloid type (morphologically similar to cancers of other exocrine organs, such as the breast and skin). Colloid carcinomas have a better prognosis than do tubular carcinomas. In one series, the five-year survival rate of patients with colloid carcinomas was 57 percent, compared with 37 percent for those with tubular carcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previously, the rate of progression from adenoma to carcinoma was thought to be extremely slow (approximately 15 to 20 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/28-30,46\">",
"     28-30,46",
"    </a>",
"    ], though more recently it has been estimated that the progression takes five to six years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The risk of developing carcinoma varies with the subtype of IPMN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/26\">",
"     26",
"    </a>",
"    ]. Colloid carcinoma develops in 30 to 50 percent of patients with intestinal type IPMN, and ductal adenocarcinoma develops in more than 50 percent of patients with pancreatobiliary type IPMN and in 10 to 30 percent of patients with gastric type (branch duct) IPMN. The rate of cancer development in patients with oncocytic type IPMN is unknown due to its rarity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5507120\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with intraductal papillary mucinous neoplasm of the pancreas (IPMN) have no symptoms, with the neoplasm being detected incidentally when imaging studies are performed for unrelated indications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/26\">",
"     26",
"    </a>",
"    ]. Other patients may have nonspecific symptoms such as nausea, vomiting, abdominal pain, back pain, weight loss, or anorexia. Because the main pancreatic duct may be obstructed by mucin, some patients have pancreatitis-like symptoms and may develop exocrine and endocrine pancreatic insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/49\">",
"     49",
"    </a>",
"    ]. Often there is a delay in diagnosis of up to several months due to the insidious nature of this disease and the lack of awareness of this entity among clinicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/50-54\">",
"     50-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although in some patients there may be elevations of pancreatic enzymes with episodes of pain (with or without biliary obstruction), in most cases routine laboratory tests are normal. Tumor markers such as carbohydrate antigen 19-9 and carcinoembryonic antigen are elevated in less 20 percent of cases and are necessarily indicative of malignant transformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/49/41753?source=see_link&amp;anchor=H5511941#H5511941\">",
"     \"Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Serum tumor markers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5506939\">",
"    <span class=\"h1\">",
"     RISK OF MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with intraductal papillary mucinous neoplasm of the pancreas (IPMN) are at risk for both pancreatic and extrapancreatic malignancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5506456\">",
"    <span class=\"h2\">",
"     Pancreatic malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of carcinoma in situ or invasive carcinoma in main duct (MD)-IPMN is approximately 70 percent, and there are no radiographic or clinical characteristics that reliably predict malignancy in MD-IPMN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/3\">",
"     3",
"    </a>",
"    ]. The majority of patients with branch duct (BD)-IPMN have a prolonged course without the development of cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/3,24,25,47,55-57\">",
"     3,24,25,47,55-57",
"    </a>",
"    ]. In one study of 74 patients with BD-IPMN, the 5- and 10-year actuarial rates of developing pancreatic cancer were 2 and 20 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The size of the tumor is an important predictor of malignancy in BD-IPMN. Studies suggest that a tumor diameter &gt;3 cm is associated with an increased risk of malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/59\">",
"     59",
"    </a>",
"    ]. Lesions between 2 and 3 cm have a risk of malignancy of 10 to 25 percent, and malignancy is rare in tumors less than 2 cm in size. Factors associated with malignancy in patients whose tumors are &lt;3 cm include older age, male gender, presence of symptoms, and presence of concerning radiographic features (eg, solid components, pancreatic ductal dilation &ge;10 mm, lymphadenopathy). In particular, the presence of mural nodules should raise concern for malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The presence of synchronous lesions and an increase in cyst size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/61\">",
"     61",
"    </a>",
"    ] during follow-up have also been considered risk factors by other experts. However, a small risk of malignancy exists even when IPMN is discovered incidentally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A concerning report of long-term close follow-up of SB-IPMN in Japan reported a fourfold higher rate of pancreatic cancer developing in SB-IPMN cases, separate and distinct from the IPMN lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/63\">",
"     63",
"    </a>",
"    ]. The 2 percent cancer rate in the SB-IPMN lesions over five years compares with other series, but the finding of an 8 percent separate ductal pancreatic cancer rate needs confirmation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5506766\">",
"    <span class=\"h2\">",
"     Extrapancreatic malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with IPMN may be at increased risk for extrapancreatic malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/64-69\">",
"     64-69",
"    </a>",
"    ]. One of the largest series included 385 patients with a pancreatic cystic neoplasm, 210 of whom had IPMNs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/66\">",
"     66",
"    </a>",
"    ]. An extrapancreatic malignancy was discovered in 34 percent of patients with IPMN compared with 12 percent of those with non-IPMN cystic neoplasms. The diagnosis of the extrapancreatic malignancy preceded the diagnosis of IPMN in 21, coincided with the diagnosis of IPMN in 51, and followed the diagnosis of IPMN in 5. The most common cancers were gastric cancer (29 patients), colon cancer (16 patients), cancer of the common bile duct (7 patients), and lymphoma (4 patients). Five patients had multiple extrapancreatic cancers. On multivariate analysis, the only predictor of an extrapancreatic malignancy was advanced age at diagnosis of the IPMN.",
"   </p>",
"   <p>",
"    A similar rate of extrapancreatic malignancies was described in another series of 61 patients who underwent resection for IPMN at a single institution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/65\">",
"     65",
"    </a>",
"    ]. An extrapancreatic neoplasm was observed in 24 patients (39 percent), including 18 patients (30 percent) who had an extrapancreatic malignant neoplasm. The most common neoplasms were gastric adenocarcinoma and colorectal cancer. These malignancies occurred much more commonly than observed in a control group of patients with mucinous cystic neoplasm of the pancreas or pancreatic ductal adenocarcinoma. Gastric and colonic malignancies were also the most common in an earlier report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33288/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The explanation for these observations is unclear. One possibility is that patients with IPMN are subjected to increased surveillance and thus detection of extrapancreatic tumors. Alternatively, patients with IPMN may have a yet uncharacterized hereditary predisposition to cancer or have been exposed to carcinogens leading to a cancer predisposition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intraductal papillary mucinous neoplasms (IPMNs) are precancerous lesions with a well described adenoma carcinoma sequence. (See",
"      <a class=\"local\" href=\"#H8191539\">",
"       'Progression to pancreatic cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IPMNs are classified as main duct-type or branch duct-type, based upon the anatomic involvement of the pancreatic duct. Patients with involvement of both the main and branch ducts are referred to as having mixed-type IPMN, though pathologically the lesions behave like main duct IPMN. (See",
"      <a class=\"local\" href=\"#H8191597\">",
"       'Anatomic classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Histologically, IPMNs are classified as intestinal type, pancreatobiliary type, oncocytic type, and gastric type. (See",
"      <a class=\"local\" href=\"#H8191604\">",
"       'Histologic classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients with IPMN have no symptoms, with the neoplasm being detected incidentally when imaging studies are performed for unrelated indications. Other patients may have nonspecific symptoms. Patients with pancreatitis related to their IPMN may have pain and elevated pancreatic enzymes.",
"     </li>",
"     <li>",
"      The risk of carcinoma in situ or invasive carcinoma in main duct IPMN is approximately 70 percent, whereas the majority of patients without main duct involvement have a prolonged course without the development of cancer. (See",
"      <a class=\"local\" href=\"#H5506456\">",
"       'Pancreatic malignancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cancers are typically characterized as either tubular type (morphologically indistinguishable from ductal adenocarcinoma) or colloid type (morphologically similar to cancers of other exocrine organs, such as the breast and skin). Colloid carcinomas have a better prognosis than do tubular carcinomas.",
"     </li>",
"     <li>",
"      Patients with IPMN appear to be at increased risk for extrapancreatic malignancies. (See",
"      <a class=\"local\" href=\"#H5506766\">",
"       'Extrapancreatic malignancies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/1\">",
"      BECKER WF, WELSH RA, PRATT HS. CYSTADENOMA AND CYSTADENOCARCINOMA OF THE PANCREAS. Ann Surg 1965; 161:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/2\">",
"      Lichtenstein DR, Carr-Locke DL. Mucin-secreting tumors of the pancreas. Gastrointest Endosc Clin N Am 1995; 5:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/3\">",
"      Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006; 6:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/4\">",
"      Longnecker DS, Adsay NV, Fernandez-del Castillo C, et al. Histopathological diagnosis of pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms: interobserver agreement. Pancreas 2005; 31:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/5\">",
"      Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004; 28:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/6\">",
"      Ohashi K, Murakami Y, Maruyama M. Four cases of mucin producing cancer of the pancreas on specific findings of the papilla of Vater. Prog Dig Endosc 1982; 20:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/7\">",
"      Klibansky DA, Reid-Lombardo KM, Gordon SR, Gardner TB. The clinical relevance of the increasing incidence of intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol 2012; 10:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/8\">",
"      Zamboni G, Scarpa A, Bogina G, et al. Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol 1999; 23:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/9\">",
"      Laffan TA, Horton KM, Klein AP, et al. Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol 2008; 191:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/10\">",
"      Lee KS, Sekhar A, Rofsky NM, Pedrosa I. Prevalence of incidental pancreatic cysts in the adult population on MR imaging. Am J Gastroenterol 2010; 105:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/11\">",
"      Kosmahl M, Pauser U, Peters K, et al. Cystic neoplasms of the pancreas and tumor-like lesions with cystic features: a review of 418 cases and a classification proposal. Virchows Arch 2004; 445:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/12\">",
"      Allen PJ, D'Angelica M, Gonen M, et al. A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg 2006; 244:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/13\">",
"      Lee CJ, Scheiman J, Anderson MA, et al. Risk of malignancy in resected cystic tumors of the pancreas &lt; or =3 cm in size: is it safe to observe asymptomatic patients? A multi-institutional report. J Gastrointest Surg 2008; 12:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/14\">",
"      Ingkakul T, Thayer SP, Ferrone CR, et al. Epidemiology of intraductal papillary mucinous neoplasms of the pancreas: gender differences between 3 geographic regions. Journal of the Japan Pancreas Society 2010; 25:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/15\">",
"      Khalid A, Brugge W. ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. Am J Gastroenterol 2007; 102:2339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/16\">",
"      Fukushima N, Mukai K. Pancreatic neoplasms with abundant mucus production: emphasis on intraductal papillary-mucinous tumors and mucinous cystic tumors. Adv Anat Pathol 1999; 6:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/17\">",
"      Sato N, Rosty C, Jansen M, et al. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol 2001; 159:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/18\">",
"      Su GH, Hruban RH, Bansal RK, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999; 154:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/19\">",
"      Maire F, Hammel P, Terris B, et al. Intraductal papillary and mucinous pancreatic tumour: a new extracolonic tumour in familial adenomatous polyposis. Gut 2002; 51:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/20\">",
"      Poley JW, Kluijt I, Gouma DJ, et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009; 104:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/21\">",
"      Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004; 2:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/22\">",
"      Kobari M, Egawa S, Shibuya K, et al. Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: differences in clinical characteristics and surgical management. Arch Surg 1999; 134:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/23\">",
"      Terris B, Ponsot P, Paye F, et al. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol 2000; 24:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/24\">",
"      Serikawa M, Sasaki T, Fujimoto Y, et al. Management of intraductal papillary-mucinous neoplasm of the pancreas: treatment strategy based on morphologic classification. J Clin Gastroenterol 2006; 40:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/25\">",
"      L&eacute;vy P, Jouannaud V, O'Toole D, et al. Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy. Clin Gastroenterol Hepatol 2006; 4:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/26\">",
"      Gr&uuml;tzmann R, Niedergethmann M, Pilarsky C, et al. Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment. Oncologist 2010; 15:1294.",
"     </a>",
"    </li>",
"    <li>",
"     Hruban RH, Pitman MB, Klimstra DS. Tumors of the pancreas. In: Atlas of tumor pathology, Fascicle 6, Armed Forces Institute of Pathology, Washington, DC 2007. Vol 4th series.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/28\">",
"      Sessa F, Solcia E, Capella C, et al. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch 1994; 425:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/29\">",
"      Z'graggen K, Rivera JA, Compton CC, et al. Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Ann Surg 1997; 226:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/30\">",
"      Shimizu Y, Yasui K, Morimoto T, et al. Case of intraductal papillary mucinous tumor (noninvasive adenocarcinoma) of the pancreas resected 27 years after onset. Int J Pancreatol 1999; 26:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/31\">",
"      Yanagisawa A, Kato Y, Ohtake K, et al. c-Ki-ras point mutations in ductectatic-type mucinous cystic neoplasms of the pancreas. Jpn J Cancer Res 1991; 82:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/32\">",
"      Raimondo M, Tachibana I, Urrutia R, et al. Invasive cancer and survival of intraductal papillary mucinous tumors of the pancreas. Am J Gastroenterol 2002; 97:2553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/33\">",
"      Nissim S, Idos GE, Wu B. Genetic markers of malignant transformation in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. Pancreas 2012; 41:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/34\">",
"      Furukawa T, Fujisaki R, Yoshida Y, et al. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod Pathol 2005; 18:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/35\">",
"      Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, et al. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol 2000; 157:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/36\">",
"      Moore PS, Orlandini S, Zamboni G, et al. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer 2001; 84:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/37\">",
"      Wu J, Jiao Y, Dal Molin M, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A 2011; 108:21188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/38\">",
"      Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011; 3:92ra66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/39\">",
"      Yonezawa S, Sato E. Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol Int 1997; 47:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/40\">",
"      Yonezawa S, Horinouchi M, Osako M, et al. Gene expression of gastric type mucin (MUC5AC) in pancreatic tumors: its relationship with the biological behavior of the tumor. Pathol Int 1999; 49:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/41\">",
"      Yonezawa S, Taira M, Osako M, et al. MUC-1 mucin expression in invasive areas of intraductal papillary mucinous tumors of the pancreas. Pathol Int 1998; 48:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/42\">",
"      Gold DV, Karanjawala Z, Modrak DE, et al. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res 2007; 13:7380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/43\">",
"      House MG, Guo M, Iacobuzio-Donahue C, Herman JG. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis 2003; 24:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/44\">",
"      Sato N, Matsubayashi H, Abe T, et al. Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin Cancer Res 2005; 11:4681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/45\">",
"      Poultsides GA, Reddy S, Cameron JL, et al. Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg 2010; 251:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/46\">",
"      Yanagisawa A, Ohashi K, Hori M, et al. Ductectatic-type mucinous cystadenoma and cystadenocarcinoma of the human pancreas: a novel clinicopathological entity. Jpn J Cancer Res 1993; 84:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/47\">",
"      Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 2004; 239:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/48\">",
"      Salvia R, Fern&aacute;ndez-del Castillo C, Bassi C, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 2004; 239:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/49\">",
"      Bassi C, Procacci C, Zamboni G, et al. Intraductal papillary mucinous tumors of the pancreas. Verona University Pancreatic Team. Int J Pancreatol 2000; 27:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/50\">",
"      Rivera JA, Fern&aacute;ndez-del Castillo C, Pins M, et al. Pancreatic mucinous ductal ectasia and intraductal papillary neoplasms. A single malignant clinicopathologic entity. Ann Surg 1997; 225:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/51\">",
"      Bastid C, Bernard JP, Sarles H, et al. Mucinous ductal ectasia of the pancreas: a premalignant disease and a cause of obstructive pancreatitis. Pancreas 1991; 6:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/52\">",
"      Cellier C, Cuillerier E, Palazzo L, et al. Intraductal papillary and mucinous tumors of the pancreas: accuracy of preoperative computed tomography, endoscopic retrograde pancreatography and endoscopic ultrasonography, and long-term outcome in a large surgical series. Gastrointest Endosc 1998; 47:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/53\">",
"      Obara T, Saitoh Y, Maguchi H, et al. Papillary adenoma of the pancreas with excessive mucin secretion. Pancreas 1992; 7:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/54\">",
"      Yamaguchi K, Chijiiwa K, Shimizu S, et al. Intraductal papillary neoplasm of the pancreas: a clinical review of 13 benign and four malignant tumours. Eur J Surg 1999; 165:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/55\">",
"      D'Angelica M, Brennan MF, Suriawinata AA, et al. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg 2004; 239:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/56\">",
"      McGrath K, Slivka A. Diagnosis and management of intraductal papillary mucinous neoplasia. Nat Clin Pract Gastroenterol Hepatol 2005; 2:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/57\">",
"      Salvia R, Partelli S, Crippa S, et al. Intraductal papillary mucinous neoplasms of the pancreas with multifocal involvement of branch ducts. Am J Surg 2009; 198:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/58\">",
"      Sawai Y, Yamao K, Bhatia V, et al. Development of pancreatic cancers during long-term follow-up of side-branch intraductal papillary mucinous neoplasms. Endoscopy 2010; 42:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/59\">",
"      Sugiyama M, Izumisato Y, Abe N, et al. Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J Surg 2003; 90:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/60\">",
"      Schmidt CM, White PB, Waters JA, et al. Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg 2007; 246:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/61\">",
"      Kang MJ, Jang JY, Kim SJ, et al. Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol 2011; 9:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/62\">",
"      Fern&aacute;ndez-del Castillo C, Targarona J, Thayer SP, et al. Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg 2003; 138:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/63\">",
"      Uehara H, Nakaizumi A, Ishikawa O, et al. Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut 2008; 57:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/64\">",
"      Sugiyama M, Atomi Y. Extrapancreatic neoplasms occur with unusual frequency in patients with intraductal papillary mucinous tumors of the pancreas. Am J Gastroenterol 1999; 94:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/65\">",
"      Choi MG, Kim SW, Han SS, et al. High incidence of extrapancreatic neoplasms in patients with intraductal papillary mucinous neoplasms. Arch Surg 2006; 141:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/66\">",
"      Yoon WJ, Ryu JK, Lee JK, et al. Extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasm of the pancreas: prevalence, associated factors, and comparison with patients with other pancreatic cystic neoplasms. Ann Surg Oncol 2008; 15:3193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/67\">",
"      Reid-Lombardo KM, Mathis KL, Wood CM, et al. Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management. Ann Surg 2010; 251:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/68\">",
"      Kamisawa T, Tu Y, Egawa N, et al. Malignancies associated with intraductal papillary mucinous neoplasm of the pancreas. World J Gastroenterol 2005; 11:5688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33288/abstract/69\">",
"      Eguchi H, Ishikawa O, Ohigashi H, et al. Patients with pancreatic intraductal papillary mucinous neoplasms are at high risk of colorectal cancer development. Surgery 2006; 139:749.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5632 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-FFFC22E1CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_32_33288=[""].join("\n");
var outline_f32_32_33288=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8190718\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8191002\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8191597\">",
"      Anatomic classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8191604\">",
"      Histologic classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8191539\">",
"      Progression to pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5507120\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5506939\">",
"      RISK OF MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5506456\">",
"      Pancreatic malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5506766\">",
"      Extrapancreatic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5632\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5632|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/16/7431\" title=\"picture 1\">",
"      Intraduct pap mucin neo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/60/11208\" title=\"picture 2\">",
"      IPMN oncocytic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/37/8791\" title=\"picture 3\">",
"      IPMN gastric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5632|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/0/38925\" title=\"table 1\">",
"      Clin features panc neoplasm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/20/15686?source=related_link\">",
"      Classification of pancreatic cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/49/41753?source=related_link\">",
"      Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13513?source=related_link\">",
"      Molecular pathogenesis of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/6/37990?source=related_link\">",
"      Overview of Peutz-Jeghers syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3368?source=related_link\">",
"      Pancreatic cystic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/27/44472?source=related_link\">",
"      Pathology of exocrine pancreatic neoplasms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_32_33289="Evaluation and diagnosis of hematogenous osteomyelitis in children";
var content_f32_32_33289=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and diagnosis of hematogenous osteomyelitis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/32/33289/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/32/33289/contributors\">",
"     Paul Krogstad, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/32/33289/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/32/33289/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/32/33289/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/32/33289/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/32/33289/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/32/33289/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomyelitis is an infection of bone that is usually bacterial in origin. Microorganisms can be introduced into bone in three ways:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hematogenous delivery",
"     </li>",
"     <li>",
"      Direct inoculation (usually traumatic, but also surgical)",
"     </li>",
"     <li>",
"      Local invasion from a contiguous infection (usually decubitus ulcer or periodontal disease)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children, acute osteomyelitis is primarily hematogenous in origin. Unique anatomic characteristics of the growing skeleton also affect the site of infection, pathogenesis, and clinical features of the disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17416?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology, pathogenesis, and microbiology of hematogenous osteomyelitis in children\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial presentation of children with osteomyelitis may be delayed, and signs and symptoms are often nonspecific. A high index of suspicion and a thorough approach to evaluation of the patient are therefore essential to establish the diagnosis.",
"   </p>",
"   <p>",
"    The evaluation and diagnosis of hematogenous osteomyelitis in children are discussed in this topic review. The epidemiology, pathogenesis, and microbiology of hematogenous osteomyelitis in children are discussed elsewhere. The clinical features of hematogenous osteomyelitis in children, as well as the treatment, are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17416?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of hematogenous osteomyelitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20087?source=see_link\">",
"     \"Clinical features of hematogenous osteomyelitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24730?source=see_link\">",
"     \"Treatment of hematogenous osteomyelitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL DIAGNOSTIC CLUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no single demographic or clinical feature that allows the clinician to identify the child with osteomyelitis. However, certain clues are consistent with bone infection. The following is an overview of findings obtained from the history and physical examination that should suggest the diagnosis in children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20087?source=see_link\">",
"     \"Clinical features of hematogenous osteomyelitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Demographics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although osteomyelitis does not occur commonly in children, the incidence is highest in the first five years of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. About one-quarter of cases are in children younger than two years of age, and one-half are in those younger than five years of age.",
"   </p>",
"   <p>",
"    Although rare in neonates, osteomyelitis may occur in newborns with certain risk factors. These include prematurity, skin infections, and complicated delivery. With adolescents, an increase in risk factors for bacteremia, such as injection drug use, is associated with an enhanced risk of osteomyelitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of symptoms in acute hematogenous osteomyelitis is usually gradual, occurring over several days to a week. The initial symptoms can be nonspecific in children of all ages and are commonly associated with those of bacteremia, such as malaise and low-grade fever. Once infection becomes established in bone, symptoms related to pain, such as decreased movement of the affected area and local swelling, develop. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20087?source=see_link\">",
"     \"Clinical features of hematogenous osteomyelitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As previously mentioned, the neonate who develops osteomyelitis often has risk factors such as prematurity, skin infections, and complicated delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/4\">",
"     4",
"    </a>",
"    ]. Osteomyelitis may be diagnosed in some infants as the result of a search for the source of bacteremia. Symptoms and signs in infants and small children are often less localized than in older patients. Nevertheless, focal findings of tenderness, erythema, and warmth suggest the possibility of osteomyelitis, with or without fever.",
"   </p>",
"   <p>",
"    The long bones of the femur, tibia, and humerus are most often involved in children other than neonates (",
"    <a class=\"graphic graphic_figure graphicRef61415 \" href=\"mobipreview.htm?34/34/35364\">",
"     figure 1",
"    </a>",
"    ). Warmth, swelling, and point tenderness of the involved site are the classic physical findings. By comparison, the pelvis is involved in about 8 percent of cases, more commonly in patients with inflammatory bowel disease. Although infection typically occurs at one site, disease in multiple sites does occur in immunocompromised children, those who are very ill at the time of presentation, and in about 20 percent of neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/4,5\">",
"     4,5",
"    </a>",
"    ] or patients with infection caused by community-associated methicillin-resistant",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    (CA-MRSA). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17416?source=see_link&amp;anchor=H15#H15\">",
"     \"Epidemiology, pathogenesis, and microbiology of hematogenous osteomyelitis in children\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subacute osteomyelitis, which generally is associated with a longer duration of symptoms (weeks to months), is most often observed in adolescents who present with complaints of pain and tenderness in the long bones. The pain is less severe, there is minimal or no fever, and there are few constitutional symptoms.",
"   </p>",
"   <p>",
"    Chronic osteomyelitis usually is recognized when it occurs in a patient with a history of osteomyelitis who is experiencing a recurrence of pain, erythema, or swelling in association with a draining sinus. In some cases, however, the diagnosis of chronic osteomyelitis is eventually made in a child who has had longstanding, mild, nonspecific musculoskeletal complaints without recognition of a preceding acute process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevations in the peripheral white blood cell count (WBC), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) in children with hematogenous osteomyelitis are variable and nonspecific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of osteomyelitis can be confirmed with imaging, which also may be used to aid in the aspiration of a periosteal collection or joint fluid for culture. Several imaging modalities are useful in the evaluation and diagnosis of osteomyelitis in children.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A plain radiograph should be performed initially in all patients. This study is often negative or inconclusive early in the course of osteomyelitis, but is helpful to exclude another diagnosis (such as a fracture or bone tumor).",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) is the modality of choice when imaging other than plain radiography is needed to establish the diagnosis of osteomyelitis (eg, early in the course) or to delineate the location and extent of bone involvement. MRI is particularly helpful with localized findings, when scintigraphy is inconclusive, and in vertebral disease and abscesses.",
"     </li>",
"     <li>",
"      Scintigraphy provides important information in patients without localizing findings. Similar to MRI, it is helpful early in the course. Unlike MRI and computed tomography (CT), it is usually readily available and does not require sedation in young children.",
"     </li>",
"     <li>",
"      Computed tomography (CT) is less time consuming than MRI and, in cases of chronic osteomyelitis, superior to MRI in identifying abnormalities in bone such as sequestra.",
"     </li>",
"     <li>",
"      Ultrasound localizes fluid collections and can be used to guide procedures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these modalities is discussed in detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A plain radiograph is performed initially in all patients with suspected osteomyelitis. A plain film may identify findings that are characteristic of bone infection or that distinguish infection from other conditions in the differential diagnosis. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Radiographic changes that are characteristic of osteomyelitis include (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51834 \" href=\"mobipreview.htm?14/6/14434\">",
"     image 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lytic sclerosis, indicating chronic infection",
"     </li>",
"     <li>",
"      Evidence of periosteal new bone formation (periosteal elevation), with compatible clinical findings",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abnormalities caused by osteomyelitis generally are not apparent, however, until sometime after the onset of clinical symptoms. The typical sequence of radiographic changes is as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      By approximately three days after symptom onset, a small area of localized, deep, soft-tissue swelling is evident in the region of the metaphysis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77957 \" href=\"mobipreview.htm?34/43/35505\">",
"       image 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Within three to seven days, interposed translucent fat planes within muscle are obliterated by edema fluid.",
"     </li>",
"     <li>",
"      Radiographic evidence of bone destruction finally becomes apparent by 10 to 21 days. Periosteal elevation or thickening may represent new bone formation, pus, or reactive edema from adjacent soft-tissue infection (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50259 \" href=\"mobipreview.htm?31/31/32241\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef71349 \" href=\"mobipreview.htm?33/52/34638\">",
"       image 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The timing of this sequence is affected by which bones are involved and the age of the child. Long tubular bones tend to show bone destruction and periosteal new bone formation two to three weeks earlier than membranous or irregular bones. By comparison, plain films of the pelvis generally are not helpful in identifying osteomyelitis. In neonates, bone destruction is often apparent by the 7",
"    <sup>",
"     th",
"    </sup>",
"    to 10",
"    <sup>",
"     th",
"    </sup>",
"    day of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children with vertebral osteomyelitis, plain films may be normal at initial presentation in more than 50 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/11\">",
"     11",
"    </a>",
"    ]. Abnormalities that are seen initially include localized rarefaction of one vertebral plateau, followed by involvement of adjacent vertebrae. Marked destruction of bone, usually anteriorly, can occur, followed by anterior osteophytic reactions with bridging and bone sclerosis.",
"   </p>",
"   <p>",
"    A different sequence of radiographic findings is observed with discitis. The radiographic changes are first noted several weeks after the onset of symptoms, with the following sequence being observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initially, the disc space is narrowed. This finding is usually not detectable until two to four weeks after the onset of symptoms.",
"     </li>",
"     <li>",
"      This is followed by destruction of the adjacent cartilaginous vertebral end-plates.",
"     </li>",
"     <li>",
"      Finally, the disc may herniate into the vertebral body.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In older children, anterior spontaneous fusion is common. Rarely, vertebral body compression or wedging is noted.",
"   </p>",
"   <p>",
"    Despite the delay in radiographic changes, findings suggestive of discitis often are apparent on presentation. In one series, as an example, radiographic changes were present on initial evaluation in more than 70 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is the modality of choice when imaging other than plain radiography is needed to establish the diagnosis of osteomyelitis (eg, early in the course) or to delineate the location and extent of bone involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/12\">",
"     12",
"    </a>",
"    ]. The major advantage of MRI is that it accurately identifies subperiosteal or soft-tissue collections of pus. In addition, the child is not exposed to ionizing radiation. The efficacy of MRI does not appear to be affected by diagnostic or surgical intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI is also particularly useful in helping identify",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    distinguish the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Differentiating involvement of the vertebral body and the adjacent disc in children with vertebral osteomyelitis",
"     </li>",
"     <li>",
"      Osteomyelitis associated with the pelvis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Areas that may require surgical drainage, such as sinus tracts and intraosseous abscesses, or subperiosteal or soft-tissue collections of pus (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81461 \" href=\"mobipreview.htm?32/0/32772\">",
"       image 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Involvement of the growth plate by the infectious process [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/16-18\">",
"       16-18",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sensitivity and specificity for the detection of bone involvement in children with suspected osteomyelitis with MRI is extremely high (97 and 92 percent, respectively, in one series) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66132 \" href=\"mobipreview.htm?25/47/26355\">",
"     image 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI demonstrates excellent anatomic detail and differentiation among soft tissue, bone marrow, and bone (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59602 \" href=\"mobipreview.htm?11/8/11392\">",
"     image 7",
"    </a>",
"    ). Areas of active inflammation show a decreased signal in T1-weighted images and an increased signal in T2-weighted images. Fat-suppression sequences, including short-tau inversion recovery, decrease the signal from fat and are more sensitive for the detection of bone-marrow edema. The signal from infected bone marrow can also be enhanced with intravenous gadolinium contrast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/19\">",
"     19",
"    </a>",
"    ], but this is seldom necessary for diagnostic purposes. At the time these changes in the marrow cavity are evident, cortical bone appears normal on plain films [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/20\">",
"     20",
"    </a>",
"    ]. Changes seen in disc infection include reduction of disc space, increased T2 signal in the adjacent vertebral end plates, and signal intensity changes in the intervening discs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/11,20\">",
"     11,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disadvantages of MRI include a longer scanning time compared with computed tomography and the requirement for sedation or general anesthesia for an adequate study in most young children. MRI also is less useful when multiple sites of bony involvement are suspected or there are no localized clinical findings. Finally, MRI may not always be readily available.",
"   </p>",
"   <p>",
"    Because of the risk of nephrogenic systemic fibrosis, imaging with gadolinium should be avoided, if possible, in patients with moderate or advanced renal failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Scintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radionuclide scanning (ie, bone scan), a widely used modality in the United States and Europe, is highly sensitive (84 to 100 percent) and specific (70 to 96 percent) for the diagnosis of osteomyelitis in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/19,21,22\">",
"     19,21,22",
"    </a>",
"    ]. In addition, scintigraphy is helpful early in the course, usually readily available, relatively inexpensive, and it may not require as much sedation as MRI in young children. However, it may not perform as well in neonates or in patients with community-associated methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    infections, and will not reveal foci of purulence within and near bone (eg, intramedullary abscesses or muscular phlegmon) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Three-phase bone scan'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Scintigraphy is useful when:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      MRI is not available and imaging other than plain radiography is needed to confirm a diagnosis of osteomyelitis",
"     </li>",
"     <li>",
"      The area of suspected infection cannot be localized",
"     </li>",
"     <li>",
"      Multiple areas of involvement are suspected",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple nuclear medicine imaging procedures are available to evaluate for osteomyelitis. The three-phase bone scan, utilizing technetium 99m (99mTc), usually is performed initially. Scans using inflammation imaging tracers such as gallium or indium can be helpful when results of the initial 99mTc study are equivocal but involve additional exposure to radiation. MRI is therefore generally preferred when further imaging is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Three-phase bone scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone imaging using technetium 99m (99mTc) diphosphate compounds is based on initial flow through the bone and adsorption of covalently bonded 99mTc phosphate adduct to the surface of hydroxyapatite crystal in bone. 99mTc is concentrated in the cement line, located at the junction of osteoid and mineralized bone.",
"   </p>",
"   <p>",
"    A scan for the evaluation of infection is usually performed in three phases. A nuclear angiogram, or flow phase, is obtained shortly after injection (two to five seconds). The blood pool phase is obtained 5 to 10 minutes after injection, and the third image, which is specific for bone uptake, is taken two to four hours after injection.",
"   </p>",
"   <p>",
"    Increased uptake of tracer in the first two phases can be caused by anything that increases blood flow and is accompanied by inflammation. Osteomyelitis causes focal uptake in the third phase, and the intensity of the signal reflects the level of osteoblastic activity. Although localization of a lesion near a growth plate can complicate interpretation of a study, the overall accuracy of 99mTc imaging to detect osteomyelitis in children other than neonates is more than 90 percent.",
"   </p>",
"   <p>",
"    In neonates, the utility of bone scans with 99mTc has been variable, with early studies suggesting sensitivities as low as 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/5,23,24\">",
"     5,23,24",
"    </a>",
"    ]. Subsequent advances in the technique may have improved the accuracy of bone scans. In one retrospective series describing 30 infants (younger than four months of age) with proven osteomyelitis, the sensitivity of bone scanning was 84 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Inflammation imaging tracers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallium scans are relatively insensitive for the diagnosis of musculoskeletal infection, but osteomyelitis is occasionally identified when they are used in the evaluation of fever of unknown origin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9706?source=see_link&amp;anchor=H26#H26\">",
"     \"Approach to the child with fever of unknown origin\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Scanning with indium 111-labelled leukocytes also has been evaluated. This involves removing leukocytes from the patient and labeling them with indium 111 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/25\">",
"     25",
"    </a>",
"    ]. The labeled leukocytes are then injected back into the patient. The requirement for obtaining blood for labeling the leukocytes and the higher organ absorption of radiation dose are limitations of this modality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI has replaced CT for evaluating suspected osteomyelitis because this technique provides superior anatomic detail and can distinguish among soft tissue, bone marrow, and bone. However, CT better delineates changes in bone and may be preferred when significant bone destruction is identified on plain films [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specifically, CT may be useful in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Delineating the extent of bone injury in chronic osteomyelitis",
"     </li>",
"     <li>",
"      Planning the surgical approach to debridement of sequestra",
"     </li>",
"     <li>",
"      Evaluating the patient being treated for osteomyelitis whose condition is worsening, although MRI is generally superior",
"     </li>",
"     <li>",
"      Further imaging when MRI is not available",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although CT was used previously to define infections of the spine, MRI is now preferred in this situation.",
"   </p>",
"   <p>",
"    CT abnormalities commonly found with osteomyelitis include increased density of bone marrow because of accumulation of purulent material and periosteal new bone formation and periosteal purulence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound can identify fluid collections associated with bone and may improve the success of percutaneous diagnostic and therapeutic drainage procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/26\">",
"     26",
"    </a>",
"    ]. Ultrasound findings consistent with osteomyelitis include fluid collection adjacent to the bone without intervening soft tissue, elevation of the periosteum by more than 2 mm, and thickening of the periosteum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12071?source=see_link&amp;anchor=H11#H11\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\", section on 'Ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolation of a pathogen from bone, periosteal collection, joint fluid, or blood confirms the diagnosis of osteomyelitis in patients with clinical and radiologic findings consistent with the disorder and is essential for planning treatment. Nevertheless, patients with clinical and radiologic findings consistent with osteomyelitis often do not have a pathogen isolated from microbiologic specimens.",
"   </p>",
"   <p>",
"    A bacteriologic diagnosis can be confirmed in 50 to 80 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/1,2,27,28\">",
"     1,2,27,28",
"    </a>",
"    ]. Although more difficult to obtain than blood, specimens from bone are most likely to identify a pathogen. Blood cultures are negative up to 50 percent of the time. As an example, in a retrospective series of 146 children who were diagnosed with osteomyelitis, only 39 of 121 blood cultures were positive for a pathogen (32 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/27\">",
"     27",
"    </a>",
"    ]. In contrast, 50 of 60 specimens from bone were positive (83 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Sites to culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because it is often difficult to identify the pathogen in patients with osteomyelitis, specimens should be obtained from as many sites as possible:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specimens for blood culture should be obtained before antibiotics are administered from all patients with suspected osteomyelitis.",
"     </li>",
"     <li>",
"      Bone, subperiosteal exudate, or joint fluid adjoining sites of suspected infection should be cultured whenever possible, as directed by imaging studies. With emergence of infection caused by resistant organisms, such as community-associated methicillin-resistant",
"      <em>",
"       S. aureus",
"      </em>",
"      (CA-MRSA), and unusual species, such as",
"      <em>",
"       Kingella kingae",
"      </em>",
"      , it is particularly important to collect specimens for culture from as many sites of infection as possible. It is preferable to obtain these specimens before antibiotics are administered. However, initiation of antibiotic therapy should not be delayed in children who have signs of systemic illness. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Needle aspiration and bone biopsy'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17416?source=see_link&amp;anchor=H15#H15\">",
"       \"Epidemiology, pathogenesis, and microbiology of hematogenous osteomyelitis in children\", section on 'Microbiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, an aggressive attempt must be made to isolate unusual pathogens in patients with suspected osteomyelitis whose initial cultures are negative and who do not respond to empiric antibiotic treatment as expected. A bone biopsy should be obtained for histopathological staining and culture for bacteria, mycobacteria, and fungi.",
"    <em>",
"     K. kingae",
"    </em>",
"    is a fastidious organism that requires aerobic conditions and may take longer to grow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/29\">",
"     29",
"    </a>",
"    ]. As a result, injection of joint fluid or aspirates from bone and periosteal collections into blood culture bottles is recommended to enhance recovery of",
"    <em>",
"     Kingella",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Needle aspiration and bone biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An orthopedic surgeon",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interventional radiologist should be consulted as early as possible in the evaluation of children with suspected osteomyelitis to assist in obtaining specimens for culture and assessing the need for surgical intervention. Specimens may be obtained by percutaneous needle aspiration. Fluoroscopy, computed tomography, and ultrasound have been used to guide this procedure.",
"   </p>",
"   <p>",
"    Specimens also can be obtained by open biopsy, or when surgery is required for therapeutic drainage and debridement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24730?source=see_link&amp;anchor=H25#H25\">",
"     \"Treatment of hematogenous osteomyelitis in children\", section on 'Indications for surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following age-related issues should be considered when choosing an approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In neonates, extensive soft-tissue and periosteal involvement is common. As a result, needle aspiration of the soft tissue or incision and drainage of bone may yield the offending organism. A plain radiograph, magnetic resonance imaging (MRI), or bedside ultrasound may be used to guide the procedure.",
"     </li>",
"     <li>",
"      For infants and young children, subperiosteal collections that can be localized by physical examination or imaging (plain radiograph, MRI, or ultrasound) often can be aspirated for culture.",
"     </li>",
"     <li>",
"      Percutaneous techniques are less successful in older children and adolescents. As a result, bone must often be aspirated or drilled to drain pus for culture. In some cases, orthopedic surgeons must weigh the risk of epiphyseal damage and further destruction of bone against the value of obtaining a specimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ADDITIONAL LABORATORY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete blood count (CBC) should be performed. Although elevation of the white blood cell count is a variable and nonspecific finding in patients with osteomyelitis, other abnormalities in the CBC, such as sickle forms or immature or abnormal white blood cells (as in a child with leukemia), may be diagnostic for conditions included in the differential diagnosis of osteomyelitis. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A measurement of the erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) levels also should be performed. Although these tests may not be helpful in establishing the diagnosis, they can serve to support it. In addition, they are important markers for assessing response to therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24730?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hematogenous osteomyelitis in children\", section on 'Monitoring response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1152154493\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of osteomyelitis is often unclear at the initial evaluation. A combination of clinical features suggestive of bone infection, an abnormal imaging study, a positive microbiologic specimen,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    response to empiric antibiotic therapy eventually substantiates the diagnosis. An approach to establishing a definitive or presumptive diagnosis of osteomyelitis is described in this section. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24730?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hematogenous osteomyelitis in children\", section on 'Monitoring response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, evaluation for possible osteomyelitis in children usually is prompted by clinical features that suggest bone infection. These may include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Constitutional symptoms (irritability, decreased appetite or activity), with or without fever",
"     </li>",
"     <li>",
"      Focal symptoms and signs of inflammation (pain, erythema, swelling, and tenderness)",
"     </li>",
"     <li>",
"      Limitation of function (limp, limited use of an extremity)",
"     </li>",
"     <li>",
"      Elevation of erythrocyte sedimentation rate (ESR)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      C-reactive protein (CRP) levels",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infrequently, findings such as a positive blood culture or an abnormal imaging study will initiate evaluation in a patient with nonspecific signs or symptoms, such as an irritable neonate or a child with a fever of unknown origin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20087?source=see_link\">",
"     \"Clinical features of hematogenous osteomyelitis in children\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical diagnostic clues'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Abnormal initial radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with suspected bone infection clinically and characteristic abnormalities on initial imaging studies (such as lytic sclerosis, periosteal new bone formation, periosteal elevation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deep soft-tissue swelling on plain films) are likely to have osteomyelitis. They should receive empiric antibiotic therapy. In addition, an aggressive attempt should be made to obtain specimens from surrounding soft tissue or bone for culture. Isolation of a pathogen from bone, periosteal collection, joint fluid, or blood confirms the diagnosis of osteomyelitis in patients with clinical and radiologic findings consistent with the disorder and is essential for planning treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24730?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of hematogenous osteomyelitis in children\", section on 'Empiric antimicrobial therapy'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H7\">",
"     'Plain radiographs'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Needle aspiration and bone biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Positive culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive culture from any specimen in a child with clinical and radiographic features characteristic of osteomyelitis confirms the diagnosis. Antibiotic therapy should generally be continued for a minimum of four weeks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24730?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of hematogenous osteomyelitis in children\", section on 'Duration and efficacy of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Negative culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some children with clinical features of osteomyelitis and an abnormal imaging study may have negative cultures from bone, periosteal collection, joint fluid, or blood. Although cultures are negative in up to 50 percent of cases, the number of those whose initial plain films are abnormal is not known. Whether or not the patient has osteomyelitis is suggested by the response to antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24730?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hematogenous osteomyelitis in children\", section on 'Monitoring response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improvement with empiric therapy &ndash; A presumptive diagnosis of osteomyelitis can be made in those with abnormal imaging and a compatible clinical history who respond to empiric antibiotic therapy. Antibiotic therapy should be continued for a minimum of four weeks. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24730?source=see_link&amp;anchor=H23#H23\">",
"       \"Treatment of hematogenous osteomyelitis in children\", section on 'Treatment of culture-negative osteomyelitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      No improvement with empiric therapy &ndash; An unusual infection or a noninfectious diagnosis is likely in children with abnormal imaging who do not improve with empiric antibiotics. Further evaluation, including obtaining a bone specimen, is indicated. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Microbiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Normal initial radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric antibiotic therapy is warranted for most children with suspected osteomyelitis whose initial plain films are normal. At least one (preferably two) blood culture should be obtained before antibiotic therapy is administered.",
"   </p>",
"   <p>",
"    However, a few such patients may be followed closely without antibiotics. These include children who are school-age or older and afebrile, with equivocal physical findings.",
"   </p>",
"   <p>",
"    Further imaging, usually with magnetic resonance imaging (MRI) or scintigraphy, should be performed for any patient whose initial radiographs are normal, regardless of whether antibiotic therapy is initiated (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66132 \" href=\"mobipreview.htm?25/47/26355\">",
"     image 6",
"    </a>",
"    ). This should be obtained within a few days of the initial radiograph. The sensitivity of MRI is sufficient to exclude the diagnosis of osteomyelitis when this study is negative. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Empiric treatment plus positive culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of osteomyelitis is confirmed in children with a positive blood culture and characteristic findings on subsequent imaging. Antibiotic therapy should be continued for a minimum of four weeks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24730?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of hematogenous osteomyelitis in children\", section on 'Duration and efficacy of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A presumptive diagnosis of osteomyelitis cannot be made when subsequent imaging studies, particularly MRI or scintigraphy, remain negative. Further evaluation may be directed by response to empiric antibiotic therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improvement with empiric therapy &ndash; A source of infection other than osteomyelitis must be sought for children with a positive blood culture who do not develop abnormal findings on MRI or scintigraphy but improve with empiric antibiotics.",
"     </li>",
"     <li>",
"      No improvement with empiric therapy &ndash; Those with a positive blood culture and no imaging abnormalities who do not improve with empiric antibiotics must be aggressively evaluated for the source of bacteremia, as well as for other noninfectious diagnoses that may have predisposed the patient to bacteremia. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Empiric treatment plus negative culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child with a negative blood culture who develops abnormalities on subsequent imaging studies can be evaluated according to the response to empiric therapy. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Negative culture'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnosis of osteomyelitis is unlikely for children with negative blood cultures whose imaging studies, particularly MRI or scintigraphy, remain negative. Response to empiric therapy may direct subsequent evaluation for these patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improvement with empiric therapy &ndash; Patients who improve with antibiotic therapy and who lack radiographic evidence of osteomyelitis may have a more superficial infection (eg, cellulitis) and can be treated with a shorter course of antibiotics.",
"     </li>",
"     <li>",
"      No improvement with empiric therapy &ndash; An infectious etiology is unlikely in those patients with negative cultures and imaging studies who do not respond to antibiotics. Subsequent evaluation for a disorder other than osteomyelitis and discontinuation of antibiotics is warranted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     No empiric treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, a few children who are school-age or older and afebrile, with equivocal physical findings and a normal initial radiograph, may be followed closely without antibiotics. Further imaging, usually with MRI or scintigraphy, should be performed within a few days of the initial radiograph. Subsequent evaluation will depend on blood culture",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    imaging results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions with features that may mimic osteomyelitis include those influenced by age-specific clinical features and those that are similar to osteomyelitis regardless of the patient's age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Age specific",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children who have a gradual onset of symptoms with minimal or no fever, an infectious process may not be obvious initially, and the diagnosis of osteomyelitis can be delayed. This is illustrated in the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A neonate or infant who is not moving an extremity and has radiographs excluding a fracture may initially be thought to have a neurologic or neuromuscular disorder. The diagnosis of osteomyelitis also may be delayed in the neonate with fever and no clearly localized findings.",
"     </li>",
"     <li>",
"      A neurologic or orthopedic condition (such as toxic synovitis) may be initially suspected in the young child with a limp.",
"     </li>",
"     <li>",
"      Older children with focal pain and minimal constitutional symptoms may be initially inaccurately diagnosed with a musculoskeletal injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In these situations, careful attention to clinical details (such as a decrease in feeding, an intermittent low-grade fever, or no history of trauma), and good follow-up, including initial and repeat imaging, can minimize delay in making the diagnosis of osteomyelitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Infectious diagnoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever, pain, and tenderness overlying bone occur in other infectious conditions that may not involve bone. These include septicemia, septic arthritis, deep abscesses, pyomyositis, and cellulitis. These disorders are principally distinguished from osteomyelitis by the absence of findings in imaging studies that are characteristic of bone infection. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Noninfectious diagnoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several noninfectious conditions can be confused with osteomyelitis. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumor growth can cause bone pain, and some children with malignancies may have fever (particularly with leukemia and Ewing sarcoma) as part of their initial presentation. Unlike those with osteomyelitis, symptoms can be intermittent in children with tumors. Affected children also fail to respond to empiric antibiotic therapy. The disorders are usually distinguished by bone biopsy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/47/5882?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical assessment of the child with suspected cancer\", section on 'Bone and joint pain'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/58/4009?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\", section on 'Musculoskeletal pain'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37769?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\", section on 'Signs and symptoms'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35673?source=see_link\">",
"       \"Bone tumors: Diagnosis and biopsy techniques\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bone infarction secondary to hemoglobinopathy, especially in infants with dactylitis, can be particularly difficult to distinguish from osteomyelitis. Plain films, bone scintigram, and magnetic resonance imaging (MRI) all show similar results in both conditions. Unlike bone disease with hemoglobinopathy, osteomyelitis does not respond to hydration and other supportive measures. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18506?source=see_link\">",
"       \"Bone and joint complications in sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with Gaucher disease can have painful bone crises similar to those that occur in patients with sickle cell disease. During bone pain crises, ischemia can be detected by technetium bone scan. Radiographs of the distal femur may demonstrate deformities caused by abnormal modeling of the metaphysis that are characteristic of Gaucher's disease. In addition, osteomyelitis should be considered in febrile patients who do not improve with hydration and other supportive measures. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/11/9402?source=see_link\">",
"       \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complex regional pain syndrome is an uncommon chronic condition that causes pain, swelling, and limited range of motion in the affected extremity. It frequently begins after an injury, surgery, or vascular event. Vasomotor instability and chronic skin changes also occur. This disorder is distinguished from osteomyelitis by characteristic findings on plain radiographs and bone scintigraphy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37768?source=see_link\">",
"       \"Complex regional pain syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Caffey's disease, or infantile cortical hyperostosis, is an inherited disease characterized by fever, subperiosteal bone hyperplasia, and swelling of overlying soft tissues. It is a rare disorder and difficult to distinguish from osteomyelitis on initial presentation. The disorders can be distinguished on bone biopsy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/23/11641?source=see_link\">",
"       \"Differential diagnosis of the orthopedic manifestations of child abuse\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bone lesions that can have a similar appearance to osteomyelitis on imaging include fibrous dysplasia, osteoid osteoma, eosinophilic granuloma and other forms of histiocytosis, osteogenic sarcoma, and chondroblastoma. The acute clinical features of osteomyelitis will usually distinguish it from these conditions. Affected children also fail to respond to empiric antibiotic therapy. These disorders can be distinguished from bone infection on bone biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24522?source=see_link\">",
"     \"Overview of benign bone tumors in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Chronic nonbacterial osteomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic nonbacterial osteomyelitis (of which chronic recurrent multifocal osteomyelitis [CRMO] is the most common type) is thought to be an autoimmune inflammatory disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/31\">",
"     31",
"    </a>",
"    ]. The initial presentation is similar to that of osteomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/32\">",
"     32",
"    </a>",
"    ]. There have been multiple case reports, but the true incidence of the disease is unknown.",
"   </p>",
"   <p>",
"    Clinical features include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It occurs in children and adolescents and is more common in girls. In a series of 70 patients, the median age at onset was 9.6 years (range 3 to 17 years), and 67 percent were girls.",
"     </li>",
"     <li>",
"      Presenting symptoms may include bone pain, localized swelling, and fever. A pustular eruption on the palms and soles may occur in cases that are chronic or recurrent.",
"     </li>",
"     <li>",
"      Virtually all patients have increased inflammatory markers (erythrocyte sedimentation rate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      C-reactive protein).",
"     </li>",
"     <li>",
"      Metaphyseal regions of tubular bones are generally involved. Unifocal disease occurs in approximately 20 percent of cases, with the mandible most frequently affected. In multifocal disease, the pattern is symmetrical in approximately one-fourth of cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CRMO is a sporadic illness in most cases, but it may also occur as part of a syndrome. Majeed syndrome, for example, is an autosomal-recessive, lifelong disorder composed of CRMO, congenital dyserythropoietic anemia, and transient inflammatory dermatosis. CRMO may also occur in the rare patient with deficiency of interleukin-1 receptor antagonist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24487?source=see_link&amp;anchor=H13#H13\">",
"     \"Cryopyrin-associated periodic syndromes and related disorders\", section on 'Deficiency of the IL-1-receptor antagonist (DIRA)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Imaging may localize the areas of bony involvement and indicate the absence of features suggestive of chronic osteomyelitis, such as an abscess or sinus tract. However, repeated biopsy of lesions that prove to be sterile usually leads to the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with glucocorticoids and nonsteroidal anti-inflammatory agents may provide transient relief of symptoms, but recurrences are common. Successful treatment with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/43/21173?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    , gamma interferon, tumor necrosis factor alpha blocking therapy, and the bisphosphonate drug",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/54/39781?source=see_link\">",
"     pamidronate",
"    </a>",
"    also has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/31,37-40\">",
"     31,37-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical course is unpredictable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]. In a series of 70 patients, 43 percent were in remission after a median of 22 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33289/abstract/31\">",
"     31",
"    </a>",
"    ]. Complications may include pathologic fractures, scoliosis, and vertebral collapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial presentation of children with osteomyelitis may be delayed, and signs and symptoms are often nonspecific. A high index of suspicion and a thorough approach to evaluation of the patient are therefore essential to establish the diagnosis.",
"   </p>",
"   <p>",
"    Although there is no single demographic or clinical feature that allows the clinician to identify the child with osteomyelitis, certain clues are consistent with bone infection. These include specific demographic elements and certain clinical features, particularly focal findings related to bone inflammation. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical diagnostic clues'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Imaging",
"      </strong>",
"      &ndash; Imaging techniques including plain radiography, magnetic resonance imaging (MRI), scintigraphy, and computed tomography (CT) are useful for identifying osteomyelitis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend that all children with suspected osteomyelitis have plain radiographs taken of the affected region. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Plain radiographs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If it is available, we recommend MRI when imaging other than plain radiography is needed to establish the diagnosis of osteomyelitis or when it is necessary to delineate the location and extent of bone involvement. Most small children will require sedation for this procedure, which may be a limiting factor in some institutions. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend scintigraphy when MRI is not available and imaging other than plain radiography is needed to make the diagnosis. Scintigraphy also may be useful when the area of suspected infection cannot be localized or multiple areas of involvement are suspected. However, it does not provide information about the extent of purulent collections that may require drainage. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Scintigraphy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CT scanning may provide useful information when significant bony injury is identified on plain films, or when MRI is not feasible. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Computed tomography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Microbiology",
"      </strong>",
"      &ndash; Isolation of a pathogen from bone, periosteal collection, joint fluid, or blood confirms the diagnosis of osteomyelitis in patients with clinical and radiologic findings consistent with the disorder and is essential for planning treatment. We recommend that all patients have at least one blood culture (preferably two) drawn before antibiotics are administered, and that bone, subperiosteal exudate, or joint fluid adjoining sites of suspected infection be cultured whenever possible. We suggest that an orthopedic surgeon or interventional radiologist be consulted as early as possible to assist in obtaining specimens from the site of infection and assessing the need for surgical intervention. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Diagnostic approach",
"      </strong>",
"      &ndash; The diagnosis of osteomyelitis is often unclear at the initial evaluation. A combination of clinical features suggestive of bone infection, an abnormal imaging study, a positive microbiologic specimen,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      response to empiric antibiotic therapy eventually substantiates the diagnosis of osteomyelitis. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Differential diagnosis",
"      </strong>",
"      &ndash; Disorders other than osteomyelitis may have a similar presentation (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Differential diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Children with a gradual onset of nonspecific symptoms (such as limp or not moving an extremity) may initially appear to have a neurologic or trauma-related diagnosis.",
"     </li>",
"     <li>",
"      Other sources of infection, such as cellulitis or septic arthritis, may have a presentation similar to osteomyelitis.",
"     </li>",
"     <li>",
"      Non-infectious conditions, such as malignancy, autoimmune disease, infarction, or inflammation of bone, may cause symptoms and signs similar to osteomyelitis.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/1\">",
"      Dich VQ, Nelson JD, Haltalin KC. Osteomyelitis in infants and children. A review of 163 cases. Am J Dis Child 1975; 129:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/2\">",
"      Bonhoeffer J, Haeberle B, Schaad UB, Heininger U. Diagnosis of acute haematogenous osteomyelitis and septic arthritis: 20 years experience at the University Children's Hospital Basel. Swiss Med Wkly 2001; 131:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/3\">",
"      Floyed RL, Steele RW. Culture-negative osteomyelitis. Pediatr Infect Dis J 2003; 22:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/4\">",
"      Knudsen CJ, Hoffman EB. Neonatal osteomyelitis. J Bone Joint Surg Br 1990; 72:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/5\">",
"      Mok PM, Reilly BJ, Ash JM. Osteomyelitis in the neonate. Clinical aspects and the role of radiography and scintigraphy in diagnosis and management. Radiology 1982; 145:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/6\">",
"      Scott RJ, Christofersen MR, Robertson WW Jr, et al. Acute osteomyelitis in children: a review of 116 cases. J Pediatr Orthop 1990; 10:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/7\">",
"      Unkila-Kallio L, Kallio MJ, Eskola J, Peltola H. Serum C-reactive protein, erythrocyte sedimentation rate, and white blood cell count in acute hematogenous osteomyelitis of children. Pediatrics 1994; 93:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/8\">",
"      Harris JC, Caesar DH, Davison C, et al. How useful are laboratory investigations in the emergency department evaluation of possible osteomyelitis? Emerg Med Australas 2011; 23:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/9\">",
"      Capitanio MA, Kirkpatrick JA. Early roentgen observations in acute osteomyelitis. Am J Roentgenol Radium Ther Nucl Med 1970; 108:488.",
"     </a>",
"    </li>",
"    <li>",
"     Overturf GD. Bacterial infections of the bones and joints. In: Infectious diseases of the fetus and newborn infant, 7th, Remington JS, Klein JO, Wilson CB, et al (Eds), Elsevier Saunders, Philadelphia  Vol 2011, p.296.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/11\">",
"      Fernandez M, Carrol CL, Baker CJ. Discitis and vertebral osteomyelitis in children: an 18-year review. Pediatrics 2000; 105:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/12\">",
"      Browne LP, Mason EO, Kaplan SL, et al. Optimal imaging strategy for community-acquired Staphylococcus aureus musculoskeletal infections in children. Pediatr Radiol 2008; 38:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/13\">",
"      Kan JH, Hilmes MA, Martus JE, et al. Value of MRI after recent diagnostic or surgical intervention in children with suspected osteomyelitis. AJR Am J Roentgenol 2008; 191:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/14\">",
"      Connolly LP, Connolly SA, Drubach LA, et al. Acute hematogenous osteomyelitis of children: assessment of skeletal scintigraphy-based diagnosis in the era of MRI. J Nucl Med 2002; 43:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/15\">",
"      Weber-Chrysochoou C, Corti N, Goetschel P, et al. Pelvic osteomyelitis: a diagnostic challenge in children. J Pediatr Surg 2007; 42:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/16\">",
"      Mazur JM, Ross G, Cummings J, et al. Usefulness of magnetic resonance imaging for the diagnosis of acute musculoskeletal infections in children. J Pediatr Orthop 1995; 15:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/17\">",
"      P&ouml;yhi&auml; T, Azouz EM. MR imaging evaluation of subacute and chronic bone abscesses in children. Pediatr Radiol 2000; 30:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/18\">",
"      Jaramillo D, Hoffer FA. Cartilaginous epiphysis and growth plate: normal and abnormal MR imaging findings. AJR Am J Roentgenol 1992; 158:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/19\">",
"      Schmit P, Glorion C. Osteomyelitis in infants and children. Eur Radiol 2004; 14 Suppl 4:L44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/20\">",
"      Saigal G, Azouz EM, Abdenour G. Imaging of osteomyelitis with special reference to children. Semin Musculoskelet Radiol 2004; 8:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/21\">",
"      Duszynski DO, Kuhn JP, Afshani E, Riddlesberger MM Jr. Early radionuclide diagnosis of acute osteomyelitis. Radiology 1975; 117:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/22\">",
"      Jaramillo D, Treves ST, Kasser JR, et al. Osteomyelitis and septic arthritis in children: appropriate use of imaging to guide treatment. AJR Am J Roentgenol 1995; 165:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/23\">",
"      Wong M, Isaacs D, Howman-Giles R, Uren R. Clinical and diagnostic features of osteomyelitis occurring in the first three months of life. Pediatr Infect Dis J 1995; 14:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/24\">",
"      Bressler EL, Conway JJ, Weiss SC. Neonatal osteomyelitis examined by bone scintigraphy. Radiology 1984; 152:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/25\">",
"      Lantto T, Kaukonen JP, Kokkola A, et al. Tc-99m HMPAO labeled leukocytes superior to bone scan in the detection of osteomyelitis in children. Clin Nucl Med 1992; 17:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/26\">",
"      Hoffer FA, Emans J. Percutaneous drainage of subperiosteal abscess: a potential treatment for osteomyelitis. Pediatr Radiol 1996; 26:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/27\">",
"      Karwowska A, Davies HD, Jadavji T. Epidemiology and outcome of osteomyelitis in the era of sequential intravenous-oral therapy. Pediatr Infect Dis J 1998; 17:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/28\">",
"      Nelson JD. Acute osteomyelitis in children. Infect Dis Clin North Am 1990; 4:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/29\">",
"      Gutierrez K. Bone and joint infections in children. Pediatr Clin North Am 2005; 52:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/30\">",
"      Centers for Disease Control and Prevention (CDC). Osteomyelitis/septic arthritis caused by Kingella kingae among day care attendees--Minnesota, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/31\">",
"      Borzutzky A, Stern S, Reiff A, et al. Pediatric chronic nonbacterial osteomyelitis. Pediatrics 2012; 130:e1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/32\">",
"      Jurik AG. Chronic recurrent multifocal osteomyelitis. Semin Musculoskelet Radiol 2004; 8:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/33\">",
"      Schultz C, Holterhus PM, Seidel A, et al. Chronic recurrent multifocal osteomyelitis in children. Pediatr Infect Dis J 1999; 18:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/34\">",
"      Ferguson PJ, Sandu M. Current understanding of the pathogenesis and management of chronic recurrent multifocal osteomyelitis. Curr Rheumatol Rep 2012; 14:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/35\">",
"      Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/36\">",
"      Sakran W, Shalev SA, Sakran W, et al. Chronic recurrent multifocal osteomyelitis and deficiency of interleukin-1-receptor antagonist. Pediatr Infect Dis J 2013; 32:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/37\">",
"      Gallagher KT, Roberts RL, MacFarlane JA, Stiehm ER. Treatment of chronic recurrent multifocal osteomyelitis with interferon gamma. J Pediatr 1997; 131:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/38\">",
"      Deutschmann A, Mache CJ, Bodo K, et al. Successful treatment of chronic recurrent multifocal osteomyelitis with tumor necrosis factor-alpha blockage. Pediatrics 2005; 116:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/39\">",
"      Simm PJ, Allen RC, Zacharin MR. Bisphosphonate treatment in chronic recurrent multifocal osteomyelitis. J Pediatr 2008; 152:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33289/abstract/40\">",
"      Gleeson H, Wiltshire E, Briody J, et al. Childhood chronic recurrent multifocal osteomyelitis: pamidronate therapy decreases pain and improves vertebral shape. J Rheumatol 2008; 35:707.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6067 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-B60670ABF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_32_33289=[""].join("\n");
var outline_f32_32_33289=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL DIAGNOSTIC CLUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Demographics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Three-phase bone scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Inflammation imaging tracers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Sites to culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Needle aspiration and bone biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ADDITIONAL LABORATORY TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1152154493\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Abnormal initial radiograph",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Positive culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Negative culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Normal initial radiograph",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Empiric treatment plus positive culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Empiric treatment plus negative culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - No empiric treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Age specific",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Infectious diagnoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Noninfectious diagnoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Chronic nonbacterial osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6067\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6067|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/6/14434\" title=\"diagnostic image 1\">",
"      Osteomyelitis limp fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/43/35505\" title=\"diagnostic image 2\">",
"      Osteomyelitis soft tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/31/32241\" title=\"diagnostic image 3\">",
"      Osteomyelitis progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/52/34638\" title=\"diagnostic image 4\">",
"      Osteomyelitis periosteal elevation plain radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?32/0/32772\" title=\"diagnostic image 5\">",
"      Subperiosteal abscess MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/47/26355\" title=\"diagnostic image 6\">",
"      Osteomyelitis radiograph MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/8/11392\" title=\"diagnostic image 7\">",
"      Osteomyelitis MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6067|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/34/35364\" title=\"figure 1\">",
"      Sites of acute osteomyelitis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12071?source=related_link\">",
"      Approach to imaging modalities in the setting of suspected osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9706?source=related_link\">",
"      Approach to the child with fever of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18506?source=related_link\">",
"      Bone and joint complications in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35673?source=related_link\">",
"      Bone tumors: Diagnosis and biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/47/5882?source=related_link\">",
"      Clinical assessment of the child with suspected cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20087?source=related_link\">",
"      Clinical features of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37769?source=related_link\">",
"      Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37768?source=related_link\">",
"      Complex regional pain syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24487?source=related_link\">",
"      Cryopyrin-associated periodic syndromes and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/23/11641?source=related_link\">",
"      Differential diagnosis of the orthopedic manifestations of child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17416?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/11/9402?source=related_link\">",
"      Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24730?source=related_link\">",
"      Treatment of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_32_33290="Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children";
var content_f32_32_33290=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/32/33290/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/32/33290/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/32/33290/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/32/33290/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/32/33290/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/32/33290/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/32/33290/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methicillin-resistant",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    (MRSA,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/59/950?source=see_link\">",
"     oxacillin",
"    </a>",
"    minimum inhibitory concentration [MIC] &ge;4",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    has increased in prevalence worldwide as both a healthcare-associated and a community-associated pathogen. Community-associated MRSA (CA-MRSA) most frequently causes skin and soft tissue infections (SSTI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. However, it is also associated with invasive infections, particularly pneumonia and musculoskeletal infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=see_link\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The substantial prevalence of CA-MRSA as a cause of SSTI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/4\">",
"     4",
"    </a>",
"    ] and the increasing prevalence of multidrug-resistant CA-MRSA calls for changes in the approach to the evaluation and management of suspected",
"    <em>",
"     S. aureus",
"    </em>",
"    SSTI in children. MRSA is the most common identifiable cause of SSTI in many communities and should be suspected (along with methicillin-susceptible",
"    <em>",
"     S. aureus",
"    </em>",
"    and group A",
"    <em>",
"     streptococcus",
"    </em>",
"    ) in children with SSTI. The evaluation and management of suspected methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    SSTI will be reviewed here. The epidemiology, prevention, and control of MRSA infections in children and the treatment of invasive MRSA infections in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=see_link\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26792?source=see_link\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General aspects of management of SSTI and the treatment of SSTI in adults also are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=see_link\">",
"     \"Cellulitis and erysipelas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43831?source=see_link\">",
"     \"Skin abscesses, furuncles, and carbuncles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21846?source=see_link\">",
"     \"Impetigo\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/55/22387?source=see_link\">",
"     \"Folliculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the history in a child with SSTI include risk factors for MRSA, underlying medical conditions, recent use of antibiotics, trauma to skin, including any foreign body that could be imbedded, exposure to ill contacts (eg, group A",
"    <em>",
"     streptococcus",
"    </em>",
"    ), animal bites, and allergy to antibiotics.",
"   </p>",
"   <p>",
"    Although it is impossible to distinguish MRSA from MSSA on clinical or epidemiologic grounds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], it is important to inquire whether children with SSTI have risk factors for MRSA, particularly a previous history of boils, abscesses, infection or colonization with MRSA in the patient or close contacts,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    underlying medical conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/7\">",
"     7",
"    </a>",
"    ]. MRSA isolates in children with healthcare risk factors are more likely to be resistant to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    and other commonly used drugs than isolates from children without risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/2,8,9\">",
"     2,8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination features determine the type and severity of SSTI. Important aspects of the examination include general appearance, the presence of systemic signs (eg, fever, hypotension, tachycardia), and the extent of involvement of the skin and soft tissues. Staphylococcal SSTI may be falsely attributed to spider bites by both patients and clinicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Localized pustules &ndash; Localized pustules have a number of infectious causes. Two common causes in children include impetigo and folliculitis. Impetigo is a superficial bacterial infection that manifests with lesions that progress from papules to vesicles, pustules, and crusts. Folliculitis is a superficial bacterial infection of the hair follicles with purulent material in the epidermis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28423?source=see_link\">",
"       \"Approach to the patient with pustular skin lesions\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21846?source=see_link\">",
"       \"Impetigo\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/55/22387?source=see_link\">",
"       \"Folliculitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Furuncles and carbuncles &ndash; A furuncle (or \"boil\") is an infection of the hair follicle in which purulent material extends through the dermis into the subcutaneous tissue, where a small abscess forms. A carbuncle is a coalescence of several inflamed follicles into a single inflammatory mass with purulent drainage from multiple follicles in the epidermis (",
"      <a class=\"graphic graphic_picture graphicRef70089 \" href=\"mobipreview.htm?35/13/36048\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/55/22387?source=see_link\">",
"       \"Folliculitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skin abscess &ndash; Skin abscesses are collections of pus within the dermis and deeper skin tissues. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43831?source=see_link\">",
"       \"Skin abscesses, furuncles, and carbuncles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cellulitis &ndash; Cellulitis is an infection of the deep dermis and subcutaneous fat without an underlying suppurative focus; it manifests with erythema, edema, and warmth. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=see_link\">",
"       \"Cellulitis and erysipelas\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation is necessary to determine the microbiologic etiology of SSTI. Various bacterial and viral pathogens can cause skin lesions that are clinically indistinguishable from MRSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21846?source=see_link\">",
"     \"Impetigo\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/55/22387?source=see_link\">",
"     \"Folliculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43831?source=see_link\">",
"     \"Skin abscesses, furuncles, and carbuncles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=see_link\">",
"     \"Cellulitis and erysipelas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Before the emergence of CA-MRSA, obtaining material for culture and susceptibility testing was not a routine part of management of SSTI in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/14\">",
"     14",
"    </a>",
"    ]. Such infections were easily treated with beta-lactam antimicrobials (eg, antistaphylococcal penicillins, first- or second-generation cephalosporins). However, given the high prevalence of MRSA as a cause of SSTI, and the geographic and temporal variability of CA-MRSA antimicrobial susceptibility, this practice may need to be reconsidered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/6,10,15-17\">",
"     6,10,15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Culture and susceptibility testing results guide decisions regarding antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/6,10,17\">",
"     6,10,17",
"    </a>",
"    ]. Culture results also are important in monitoring the local proportion of",
"    <em>",
"     S. aureus",
"    </em>",
"    infections caused by MRSA and the prevalence of resistance to various classes of antimicrobials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/6,10,12,16\">",
"     6,10,12,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wound cultures &ndash; We suggest that specimens for Gram stain, culture, and susceptibility testing be obtained from patients with abscesses or purulent skin lesions if purulent material can be obtained [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/11,12,18\">",
"       11,12,18",
"      </a>",
"      ]. It is particularly important to obtain wound cultures from immunocompromised patients and those with severe local infections, systemic signs of infection, recurrent or multiple abscesses, an epidemiologic link to individuals with MRSA infection, and those who have failed initial treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/12,19\">",
"       12,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Blood culture &ndash; We suggest blood cultures be obtained from patients who have signs of systemic infection (eg, prolonged fever, tachycardia, hypotension), especially those with cellulitis and underlying conditions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nasal cultures &ndash; We do not suggest obtaining routine nasal cultures from patients presenting with possible MRSA infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/12\">",
"       12",
"      </a>",
"      ]. The predictive value of screening for colonization is not known [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/21\">",
"       21",
"      </a>",
"      ]. In addition, nasal and wound isolates may be discordant with respect to antimicrobial susceptibility and pulsed-field gel electrophoresis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gram stain &ndash; Gram stain identification of gram-positive cocci in clusters provides early indication of staphylococcal infection, which can help guide empiric therapy. If",
"      <em>",
"       S. aureus",
"      </em>",
"      is isolated in bacterial culture, susceptibility testing is necessary to distinguish MRSA from MSSA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/5\">",
"       5",
"      </a>",
"      ]. In some laboratories, methicillin-resistance maybe detected rapidly using commercially available molecular tests for the mecA gene that leads to methicillin-resistance. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31654?source=see_link\">",
"       \"Rapid detection of methicillin-resistant Staphylococcus aureus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Susceptibility testing &ndash;",
"      <em>",
"       S. aureus",
"      </em>",
"      isolates should be tested for susceptibility to beta-lactam antibiotics,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX), tetracyclines,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"       linezolid",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/39/39542?source=see_link\">",
"       daptomycin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/23\">",
"       23",
"      </a>",
"      ]. A D test for inducible resistance to clindamycin should be performed on isolates that are resistant to erythromycin but susceptible to clindamycin if clindamycin therapy is being considered. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=see_link&amp;anchor=H8#H8\">",
"       \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Microbiologic characteristics'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/5/17495?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of antibacterial susceptibility testing\", section on 'D test'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of controlled studies of the treatment of suspected MRSA SSTI in children, treatment is based upon clinical factors and local susceptibility patterns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/11\">",
"     11",
"    </a>",
"    ]. Information regarding local susceptibility patterns can be obtained from local public health officials or hospital laboratories.",
"   </p>",
"   <p>",
"    The approach to treatment provided below is based upon that suggested by the American Academy of Pediatrics Committee on Infectious Diseases and the Infectious Diseases Society of America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/11,18\">",
"     11,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drainage, adjunctive antimicrobial therapy, wound care, patient education, and reliable follow-up are the primary components of management of MRSA SSTI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/11,18\">",
"     11,18",
"    </a>",
"    ]. Empiric management strategies vary depending upon patient age, comorbid conditions, and the severity of the infection.",
"   </p>",
"   <p>",
"    Mild superficial infections (eg, localized impetigo, pustules, or folliculitis) can usually be managed in the outpatient setting with topical antimicrobials. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Topical agents'",
"    </a>",
"    below.) Small abscesses (&lt;5 cm in diameter) in patients without systemic signs or underlying conditions can usually be managed with incision and drainage (with or without oral antimicrobials). Deeper abscesses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infections in children with underlying medical problems usually require hospitalization for surgical drainage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parenteral antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/10,11,18\">",
"     10,11,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend drainage of purulent and fluctuant lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/10-12,18,24,25\">",
"     10-12,18,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Purulent fluid should be sent for Gram stain, culture, and susceptibility testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/11\">",
"     11",
"    </a>",
"    ]. For patients with small furuncles that are not amenable to incision and drainage, application of moist heat may help to promote drainage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/10,12,26\">",
"     10,12,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5865?source=see_link\">",
"     \"Technique of incision and drainage for skin abscess\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'Laboratory evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The importance of incision and drainage is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the pre-CA-MRSA era, similar outcomes were achieved in patients with cutaneous abscesses who were treated with incision and drainage alone or incision and drainage plus antibiotics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In a prospective review of 201 patients with staphylococcal SSTI, lack of incision and drainage was associated with clinical nonresponse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In observational and randomized studies, most patients with uncomplicated skin abscesses who underwent incision and drainage or spontaneous drainage improved despite adjunctive therapy with antibiotics to which their isolates were not susceptible [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/30-33\">",
"       30-33",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Drainage alone may be adequate therapy for previously healthy children with uncomplicated skin lesions &lt;5 cm in diameter and no systemic signs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/25,30,33\">",
"     25,30,33",
"    </a>",
"    ]. However, we suggest adjunctive oral antimicrobial therapy in selected circumstances, as noted below. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Antimicrobial therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Treatment of skin abscess with drainage alone was evaluated in a randomized trial in 161 children without underlying medical conditions who presented to an emergency department with skin abscess and temperature &lt;38.4&ordm;C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/25\">",
"     25",
"    </a>",
"    ]. After drainage, the children were randomly assigned to receive 10 days of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) or placebo. More than 90 percent of the lesions were &lt;5 cm in diameter on ultrasonography, and approximately 80 percent of the lesions in both groups grew CA-MRSA. At the 10-day follow-up, clinical resolution was similar in the TMP-SMX and placebo groups (96 and 95 percent, respectively). New lesions were more common in the placebo group at 10 days (26 versus 3 percent), but not at 30 days (approximately 28 percent in both groups). These findings suggest that antibiotics may not be necessary for resolution of skin abscess, but may be helpful in preventing short-term recurrence.",
"   </p>",
"   <p>",
"    In a randomized trial comparing an agent with high MRSA activity (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    ) and an agent without MRSA activity (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/5/30804?source=see_link\">",
"     cephalexin",
"    </a>",
"    ) for uncomplicated SSTI in 200 children, spontaneous drainage occurred or a drainage procedure was performed in 97 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/33\">",
"     33",
"    </a>",
"    ]. Although MRSA was isolated from 69 percent of wound cultures, there was no difference in the rates of improvement at 48 to 72 hours (97 and 94 percent, respectively) or complete resolution at seven days (94 and 97 percent, respectively) between groups. These findings confirm those of an observational study in 69 children with MRSA SSTI (most with lesions &lt;5 cm in diameter) who improved after incision and drainage even if they were treated with an antimicrobial to which their isolate was not susceptible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/30\">",
"     30",
"    </a>",
"    ]. Together, these studies suggest that drainage and close follow-up are more important than antimicrobial choice for successful treatment of MRSA SSTI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to drainage, adjunctive antimicrobial therapy may be warranted for certain patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/11,12,18\">",
"     11,12,18",
"    </a>",
"    ]. There is some evidence from observational studies that appropriate antimicrobial therapy is beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/17,34-36\">",
"     17,34-36",
"    </a>",
"    ], particularly for children with lesions &gt;5 cm in diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/30\">",
"     30",
"    </a>",
"    ]. The effect of adjunctive antimicrobial therapy on the recurrence, secondary spread, and progression of disease has not been adequately studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors to be considered in the decision to use adjunctive antimicrobial therapy include age, severity and progression of local symptoms, signs or symptoms of systemic infection, associated chronic illness or immunosuppression, site of infection (eg, face, hands, or perineum) response to initial treatment with incision and drainage, and potential adverse effects of antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/11,12,18\">",
"     11,12,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend adjunctive systemic antimicrobial therapy for children with SSTI &gt;5 cm in diameter; those with systemic signs of illness; infections of the face, hands, and perineum; those under 12 months of age; those with underlying medical conditions (other than asthma or eczema); and those who have failed treatment with incision and drainage alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/11,12,18\">",
"     11,12,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial options for oral therapy in children with SSTI include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    , or tetracyclines;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    is a second-line agent (",
"    <a class=\"graphic graphic_table graphicRef63973 \" href=\"mobipreview.htm?2/60/3020\">",
"     table 1",
"    </a>",
"    ). Each of these agents has advantages and disadvantages, described below. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Systemic agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient education regarding methods to limit spread of infection is an essential component of management of MRSA SSTI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26792?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in children\", section on 'In the community'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     APPROACH FOR CHILDREN &gt;30 DAYS OF AGE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric treatment strategies for children &gt;30 days of age with SSTI depend upon severity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Mild SSTI",
"    </span>",
"    &nbsp;&mdash;&nbsp;SSTI that occur in children who are afebrile and previously healthy are classified as mild [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/11\">",
"     11",
"    </a>",
"    ]. Incision and drainage (if the lesions are fluctuant) alone may be adequate for mild SSTI. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Drainage'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Folliculitis and localized pustules can usually be treated topically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/18\">",
"     18",
"    </a>",
"    ]. Empiric oral therapy depends upon local susceptibility patterns, the likelihood of",
"    <em>",
"     Streptococcus pyogenes",
"    </em>",
"    (group A",
"    <em>",
"     streptococcus",
"    </em>",
"    ), and the age of the child. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Topical agents'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H24\">",
"     'Systemic agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When MRSA is a consideration in children with mild SSTI, if systemic antibiotic therapy is warranted, we suggest oral empiric therapy with a non-beta-lactam antibiotic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/23\">",
"     23",
"    </a>",
"    ]. Options for oral therapy include (",
"    <a class=\"graphic graphic_table graphicRef63973 \" href=\"mobipreview.htm?2/60/3020\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/11,18,23,37\">",
"     11,18,23,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       Clindamycin",
"      </a>",
"      (if the prevalence of clindamycin-resistant MSSA and MRSA in the community is low (ie, &lt;10 percent))",
"     </li>",
"     <li>",
"      TMP-SMX (if",
"      <em>",
"       S. pyogenes",
"      </em>",
"      is unlikely)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/54/12136?source=see_link\">",
"       Doxycycline",
"      </a>",
"      (if the child is &ge;8 years of age and",
"      <em>",
"       S. pyogenes",
"      </em>",
"      is unlikely)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a retrospective cohort of 41,094 children with SSTI who were treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    , TMP-SMX, or a beta-lactam antibiotic without drainage, the rates of treatment failure and recurrence were 6 and 18 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/36\">",
"     36",
"    </a>",
"    ]. The risk of treatment failure and recurrence were increased in children treated with TMP-SMX compared with clindamycin (adjusted odds ratio 1.67 [95% CI 1.44-1.95] for treatment failure and adjusted hazard ratio 1.3 [95% CI 1.18-1.44] for recurrence) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/36\">",
"     36",
"    </a>",
"    ]. Pending additional data from randomized trials, we do not have a preference for clindamycin or TMP-SMX for patients who have undergone drainage. For patients that have not undergone drainage, clindamycin may have some advantage. However, increased use of clindamycin may result in increased clindamycin resistance. Other advantages and disadvantages of these agents are discussed below. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Systemic agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In communities with a low prevalence of MRSA (ie, &lt;10 percent), empiric therapy with a beta-lactam agent is an alternative for infants and children without underlying conditions, and for infections not involving the face, hands, or perineum (eg, a first- or second-generation cephalosporin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/45/31446?source=see_link\">",
"     cloxacillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/61/17363?source=see_link\">",
"     dicloxacillin",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The provision of empiric MRSA coverage does not necessarily result in improved outcomes for children with mild SSTI. A retrospective case-control study assessed treatment failure among 2096 children from an area with a high prevalence of MRSA who were treated with a single oral antimicrobial agent for SSTI that, in the opinion of the treating provider, did not require drainage or culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/38\">",
"     38",
"    </a>",
"    ]. Treatment failure occurred in 5 percent. Compared with beta-lactam therapy,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    provided no benefit (OR for treatment failure 1.4, 95% CI 0.76-2.59), whereas TMP-SMX was associated with an increased risk of treatment failure (OR 2.35, 95% CI 1.28-4.34). These findings suggest that",
"    <em>",
"     S. pyogenes",
"    </em>",
"    may be a more common cause, and MRSA a less common cause, of mild SSTI (even in MRSA-endemic areas) and that empiric coverage for MRSA may not be necessary for skin infections that are not drained, especially impetigo. However, the findings must be validated in prospective studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Moderate SSTI",
"    </span>",
"    &nbsp;&mdash;&nbsp;SSTI that occur in children who are febrile",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ill appearing, but previously healthy, are classified as moderate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/11\">",
"     11",
"    </a>",
"    ]. We recommend that moderate SSTI be treated with incision and drainage (if the lesions are fluctuant) and adjunctive antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/11,18\">",
"     11,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decisions regarding oral versus parenteral therapy depend upon the presence of systemic signs; age of the child; size and location of the lesions; and concerns regarding adherence to therapy and follow-up plans. We suggest initial parenteral therapy for children with systemic signs of illness. We also suggest initial parenteral therapy (one to two doses) for children (of any age) with multiple sites of infection; and for preschool children with abscesses on the face or perineum, or lesions larger than 5 cm. Initial parenteral therapy for children may be administered in an emergency department observation or &ldquo;short-stay&rdquo; unit if one is available.",
"   </p>",
"   <p>",
"    When MRSA is a consideration in children with moderate SSTI, options for oral therapy include (",
"    <a class=\"graphic graphic_table graphicRef63973 \" href=\"mobipreview.htm?2/60/3020\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/11,18,23,37\">",
"     11,18,23,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       Clindamycin",
"      </a>",
"      (if the prevalence of clindamycin-resistant MSSA and MRSA in the community is low (ie, &lt;10 percent))",
"     </li>",
"     <li>",
"      TMP-SMX (if",
"      <em>",
"       S. pyogenes",
"      </em>",
"      is unlikely)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/54/12136?source=see_link\">",
"       Doxycycline",
"      </a>",
"      (if the child is &ge;8 years of age and",
"      <em>",
"       S. pyogenes",
"      </em>",
"      is unlikely)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a retrospective cohort of 6407 children with SSTI who were treated with a drainage procedure and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    , TMP-SMX or a beta-lactam antibiotic, the rates of treatment failure and recurrence were 9 and 23 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/36\">",
"     36",
"    </a>",
"    ]. The risk of treatment failure and recurrence were increased in children treated with TMP-SMX compared with clindamycin (adjusted odds ratio 1.92 [95% CI 1.49-2.47] for treatment failure and adjusted hazard ratio 1.26 [95% CI 1.06-1.49] for recurrence) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/36\">",
"     36",
"    </a>",
"    ]. Pending additional data from randomized trials, we do not have a preference for clindamycin or TMP-SMX for children who have undergone drainage and are treated as outpatients; increased use of clindamycin may result in increased clindamycin resistance.",
"   </p>",
"   <p>",
"    Options for parenteral therapy include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    (if the prevalence of clindamycin-resistant MRSA is less than 10 percent in the community), pending results of culture and susceptibility testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/11,18,23\">",
"     11,18,23",
"    </a>",
"    ]. The advantages and disadvantages of these agents are discussed below. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Systemic agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Severe SSTI",
"    </span>",
"    &nbsp;&mdash;&nbsp;SSTI that are limb-threatening or occur in children who are toxic appearing are classified as severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, immunocompromised children or those with chronic conditions other than asthma or eczema should generally be managed in the same manner as children with severe SSTI, even if the SSTI does not appear to be limb- or life-threatening.",
"   </p>",
"   <p>",
"    We recommend that children with severe SSTI be treated with incision and drainage (if the lesions are fluctuant) and hospitalized for parenteral antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/11,18\">",
"     11,18",
"    </a>",
"    ]. Options for parenteral therapy include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    (if the prevalence of clindamycin-resistant MRSA is less than 10 percent in the community), pending results of culture and susceptibility testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/11,18,23\">",
"     11,18,23",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     Linezolid",
"    </a>",
"    (600 mg twice daily intravenously [IV] for children &ge;12 years of age; 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose [maximum dose 600 mg] every 8 hours IV for children &lt;12 years) is another alternative for parenteral therapy in hospitalized children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/18\">",
"     18",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Treatment of invasive MRSA infection (ie, infection that has spread beyond the skin and soft tissues) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Treatment approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Critically ill patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that critically ill patients (eg, those with hemodynamic compromise) be hospitalized for incision and drainage (if the lesions are fluctuant) and parenteral antimicrobial therapy. We suggest an empiric regimen of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    plus",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/57/26519?source=see_link\">",
"     nafcillin",
"    </a>",
"    for critically ill patients with suspected MRSA SSTI. The combination of vancomycin and nafcillin is necessary to maximize coverage for both MRSA and methicillin-susceptible MSSA. Given that there is little to no evidence that adding",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    for potential synergy is beneficial in adults, we do not suggest the addition of gentamicin; even at low doses, gentamicin is associated with increased nephrotoxicity in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of invasive MRSA infection (ie, infection that has spread beyond the skin and soft tissues) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'For critically ill'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Definitive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the etiologic agent and susceptibility are known, antimicrobial therapy can be narrowed as indicated. MSSA infections can be treated orally with a beta-lactam agent (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/61/17363?source=see_link\">",
"     dicloxacillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/5/30804?source=see_link\">",
"     cephalexin",
"    </a>",
"    ) or intravenously with a semisynthetic penicillin (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/57/26519?source=see_link\">",
"     nafcillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/59/950?source=see_link\">",
"     oxacillin",
"    </a>",
"    ) or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/36/9797?source=see_link\">",
"     cefazolin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/11\">",
"     11",
"    </a>",
"    ]. MRSA can be treated orally or intravenously with agents to which they are susceptible (",
"    <a class=\"graphic graphic_table graphicRef63973 \" href=\"mobipreview.htm?2/60/3020\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Avoiding the use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    when the isolate is susceptible to other drugs may help to minimize promotion of resistance to these drugs (which are crucial to the treatment of invasive infections) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Treatment approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total duration of therapy for staphylococcal SSTI depends upon clinical response; a total of 7 to 14 days is usually adequate if there are no complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     APPROACH FOR CHILDREN &le;30 DAYS OF AGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Infectious Diseases Society of America provides guidance for the management of invasive methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA) infections in infants (&le;30 days of age) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/18\">",
"     18",
"    </a>",
"    ]. The guidelines are based upon observations from a single-institution review of 126 cases treated between 2001 and 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/40\">",
"     40",
"    </a>",
"    ]. The safety and efficacy of topical, oral, and parenteral therapy for CA-MRSA infections have not been well evaluated in this age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that local pustulosis in full-term neonates without other signs or symptoms of infection be treated with topical antibiotic therapy (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/18/43300?source=see_link\">",
"     mupirocin",
"    </a>",
"    ) in the outpatient setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]; close follow-up of such patients is imperative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/40\">",
"     40",
"    </a>",
"    ]. Blood culture and lumbar puncture are not necessary in such infants unless they have signs of sepsis. We recommend that local pustulosis in premature or very low-birth weight infants be treated parenterally at least until bacteremia is excluded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend hospital admission for infants &le;30 days with more severe SSTI (eg, cellulitis, abscess, mastitis, pustulosis involving multiple sites) and for those who undergo evaluation for serious bacterial infection (eg, bacteremia, urinary tract infection, meningitis, arthritis, osteomyelitis). We suggest that all neonates with infections that are more severe than localized pustulosis and those with systemic symptoms or fever undergo evaluation with blood and urine cultures; cerebrospinal fluid cultures should be obtained as clinically indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/40\">",
"     40",
"    </a>",
"    ]. Significant cerebrospinal (CSF) pleocytosis with sterile CSF culture may be seen in association with CA-MRSA infection in neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/40\">",
"     40",
"    </a>",
"    ]. The pathogenesis of the pleocytosis is unclear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28074?source=see_link\">",
"     \"Evaluation and management of fever in the neonate and young infant (less than three months of age)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4680?source=see_link&amp;anchor=H18#H18\">",
"     \"Mastitis and breast abscess in infants, children, and adolescents\", section on 'In neonates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Empiric parenteral antibiotics for SSTI in neonates should be based upon the local susceptibility pattern of community-associated",
"    <em>",
"     S. aureus",
"    </em>",
"    isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/13\">",
"     13",
"    </a>",
"    ]. We suggest",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    for neonates with staphylococcal infection limited to the skin and soft tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/13,18,40\">",
"     13,18,40",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"     Gentamicin",
"    </a>",
"    may be added to broaden coverage for other neonatal pathogens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6410?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features and diagnosis of sepsis in term and late preterm infants\", section on 'Etiologic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of infants &le;30 days with MRSA infections that have extended beyond the skin and skin structures is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Treatment of neonates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The total duration of therapy for staphylococcal SSTI in neonates depends upon clinical response; a total of 7 to 14 days is usually adequate if there are no complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/40\">",
"     40",
"    </a>",
"    ]. Parenteral therapy for infants with noninvasive infection should continue until all of the following criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Resolution of systemic symptoms and fever",
"     </li>",
"     <li>",
"      Improvement in other clinical findings",
"     </li>",
"     <li>",
"      Antibiotic susceptibility results are available",
"     </li>",
"     <li>",
"      Systemic bacterial cultures (urine, blood, CSF) isolate no pathogens during at least 48 hours of incubation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results of antibiotic susceptibility testing should be used to make decisions about which oral antibiotic to use for continuation of systemic therapy. Appropriate oral agents for neonates with noninvasive infection include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/5/30804?source=see_link\">",
"     cephalexin",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    , depending upon the susceptibilities of the",
"    <em>",
"     S. aureus",
"    </em>",
"    isolated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     Linezolid",
"    </a>",
"    may be used when the isolate is resistant to other agents, but should be used under close supervision by an expert in infectious disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/40\">",
"     40",
"    </a>",
"    ]. TMP-SMX should not be used in the immediate neonatal period because it may displace bilirubin, increasing the risk for bilirubin toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/39/11898?source=see_link&amp;anchor=H21#H21\">",
"     \"Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Bilirubin/albumin ratio'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are treated for suspected MRSA in the outpatient setting should be instructed to seek medical care promptly if they develop systemic symptoms or if local symptoms worsen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/10\">",
"     10",
"    </a>",
"    ]. They should be seen for follow-up within 48 hours (whether or not antimicrobial therapy is prescribed) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/26\">",
"     26",
"    </a>",
"    ]. Follow-up is essential to ensure clinical improvement and determine the need for additional drainage or change in antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Failure to respond",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiation of or change in antimicrobial therapy (guided by culture and susceptibility results, if available) may be warranted for patients who have not improved after 48 hours of antimicrobial therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alternatives for children who fail to improve while being treated with beta-lactam antibiotics include TMP-SMX,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      , or a",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/38/28262?source=see_link\">",
"       tetracycline",
"      </a>",
"      (if &ge;8 years of age).",
"     </li>",
"     <li>",
"      Alternatives for children who fail to improve with TMP-SMX,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      , or a",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/38/28262?source=see_link\">",
"       tetracycline",
"      </a>",
"      include parenteral",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      or oral or parenteral",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"       linezolid",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Alternatives for children who fail to improve with parenteral",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      include",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"       linezolid",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/39/39542?source=see_link\">",
"       daptomycin",
"      </a>",
"      ; consultation with an expert in infectious diseases is suggested.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recurrence rate for MRSA SSTI is believed to be at least 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/43\">",
"     43",
"    </a>",
"    ]. Recurrence is usually treated in the same way as the initial episode. Strategies to eliminate colonization are sometimes used, but the effectiveness of this approach in reducing recurrences is not clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26792?source=see_link&amp;anchor=H7#H7\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in children\", section on 'Eradication of carriage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most strains of MRSA that cause SSTI in the community are relatively susceptible to non-beta-lactam antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/2,10,12,44-46\">",
"     2,10,12,44-46",
"    </a>",
"    ]. However, there is temporal and geographic variability. Some strains are resistant to one or more non-beta-lactam antibiotics and some have susceptibility patterns similar to nosocomial isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. Local susceptibility data should be used to guide empiric treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/12\">",
"     12",
"    </a>",
"    ]. Definitive treatment is guided by results of susceptibility testing (if cultures are obtained). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Definitive therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Topical agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical therapy with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/18/43300?source=see_link\">",
"     mupirocin",
"    </a>",
"    is an option for children with mild, localized, superficial infections and no systemic signs.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/47/4851?source=see_link\">",
"     Retapamulin",
"    </a>",
"    (for children older than nine months) may be effective but is not approved for treatment of MRSA infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/43\">",
"     43",
"    </a>",
"    ]. High-level resistance to mupirocin associated with treatment failure and",
"    <em>",
"     S. aureus",
"    </em>",
"    mutants with decreased activity to retapamulin have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/51-54\">",
"     51-54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Systemic agents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TMP-SMX &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX) is not approved by the US Food and Drug Administration (FDA) for the treatment of staphylococcal infection. Its use is supported by in vitro data demonstrating high levels of susceptibility and clinical experience [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/2,3,16,35,55-57\">",
"       2,3,16,35,55-57",
"      </a>",
"      ]. In a large retrospective cohort of children with SSTI, treatment with TMP-SMX was associated with increased risk of treatment failure and recurrence compared with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/36\">",
"       36",
"      </a>",
"      ]. TMP-SMX is available in oral (liquid and tablet) and parenteral formulations, although there is currently a shortage of the intravenous formulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/58\">",
"       58",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      TMP-SMX is often used in communities with a high prevalence (&gt;10 percent) of MRSA with resistance to clindamycin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/2,15,59,60\">",
"       2,15,59,60",
"      </a>",
"      ]. The preferential use of TMP-SMX rather than clindamycin in communities with low prevalence MRSA resistance to clindamycin may help minimize promotion of resistance to clindamycin, which is also used in invasive infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/16,47,61\">",
"       16,47,61",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      TMP-SMX is not active against",
"      <em>",
"       Streptococcus pyogenes",
"      </em>",
"      (group A",
"      <em>",
"       streptococcus",
"      </em>",
"      ), another common cause of SSTI. It should not be used as a single agent if",
"      <em>",
"       S. pyogenes",
"      </em>",
"      SSTI is a consideration; some favor combination therapy with a beta-lactam antibiotic if",
"      <em>",
"       S. pyogenes",
"      </em>",
"      cannot be excluded [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       Clindamycin",
"      </a>",
"      &ndash; Clindamycin is approved by the FDA for the treatment of serious",
"      <em>",
"       S. aureus",
"      </em>",
"      infections in children, including neonates. Its use is supported by in vitro susceptibility studies and clinical experience [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/36,47,61-63\">",
"       36,47,61-63",
"      </a>",
"      ]. In a large retrospective cohort of children with SSTI, treatment with clindamycin was associated with decreased risk of treatment failure and recurrence than treatment with TMP-SMX [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/36\">",
"       36",
"      </a>",
"      ]. Clindamycin is available in parenteral and oral (capsules and granules for oral solution) formulations. The oral solution may have an unpleasant taste for some children, which can be overcome by the addition of flavoring [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/64\">",
"       64",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      MRSA resistance to clindamycin varies from community to community, and appears to be increasing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/16,45,47\">",
"       16,45,47",
"      </a>",
"      ]. Clindamycin resistance is more likely in children with risk factors for MRSA than in previously healthy children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. In addition, resistance to clindamycin may emerge during therapy in MRSA strains with inducible resistance; these isolates appear susceptible to clindamycin and resistant to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      by most standard techniques, but can be detected using the \"D test\" (",
"      <a class=\"graphic graphic_picture graphicRef54213 \" href=\"mobipreview.htm?30/31/31217\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/47,48,65,66\">",
"       47,48,65,66",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/5/17495?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of antibacterial susceptibility testing\", section on 'D test'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Clindamycin is an option for the empiric treatment of suspected MRSA SSTI in communities where the prevalence of clindamycin resistance is &lt;10 percent. Although there are case reports of successful clindamycin therapy for SSTI caused by",
"      <em>",
"       S. aureus",
"      </em>",
"      with inducible clindamycin resistance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/67,68\">",
"       67,68",
"      </a>",
"      ], clindamycin is best avoided when the D test (",
"      <a class=\"graphic graphic_picture graphicRef54213 \" href=\"mobipreview.htm?30/31/31217\">",
"       picture 2",
"      </a>",
"      ) is positive.",
"     </li>",
"     <li>",
"      Tetracyclines &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/54/12136?source=see_link\">",
"       Doxycycline",
"      </a>",
"      is FDA-approved for the treatment of",
"      <em>",
"       S. aureus",
"      </em>",
"      skin infections (but not specifically for those caused by MRSA) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/12\">",
"       12",
"      </a>",
"      ]. Support for the use of tetracyclines comes from observational studies in adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/69,70\">",
"       69,70",
"      </a>",
"      ] and in vitro susceptibility data [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/31\">",
"       31",
"      </a>",
"      ]. In a small case-series, doxycycline and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/20/43334?source=see_link\">",
"       minocycline",
"      </a>",
"      appeared to be adequate for the treatment of MRSA SSTI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/69\">",
"       69",
"      </a>",
"      ]. Doxycycline is available in parenteral and oral formulations; minocycline is only available in an oral formulation.",
"      <br/>",
"      <br/>",
"      Tetracyclines are an option for the treatment of SSTI in children &ge;8 years of age. Similar to TMP-SMX, tetracyclines are not active against",
"      <em>",
"       S. pyogenes",
"      </em>",
"      and should not be used as a single agent if",
"      <em>",
"       S. pyogenes",
"      </em>",
"      SSTI is a consideration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/71\">",
"       71",
"      </a>",
"      ]; some favor combination therapy with a beta-lactam antibiotic if",
"      <em>",
"       S. pyogenes",
"      </em>",
"      cannot be excluded [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"       Linezolid",
"      </a>",
"      &ndash; Linezolid is an oxazolidinone antibiotic active against many antibiotic-resistant gram-positive cocci. It is bacteriostatic for",
"      <em>",
"       S. aureus",
"      </em>",
"      and is approved by the FDA for use in complicated skin infections, including cases caused by MRSA in neonates, children, and adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/72,73\">",
"       72,73",
"      </a>",
"      ]. It is available in oral (tablets and powder for oral suspension) and parenteral formulations.",
"      <br/>",
"      <br/>",
"      In controlled trials, linezolid was as effective as",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/32/32259?source=see_link\">",
"       cefadroxil",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      for uncomplicated SSTI in children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/73-75\">",
"       73-75",
"      </a>",
"      ]. In a study in adults with complicated SSTI, it was at least as effective as vancomycin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/76\">",
"       76",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The use of linezolid for SSTI is limited by cost and toxicity (bone marrow suppression, peripheral and optic neuropathy) if used for a prolonged time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/18,77\">",
"       18,77",
"      </a>",
"      ]. It should be reserved for those who do not respond to or cannot tolerate other agents or whose isolates are resistant to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      and TMP-SMX.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"       Rifampin",
"      </a>",
"      &ndash; Rifampin is not recommended in the treatment of SSTI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      &ndash; Vancomycin is the drug of choice for the treatment of invasive infections caused by MRSA. Vancomycin (plus",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/57/26519?source=see_link\">",
"       nafcillin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/59/950?source=see_link\">",
"       oxacillin",
"      </a>",
"      ) should be used for empiric treatment of critically ill children with SSTI. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Critically ill patient'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link&amp;anchor=H13#H13\">",
"       \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'For critically ill'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Vancomycin is also an option for children with moderate or severe SSTI in communities with a high prevalence of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      resistance. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Moderate SSTI'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Severe SSTI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/39/39542?source=see_link\">",
"       Daptomycin",
"      </a>",
"      &ndash; Daptomycin is a lipopeptide antibiotic that is approved for the treatment of complicated SSTI in adults. The pharmacokinetics, safety, and efficacy of daptomycin for children with SSTI are under investigation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/78,79\">",
"       78,79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/33/4628?source=see_link\">",
"       Ceftaroline",
"      </a>",
"      &ndash; Ceftaroline is a fifth generation cephalosporin that is approved for the treatment of complicated MRSA SSTI in adults. The pharmacokinetics, safety and efficacy of ceftaroline in children with SSTI are unknown.",
"     </li>",
"     <li>",
"      Other drugs &ndash; Fluoroquinolones (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/15/38128?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      ) and macrolides (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/15/35056?source=see_link\">",
"       azithromycin",
"      </a>",
"      ) are not suggested for the treatment of suspected MRSA SSTI because there is a relatively high prevalence of resistance among",
"      <em>",
"       S. aureus",
"      </em>",
"      isolates in the community [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/32/33290/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/4/22595?source=see_link\">",
"       \"Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend drainage of purulent or fluctuant lesions (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Purulent fluid should be sent for Gram stain, culture, and susceptibility testing. Blood culture should be obtained from patients with signs of systemic infection. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Drainage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that localized superficial infections (eg, impetigo, pustulosis, folliculitis) be treated with topical antibiotic therapy in the outpatient setting (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Topical agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Children &gt;30 days",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Incision and drainage alone may be adequate therapy for skin and soft-tissue infections (SSTI) &lt;5 cm in diameter in previously healthy children without systemic signs. However, when methicillin-resistant",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      (MRSA) is a consideration in such children with selected features including young age, underlying condition, and certain sites of infection, we suggest adjunctive oral antimicrobial therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Drainage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Mild SSTI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Options for oral therapy include",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (if",
"      <em>",
"       Streptococcus pyogenes",
"      </em>",
"      is not a consideration),",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      (if local resistance is &lt;10 percent), or tetracyclines (if",
"      <em>",
"       S. pyogenes",
"      </em>",
"      is not a consideration and the child is &ge;8 years old) (",
"      <a class=\"graphic graphic_table graphicRef63973 \" href=\"mobipreview.htm?2/60/3020\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Mild SSTI'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Systemic agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest parenteral antimicrobial therapy for children with SSTI and systemic signs of illness, underlying medical conditions, or limb-threatening infections (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The location of the infection, age of the child, and presence of multiple sites of infection also influence the decision to hospitalize the child. We also suggest initial parenteral therapy (one to two doses) for children (of any age) with multiple sites of infection; and for preschool children with abscesses on the face or perineum, or lesions larger than 5 cm in diameter (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Initial parenteral therapy may be administered in an emergency department observation or &ldquo;short-stay&rdquo; unit if one is available. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Moderate SSTI'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Severe SSTI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Options for empiric parenteral therapy include",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      (if the prevalence of clindamycin-resistant MRSA is less than 10 percent in the community), or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"       linezolid",
"      </a>",
"      . We suggest vancomycin plus",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/57/26519?source=see_link\">",
"       nafcillin",
"      </a>",
"      for critically ill patients with suspected MRSA SSTI (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Moderate SSTI'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Critically ill patient'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link&amp;anchor=H13#H13\">",
"       \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'For critically ill'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Children &le;30 days",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend hospital admission and parenteral antimicrobial therapy for local pustulosis in premature or very low-birth-weight infants (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We recommend hospital admission for infants &le;30 days with SSTI more severe than localized pustulosis (eg, pustulosis in multiple sites, cellulitis, abscess, mastitis) and for those who undergo evaluation for serious bacterial infection (eg, bacteremia, urinary tract infection, meningitis, arthritis, osteomyelitis) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Approach for children &le;30 days of age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Empiric parenteral antibiotics for SSTI in neonates should be based upon the local susceptibility pattern of community-associated",
"      <em>",
"       S. aureus",
"      </em>",
"      isolates.",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"       linezolid",
"      </a>",
"      are appropriate alternatives for infection limited to the skin and soft tissues;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      may be added to broaden coverage. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Approach for children &le;30 days of age'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/1\">",
"      Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005; 40:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/2\">",
"      Purcell K, Fergie J. Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children's Hospital. Arch Pediatr Adolesc Med 2005; 159:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/3\">",
"      Hasty MB, Klasner A, Kness S, et al. Cutaneous community-associated methicillin-resistant staphylococcus aureus among all skin and soft-tissue infections in two geographically distant pediatric emergency departments. Acad Emerg Med 2007; 14:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/4\">",
"      Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/5\">",
"      Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis 2007; 44:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/6\">",
"      Heilpern KL. Skin and soft tissue abscesses: the case for culturing abscess fluid. Ann Emerg Med 2007; 50:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/7\">",
"      Baker CJ. Large CA-MRSA disease burden mandates prompt diagnosis, appropriate management. AAP News 2007; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/8\">",
"      Zaoutis TE, Toltzis P, Chu J, et al. Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among children with risk factors for health care-associated infection: 2001-2003. Pediatr Infect Dis J 2006; 25:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/9\">",
"      Hult&eacute;n KG, Kaplan SL, Gonzalez BE, et al. Three-year surveillance of community onset health care-associated staphylococcus aureus infections in children. Pediatr Infect Dis J 2006; 25:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/10\">",
"      Gorwitz RJ. A review of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J 2008; 27:1.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Staphylococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.653.",
"    </li>",
"    <li>",
"     Gorwitz RJ, Jernigan DB, Powers JH, et al. Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the Centers for Disease Control and Prevention 2006. www.cdc.gov/ncidod/dhqp/pdf/ar/CAMRSA_ExpMtgStrategies.pdf (Accessed on January 23, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/13\">",
"      Bradley J, Frenck R. CA-MRSA infections an increasing concern in early infancy. AAP News 2006; 27:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/14\">",
"      Swartz MN. Clinical practice. Cellulitis. N Engl J Med 2004; 350:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/15\">",
"      Paintsil E. Pediatric community-acquired methicillin-resistant Staphylococcus aureus infection and colonization: trends and management. Curr Opin Pediatr 2007; 19:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/16\">",
"      Braun L, Craft D, Williams R, et al. Increasing clindamycin resistance among methicillin-resistant Staphylococcus aureus in 57 northeast United States military treatment facilities. Pediatr Infect Dis J 2005; 24:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/17\">",
"      Rihn JA, Posfay-Barbe K, Harner CD, et al. Community-acquired methicillin-resistant Staphylococcus aureus outbreak in a local high school football team unsuccessful interventions. Pediatr Infect Dis J 2005; 24:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/18\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/19\">",
"      Abrahamian FM, Shroff SD. Use of routine wound cultures to evaluate cutaneous abscesses for community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med 2007; 50:66.",
"     </a>",
"    </li>",
"    <li>",
"     Carrillo-Marquez M, Hulten K, Lamberth L, et al. Staphylococcus aureus bacteremia associated with skin and soft-tissue infection in children (abstract 2863.493). Pediatric Academic Societies Meeting, Vancouver, BC 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/21\">",
"      von Eiff C, Becker K, Machka K, et al. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001; 344:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/22\">",
"      Chen AE, Cantey JB, Carroll KC, et al. Discordance between Staphylococcus aureus nasal colonization and skin infections in children. Pediatr Infect Dis J 2009; 28:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/23\">",
"      Kaplan SL. Treatment of community-associated methicillin-resistant Staphylococcus aureus infections. Pediatr Infect Dis J 2005; 24:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/24\">",
"      Fergie J, Purcell K. The treatment of community-acquired methicillin-resistant Staphylococcus aureus infections. Pediatr Infect Dis J 2008; 27:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/25\">",
"      Duong M, Markwell S, Peter J, Barenkamp S. Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. Ann Emerg Med 2010; 55:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/26\">",
"      Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/27\">",
"      Llera JL, Levy RC. Treatment of cutaneous abscess: a double-blind clinical study. Ann Emerg Med 1985; 14:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/28\">",
"      Macfie J, Harvey J. The treatment of acute superficial abscesses: a prospective clinical trial. Br J Surg 1977; 64:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/29\">",
"      Miller LG, Quan C, Shay A, et al. A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. Clin Infect Dis 2007; 44:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/30\">",
"      Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004; 23:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/31\">",
"      Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/32\">",
"      Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007; 51:4044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/33\">",
"      Chen AE, Carroll KC, Diener-West M, et al. Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections. Pediatrics 2011; 127:e573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/34\">",
"      Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 2007; 44:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/35\">",
"      Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007; 51:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/36\">",
"      Williams DJ, Cooper WO, Kaltenbach LA, et al. Comparative effectiveness of antibiotic treatment strategies for pediatric skin and soft-tissue infections. Pediatrics 2011; 128:e479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/37\">",
"      Hyun DY, Mason EO, Forbes A, Kaplan SL. Trimethoprim-sulfamethoxazole or clindamycin for treatment of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J 2009; 28:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/38\">",
"      Elliott DJ, Zaoutis TE, Troxel AB, et al. Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus. Pediatrics 2009; 123:e959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/39\">",
"      Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/40\">",
"      Fortunov RM, Hulten KG, Hammerman WA, et al. Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates. Pediatrics 2007; 120:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/41\">",
"      Autret E, Laugier J, Marimbu J, et al. [Comparison of plasma levels of amoxicillin administered by oral and intravenous routes in neonatal bacterial colonization]. Arch Fr Pediatr 1988; 45:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/42\">",
"      Boothman R, Kerr MM, Marshall MJ, Burland WL. Absorption and excretion of cephalexin by the newborn infant. Arch Dis Child 1973; 48:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/43\">",
"      Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 2007; 357:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/44\">",
"      Naimi TS, LeDell KH, Boxrud DJ, et al. Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis 2001; 33:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/45\">",
"      Sattler CA, Mason EO Jr, Kaplan SL. Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis J 2002; 21:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/46\">",
"      Frank AL, Marcinak JF, Mangat PD, Schreckenberger PC. Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children. Pediatr Infect Dis J 1999; 18:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/47\">",
"      Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002; 21:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/48\">",
"      Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003; 37:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/49\">",
"      Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001; 7:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/50\">",
"      Almer LS, Shortridge VD, Nilius AM, et al. Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2002; 43:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/51\">",
"      Han LL, McDougal LK, Gorwitz RJ, et al. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol 2007; 45:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/52\">",
"      Diep BA, Gill SR, Chang RF, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 2006; 367:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/53\">",
"      Gentry DR, Rittenhouse SF, McCloskey L, Holmes DJ. Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin. Antimicrob Agents Chemother 2007; 51:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/54\">",
"      McNeil JC, Hulten KG, Kaplan SL, Mason EO. Mupirocin resistance in Staphylococcus aureus causing recurrent skin and soft tissue infections in children. Antimicrob Agents Chemother 2011; 55:2431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/55\">",
"      Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006; 5:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/56\">",
"      Seligman SJ, Madhavan T, Alcid D. Trimethoprim-sulfamethoxazole in the treatment of bacterial endocarditis. J Infect Dis 1973; 128:Suppl:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/57\">",
"      Tamer MA, Bray JD. Trimethoprim-sulfamethoxazole treatment of multiantibiotic-resistant staphylococcal endocarditis and meningitis. Clin Pediatr (Phila) 1982; 21:125.",
"     </a>",
"    </li>",
"    <li>",
"     U. S. Food and Drug Administration. Current drug shortages. file://www.fda.gov/drugs/drugsafety/drugshortages/ucm050792.htm (Accessed on August 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/59\">",
"      Kaplan SL. Implications of methicillin-resistant Staphylococcus aureus as a community-acquired pathogen in pediatric patients. Infect Dis Clin North Am 2005; 19:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/60\">",
"      Mongkolrattanothai K, Daum RS. Impact of community-associated, methicillin-resistant Staphylococcus aureus on management of the skin and soft tissue infections in children. Curr Infect Dis Rep 2005; 7:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/61\">",
"      Mart&iacute;nez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003; 22:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/62\">",
"      Wilson DH. Clindamycin in the treatment of soft tissue infections: a review of 15 019 patients. Br J Surg 1980; 67:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/63\">",
"      Faden H, Ferguson S. Community-acquired methicillin-resistant Staphylococcus aureus and intrafamily spread of pustular disease. Pediatr Infect Dis J 2001; 20:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/64\">",
"      Steele RW, Russo TM, Thomas MP. Adherence issues related to the selection of antistaphylococcal or antifungal antibiotic suspensions for children. Clin Pediatr (Phila) 2006; 45:245.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/66\">",
"      Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH. Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J Clin Microbiol 2003; 41:4740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/67\">",
"      Drinkovic D, Fuller ER, Shore KP, et al. Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J Antimicrob Chemother 2001; 48:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/68\">",
"      Rao GG. Should clindamycin be used in treatment of patients with infections caused by erythromycin-resistant staphylococci? J Antimicrob Chemother 2000; 45:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/69\">",
"      Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005; 40:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/70\">",
"      Ruhe JJ, Menon A. Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:3298.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Group A streptococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.668.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/72\">",
"      Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/73\">",
"      Kaplan SL, Deville JG, Yogev R, et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 2003; 22:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/74\">",
"      Wible K, Tregnaghi M, Bruss J, et al. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. Pediatr Infect Dis J 2003; 22:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/75\">",
"      Kaplan SL, Afghani B, Lopez P, et al. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2003; 22:S178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/76\">",
"      Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/77\">",
"      Peeters MJ, Sarria JC. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am J Med Sci 2005; 330:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/78\">",
"      Abdel-Rahman SM, Benziger DP, Jacobs RF, et al. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J 2008; 27:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/32/33290/abstract/79\">",
"      Abdel-Rahman SM, Chandorkar G, Akins RL, et al. Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections. Pediatr Infect Dis J 2011; 30:712.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6027 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-CCB85E928E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_32_33290=[""].join("\n");
var outline_f32_32_33290=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      APPROACH FOR CHILDREN &gt;30 DAYS OF AGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Mild SSTI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Moderate SSTI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Severe SSTI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Critically ill patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Definitive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      APPROACH FOR CHILDREN &le;30 DAYS OF AGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Failure to respond",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ANTIMICROBIAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Topical agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Systemic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Children &gt;30 days",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Children &le;30 days",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6027\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6027|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/13/36048\" title=\"picture 1\">",
"      Carbuncle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/31/31217\" title=\"picture 2\">",
"      MRSA susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6027|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/60/3020\" title=\"table 1\">",
"      Rx MRSA skin infections in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28423?source=related_link\">",
"      Approach to the patient with pustular skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6410?source=related_link\">",
"      Clinical features and diagnosis of sepsis in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=related_link\">",
"      Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28074?source=related_link\">",
"      Evaluation and management of fever in the neonate and young infant (less than three months of age)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/39/11898?source=related_link\">",
"      Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/55/22387?source=related_link\">",
"      Folliculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21846?source=related_link\">",
"      Impetigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4680?source=related_link\">",
"      Mastitis and breast abscess in infants, children, and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/5/17495?source=related_link\">",
"      Overview of antibacterial susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/4/22595?source=related_link\">",
"      Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26792?source=related_link\">",
"      Prevention and control of methicillin-resistant Staphylococcus aureus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31654?source=related_link\">",
"      Rapid detection of methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43831?source=related_link\">",
"      Skin abscesses, furuncles, and carbuncles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5865?source=related_link\">",
"      Technique of incision and drainage for skin abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_32_33291="Sources of data";
var content_f32_32_33291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sources of data for a decision analysis problem",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Sources of data",
"      </td>",
"      <td class=\"subtitle1\">",
"       Comments",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Randomized controlled trials (RCT)",
"      </td>",
"      <td>",
"       Excellent source of data on effects of therapies. Often the study requirements (entry and exclusion criteria) will make the results of the trial applicable to only a narrow range of patients.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cohort studies",
"      </td>",
"      <td>",
"       Useful for risk factor determination, natural history",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Administrative databases",
"      </td>",
"      <td>",
"       Excellent sources for broad population-based estimates of disease; often more accurate as estimate of effectiveness for various procedures than RCTs, which, in general, estimate efficacy. However, it is difficult to be sure that confounding variables are controlled for.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Meta-analysis/systematic review",
"      </td>",
"      <td>",
"       Provides summary measures over several different studies for a particular parameter. Generally restricted to RCTs, so often global population data are not well represented.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Expert opinion",
"      </td>",
"      <td>",
"       Often plagued by biases and dependent upon the method used to assess opinion. Most closely resembles the methods used to make clinical decisions in current clinical practice (use of consultants, etc); therefore, the use of expert opinion has face validity.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Investigator estimates",
"      </td>",
"      <td>",
"       A last resort, if there are no other good sources of data. When combined with appropriate sensitivity analysis, can be a useful first start.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_32_33291=[""].join("\n");
var outline_f32_32_33291=null;
var title_f32_32_33292="HIV medications affecting pituitary or adrenal function";
var content_f32_32_33292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medications used in the treatment of HIV or its complications that may affect pituitary or adrenal gland function",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Intended clinical use",
"       </td>",
"       <td class=\"subtitle1\">",
"        Endocrine dysfunction",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism of action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corticosteroids",
"       </td>",
"       <td>",
"        Anti-inflammatory (eg, adjunctive use in",
"        <em>",
"         Pneumocystis carinii",
"        </em>",
"        pneumonia)",
"       </td>",
"       <td>",
"        Exogenous Cushing's syndrome; glucocorticoid deficiency upon discontinuation; hypogonadism",
"       </td>",
"       <td>",
"        Suppresses hypothalamic-pituitary-adrenal (HPA) axis and hypothalamic-pituitary-gonadal (HPG) axes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Interferon-&alpha; (IFN-&alpha;)",
"       </td>",
"       <td>",
"        Treatment of co-infection with Hepatitis C",
"       </td>",
"       <td>",
"        Panhypopituarism",
"       </td>",
"       <td>",
"        Immune-mediated",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Ketoconazole",
"       </td>",
"       <td>",
"        Anti-fungal",
"       </td>",
"       <td>",
"        Adrenal insufficiency; hypogonadism",
"       </td>",
"       <td>",
"        Impairs steroid hormone synthesis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Megestrol acetate",
"       </td>",
"       <td>",
"        Appetite stimulant",
"       </td>",
"       <td>",
"        Cushing's syndrome (rarely); hyperglycemia; hypogonadism; glucocorticoid deficiency upon discontinuation",
"       </td>",
"       <td>",
"        Intrinsic glucocorticoid-like and progestational activity",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Opiates",
"       </td>",
"       <td>",
"        Analgesic",
"       </td>",
"       <td>",
"        Impaired cortisol response to ACTH stimulation; hypogonadism",
"       </td>",
"       <td>",
"        Alterations in HPA &amp; HPG axes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Protease inhibitors (PIs)",
"       </td>",
"       <td>",
"        Anti-retroviral",
"       </td>",
"       <td>",
"        Hyperprolactinemia",
"       </td>",
"       <td>",
"        May stimulate lactotrophs directly or inhibit metabolism of other medications",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Ritonavir",
"       </td>",
"       <td>",
"        Anti-retroviral",
"       </td>",
"       <td>",
"        Exogenous Cushing's syndrome (with concomitant use of inhaled fluticasone)",
"       </td>",
"       <td>",
"        Effects on hepatic cytochromes and drug metabolism",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Rifampin",
"       </td>",
"       <td>",
"        Antibiotic and anti-mycobacterial agent (eg, tuberculosis)",
"       </td>",
"       <td>",
"        Adrenal insufficiency",
"       </td>",
"       <td>",
"        Increases metabolic clearance of hormones",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Sulfonamides",
"       </td>",
"       <td>",
"        Antibiotic",
"       </td>",
"       <td>",
"        Hyporeninemic hypoaldosteronism",
"       </td>",
"       <td>",
"        Interstitial nephritis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Melissa Weinberg, MD and Morris Schambelan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_32_33292=[""].join("\n");
var outline_f32_32_33292=null;
var title_f32_32_33293="LVEF predicts one-year mortality after thrombolysis";
var content_f32_32_33293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    LVEF after thrombolysis predicts one-year mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 415px; height: 265px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the GUSTO-I trial of 11,228 patients, the only predictor of mortality at one year was the left ventricular ejection fraction (LVEF) measured at the time of first catheterization; the relationship between LVEF and one year mortality was continuous. The red line is the point estimate; the blue lines are 95 percent confidence intervals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Puma JA, Sketch MH Jr, Thompson TD, et al. J Am Cardiol 1999; 83:482.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_32_33293=[""].join("\n");
var outline_f32_32_33293=null;
var title_f32_32_33294="PUV VUR";
var content_f32_32_33294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Voiding cystourethrogram of patient with posterior urethral valves",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 401px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    White arrows outline dilated urethra. Black arrows outline dilated ureter with associated vesicoureteral reflux.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nicholas Holmes, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_32_33294=[""].join("\n");
var outline_f32_32_33294=null;
var title_f32_32_33295="MUAP measurements";
var content_f32_32_33295=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F54013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F54013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Motor unit action potential (MUAP) measurements",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 394px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Duration is measured as the time from the initial deflection of the MUAP from baseline to its final return to baseline. It is the parameter that best reflects the number of muscle fibers in the motor unit. Amplitude reflects only muscle fibers very close to the needle and is measured peak to peak. Phases (shaded areas) can be determined by counting the number of baseline crossings and adding 1. MUAPs are generally triphasic. Serrations (also called turns) are changes in direction of the potential that do not cross the baseline. The major spike is the largest positive-to-negative deflection, usually occurring after the first positive peak. Satellite, or linked, potentials occur after the main potential and usually represent early reinnervation of muscle fibers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Preston, DC, Shapiro, BE. Electromyography and neuromuscular disorders, Butterworth-Heinemann, Boston 1998. Copyright &copy; 1998 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_32_33295=[""].join("\n");
var outline_f32_32_33295=null;
